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Rho (Ras homology) small GTPases (or p21s) play important roles in a wide variety 
of cellular process most importantly the organization of the actin cytoskeleton and 
establishment of cell polarity, which allows coordinated movement of cells and 
tissues. The PAKs (p21 activated kinases) are an important class of effector for Cdc42 
and Rac-like Rho proteins, with PAK1-3 constituting the conventional or 'group I' 
kinases and PAK4-6 the group II kinases. Both groups are represented in all 
metazoans and are characterized by a C-terminal catalytic domain and an N-terminal 
p21 binding domain (PBD) and auto-inhibitory domain (AID). The 85 kDa human 
PAK5 does not appear to be auto-inhibited since it is active when purified from 
mammalian cells, even without Cdc42 bound. I revealed that PAK5 has the ability to 
undergo oligomerization through PAK5-unique residues 120-425 which are 
responsible for the elevated basal activity of the kinase relative to the monomeric 65 
kDa PAK4. Analysis of PAK5 localization in various mammalian cell lines indicated 
that regardless of 'tag', the protein equilibrates between the cytoplasm and 
characteristic PAK5 puncta which are driven by its oligomerization. This does not 
appear to result from non-specific aggregation. Although some previous studies found 
that these puncta co-localized with mitochondria, I could not reproduce this result. 
Instead, I show convincingly in multiple stable cell lines expressing GFP-PAK5 that 
the kinase is junctional. This unexpected observation was followed up by an analysis 
of PAK5 proximal proteins using a technique termed BioID that utilizes a mutant 
version of the E.coli protein BirA fused to PAK5 to modify nearby cellular proteins 
with biotin. To this end, I generated osteosarcoma U2OS stable cell lines expressing 
GFP-BirA*-PAK5 or control GFP-BirA*. By using stable isotopic labelling of cells 
(SILAC), it was possible to greatly increase the specificity of protein identification 
IX 
 
using LC-MS/MS mass spectrometry. The majority of proteins identified with BioID 
in the GFP-BirA*-PAK5 assay were indeed associated with cell-cell junctions, 
including Afadin and Nectin-2. In addition, it was interesting to note that PAK5 can 
be seen in the centrosomal region where it may associate with CEP85. The leucine 
zipper tumor suppressor protein LZTS2 was identified as proximal to PAK5, which 
was of interest given the proposed role of PAK5 in cancer progression. Biochemical 
experiments confirmed the direct interaction between PAK5 and LZTS2. Interestingly 
PAK5 self-association promoted this interaction with LZTS2, which binds much more 
weakly to PAK4. Based on previous work from our laboratory and new experiments 
using an LZTS2 specific antibody, I showed that the junctional form of LZTS2 is 
derived from an alternate translational start site that generates a shorter membrane 
bound myristoylated isoform (LZTS2b). Knockdown of LZTS2 by siRNA indicated 
that PAK5 was not dependent on this adaptor for its junctional localization. 
Conversely, LZTS2 did not affect PAK5 activity in vitro. Interestingly a fraction of 
PAK5 was translocated to the mitochondria when was co-expressed with the 
myristoylated LZTS2b. This is because the myristolated signal of LZTS2b can target 
the protein both to the plasma membrane and mitochondria. Further I suggest an 
interplay between Raf-1 and LZTS2 may allow specific function of PAK5 and Raf-1 
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Chapter 1: Introduction 
 
1.1 Overview of Rho GTPases 
Rho (Ras homology) small GTPases are small (21-25kD) proteins which 
belong to the Ras superfamily of GTPases. They are evolutionarily conserved proteins 
that are expressed in all eukaryotes. The  20 members of this family are sub divided to 
8 groups based on their amino acid sequence homology, structure, and biological 
functions; including Rho proteins (RhoA, RhoB and RhoC), Rac proteins (Rac1, 
Rac2, Rac3 and RhoG), Cdc42 proteins (Cdc42, TC10 and TCL), Rnd proteins 
(Rnd1, Rnd2, and Rnd3), RhoH, RhoUV (RhoU and RhoV), RhoBTB proteins 
(RhoBTB1, RhoBTB2) and the RhoF (RhoD and RhoF) [1]. Like other GTP-ases, 
most of the Rho proteins family members switch between active GTP bound and 
inactive GDP bound forms that are mainly regulated by three groups of regulatory 
factors (Figure 1.1) [2]:1. Guanine Nucleotide exchange factors (GEFs) that catalyse 
exchange of GDP to GTP, 2. GTPase activating proteins (GAPs) that enhance activity 
of the GTPases and converse GTP to GDP and 3. Guanine nucleotide dissociation 
inhibitors (GDIs) that bind to the inactive cytosolic GTPases and prevent their 
membrane association. Some of the members of this family are known to be 
constitutively activated by permanent binding to GTP. In these cases, alternative 
mechanisms of regulation such as modulating gene expression, post translational 
modification like phosphorylation and protein degradation are involved in regulation 
of these proteins [1, 2]. 
Activated Rho GTPases interact with many downstream effectors and regulate 
a wide variety of cellular functions such as reorganization of the actin cytoskeleton 
and cell morphology, adhesion and migration, cytokinesis, cell proliferation and 
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survival [3-5]. PAKs (p21 activated kinases) are one of the well-known effectors of 





Figure 1.1 Schematic diagram of Rho-GTPases activation cycle 
(Adapted from the review by Huveneers and Danen. 2009 [7]). Inactive Rho-GDP is 
targeted to the membrane when dissociated from Rho-GDP dissociation inhibitor 
(Rho-GDI). In the membrane, guanine Nucleotide exchange factor (GEF) induces 
activation of Rho-GDP by replacing GDP to GTP. In GTP-bound form, the Rho 
protein is active and interacts with the downstream effectors. GTPase activating 
protein (GAP) catalyses GTPase activity of the Rho-GTP leads to hydrolysis of GTP 
to GDP and inactivation of the Rho protein.  
 
1.2 Overview of P21 activated kinases (PAKs) 
PAKS are a family of serine threonine kinases that were initially discovered in 
1994 via interaction with GTP bound forms of Rac1 and Cdc42 [8]. So far, 6 
mammalian PAKs have been identified that are classified into two groups based on 
their sequence homology and structure. The conventional group I PAKs contains 
PAK1-3 and non-conventional group II PAKs includes PAK4-6 [9]. PAK1 and PAK4 
are the best characterized members of the PAK family. PAKs play an important role 
in a variety of cellular functions including cytoskeleton organization, cell proliferation 
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and survival. Overexpression of PAKs is contributed to some diseases such as cancer 
and inflammatory diseases [10, 11]. Group I and II PAKs differ in their binding 
partners and mechanisms of regulation. 
 
1.2.1 Domain structure of group I and II PAKs 
Basically PAKs family domains structure can be divided to three main 
domains: 1. The Regulatory domain at the N-terminal containing PBD (p21 binding 
domain) and AID (Autoinhibitory domain); 2. The central region, and 3. Serine 
threonine kinase domain at C-terminal (Figure 1.2).  
PBD of Group I PAKs binds to Cdc42 and Rac1 whereas group II 
preferentially binds Cdc42 [12]. The catalytic domain contains an activation loop and 
phosphorylation on this residue is essential for full activity of the protein. The AID 
interacts with the catalytic domain in the inactive state of the kinase. Upon PBD 
interaction with Rho GTPases, the AID dissociates from the kinase domain which 
leads to activation of the protein.   
 Group I PAKs contains three proline rich conserved sequences at the N-
terminal and Central region that interact with the SH3 domain of NCK (non-catalytic 
region of tyrosine kinase adaptor protein 1), Grb2 (growth-factor-receptor-bound 

















Figure 1.2 Schematic diagrams of PAK1 and PAK4 domains  
(Adapted from the review by Zhao, et.al. 2012 [6], with some modifications) All 
isoforms of PAKs have an N-terminal regulatory domain; contains the P21 binding 
domain (PBD) and an auto inhibitory domain (AID), a central region and the C-
terminal catalytic domain. The N-terminal and central region have several proline rich 
domains that are marked in yellow. In group I PAKs the proline rich domains are SH3 
binding sites which interact with the indicated proteins. 
 
1.2.2 Regulation of group I and II PAKs 
Regulatory mechanism of group I PAKs activity was uncovered through 
identification of its AID domain, and the crystal structure of the auto-inhibited PAK1 
suggested a dimeric conformation in which the AID sequence itself dimerizes [16]: 
later this was found to be a crystallization artifact. Group I PAKs are likely all 
regulated via a trans auto-inhibited mechanism in which the AID of one PAK 
molecule binds and inhibits the kinase domain of the other (Figure 1.3) [17]. 
Conformational changes in the AID, upon binding to active RhoGTPases, drive its 
dissociation from the kinase domain and allows autophosphorylation at multiple sites 
including the activation loop (T423) that is essential for full kinase activity [18-20].  
PAK1 is a cytoplasmic kinase and its translocation to the cell membrane 
regulates its activity [21]. Binding to PIX proteins recruits PAK1 to the focal 






























containing adaptor proteins Grb2 and Nck may also recruits PAK1 in response to 
trans-membrane receptors such as EGFR [13, 14, 23]. PAK1 activity is negatively 
regulated by binding to and de-phosphorylation by protein phosphatases such as 
protein phosphatase type 2A (PP2A) and partner of PIX 1 and 2 (POPX1 and POPX2) 
[24]. In addition, direct binding of hPIP (human PAK1-interacting protein 1), 
CRIPAK (Cys-rich inhibitor of PAK1) or Nischarin has been suggested to prevent 
PAK1 activation [25-27]. 
The group II PAKs do not have a homologous AID resembling PAK1, and 
their mechanism of regulation was unrecognized for more than 10 years after their 
discovery. In 2012, our group and others identified an AID in group II PAKs that 
binds in a pseudo-substrate-like manner to PAK4 catalytic domain [28, 29]. In 
addition, the realization that PAK4 is constitutively phosphorylated on its activation 
loop Ser-474, showed that the kinase domain of group II PAKs is always in an active 
state. The mechanism by which the PAK4 AID is regulated is not currently 
understood since in vitro Cdc42 binding to the flanking CRIB sequence does not 
change the binding of the AID to the kinase (Figure 1.4) [28]. One possibility is that 
the proline containing sequence (R
49
PKPLV) interacts with the SH3 domains [29] to 
relieve the auto-inhibited state of PAK4.  
Group II PAKs preferentially bind to Cdc42: some studies have shown that 
Cdc42 binding regulates both PAK4 and PAK5 activity [28, 30], but as mentioned 
above this interaction does not significantly affect PAK4 activity in vitro [29].  
Interaction with Cdc42 might serve primarily to affect kinase localization [31, 32]. 
For example, it has been reported that co-expression of PAK5 with active 
Cdc42(G12V) targets PAK5 to the filopodia, or that co-expression of RhoD leads to 
PAK5 translocation to mitochondria [31].   
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Among group II PAKs, it is generally agreed that PAK5 and PAK6 are basally 
more active than PAK4 [32-34]. In the case of PAK6 binding to androgen receptor 
may increase its activity [34, 35]. The p38 MAPK (mitogen-activated protein kinase) 
MKK6 stimulates PAK6 activity [36] by phosphorylating Ser165 and Tyr 566 of 
PAK6. Co-expression of activated MKK6 has been shown to stimulate PAK4 and 
PAK5 activity by phosphorylating Tyr 480 and 608 respectively [36] although it is 




Figure 1.3 Schematic of group I PAKs activation  
(Adapted from the review by Zhao and Manser. 2012 [6]). PAK1 forms dimer in 
inactive conformation. AID of one molecule binds to the kinase domain of another 
molecule and prevents auto-phosphorylation of the kinase. Binding to PIX targets 
PAK1 for activation. Rac1.GTP binding to the PBD domain induces some 
conformational changes that allow auto-phosphorylation and activation of the protein. 
Auto-phosphorylated PAK1 has reduced affinity for PIX. 
 
 





Figure 1.4 A model for regulation of group II PAKs activity through binding to 
Cdc42. 
(Baskaran, et.al. 2012 [28], used with permission). PAK4 is constitutively 
phosphorylated on Ser 474 (activation loop). In inactive conformation, the AID binds 
to the kinase domain and prevents access to substrate. Binding to the Cdc42.GTP 
induces kinase activation by dissociation of the AID from the kinase domain which 
allows to substrate binding.  
 
1.2.3 Expression pattern and subcellular localization of PAK5  
PAK4 is the first member of group II PAKs to be identified [32] and is the 
most investigated member of this group. PAK4 is a ubiquitously expressed protein 
[37] and has been implicated in many signalling pathways including reorganization of 
the actin cytoskeleton, cell migration and cell survival [12]. It drives the oncogenic 
transformation of cells and therefore involves in tumorigenesis [38-42]. PAK6 was 
identified as an androgen receptor (AR) interacting partner in yeast two hybrid assay 
[34]. Later, it was revealed that PAK6 can interact with both AR and estrogen 
receptor α (ER α) and inhibits their transcriptional activity independent of binding to 
RhoGTPases [43, 44]. Unlike PAK4, PAK6 has restricted expression pattern and is 
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mostly expressed in the brain, placenta, testis and prostate based on mRNA analysis 
data [9].  
PAK5, also sometimes named PAK7, was isolated and characterized by 
Pandey et al at 2002 [45]. The human PAK5 gene is located at 20p12 and is encoded 
by 12 exons. The protein is expressed only in vertebrates and unlike the ubiquitous 
PAK4 [32], its expression is limited to neuronal tissues however; northern blot 
analysis has been detected its mRNA expression in several tissues such as brain, eye, 
muscles, pancreas, adrenal gland, prostate, ovary and testis [33, 37, 46].  
PAK4 is highly expressed in the early stages of development and the 
expression is reduced in the adult tissues, therefore PAK4 is suggested to plays a key 
role in early development [47]. Loss of PAK4 is embryonic lethal due to defects in 
heart, however other abnormalities for example in the nervous system are reported as 
well [48]. In contrast, PAK5 and PAK6 are expressed in the brain later in 
development and they might be required for neuronal system maintenance. PAK5-null 
mice develop normally as has been reported for PAK6 knockout mice [46, 49]. 
Because both PAK5 and PAK6 are highly expressed in the brain, a functional 
redundancy is suggested between these two kinases. Although Pak5/Pak6 double 
knockout mice are also viable and fertile they have deficits in locomotive activity, as 
well as impaired learning and memory functions [49]. Primary cortical neurons from 
the double knockout mice have impaired neurite outgrowth. Thus, the decreased 
motor function in the Pak5/Pak6 KO mice likely results from decreased synaptic 
function among motor neurons. 
The subcellular localization of PAK5 is ambiguous. Similar to other members 
of group II PAKs, PAK5 has nuclear localization sequences (NLS) at N-terminal 
(amino acids 5-10) but the protein is exported from the nucleus to the cytoplasm by 
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the function of  nuclear export signal (NES) which is mapped in residues 400-411 [32, 
50]. Mitochondrial localization sequences have been mapped within the PAK5 N-
terminal and C-terminal and the protein is reported to localize on mitochondria by a 
number of studies [31, 50-52]. However, other studies have shown a dotted 
appearance of transiently expressed PAK5 in CHO cells and NIH-3T3 cells which is 
not associated with mitochondrial signal [53, 54].  
1.2.4 Phosphorylation targets of PAK5 
Group II PAKs kinases including PAK4-6, differ in structure and function 
from group I PAKs. Although the PBD and kinase domains are very well conserved 
in PAK4, 5 and 6, these domains are more diverged between the two groups [37]; 
therefore it is not unexpected that group I and II show different substrate specificity 
although there are some overlaps as well.  A few specific targets of PAK5 have been 
identified (Figure 1.5), however PAK5 likely shares many substrates in common with 




























Figure 1.5 Schematic diagram of the known targets of PAK5 
A few numbers of PAK5 interacting partners (or substrates) have been identifies that 
implicated the protein in some signalling pathways. Cdc42.GTP binds to PAK5 and 
may regulate PAK5 activity. MKK6 has also been reported to act upstream of PAK5 
and [36], however the in vivo effect is not clear [12].   
 
1.2.5 The role of PAK5 in cytoskeleton organization 
Rho small GTPases play a key role in the organization of the actin 
cytoskeleton [1] and PAKs , as a well-known effectors of these proteins, are 
implicated in this phenomenon. In contrast with PAK4, little is known about the 
PAK5 interplay with the actin cytoskeleton [12]. While PAK4 inhibits neurite 
outgrowth by activating LIMK which in turn deactivates Cofilin [55], over-expression 

























however the underlying mechanism is not understood. One suggestion is that PAK5 
acts through the inhibition of Rho-A [33] which, in turn, stimulates neuritis 
production in N1E115 cells [56, 57]; but PAK5 has not been shown to interact with 
any of the Rho-A GEFs. Instead, another study has shown that GEFT which is an 
activator of Rho, Rac and Cdc42 and is highly expressed in the brain, induces neurite 
outgrowth through the Rac-PAK5 pathway [58]. 
Furthermore, PAK5 has been implicated in microtubule stabilization via 
negative regulation of MARK-2 in non-neural cells [53]. PAK5 and MARK2 interact 
via their kinase domain and this interaction is independent of kinase activity of the 
two proteins. 
 
1.2.6 Group II PAKs and adherens junctions 
1.2.6.1 Background on adherens junctions 
The adherens junction is a cell-cell adhesion in which the neighbouring plasma 
membranes are bridged by transmembrane cell adhesion molecules. Adherens 
junctions localise to the basal side of tight junctions in mammalian cells and play an 
important role in regulating tissue formation and morphogenesis during development 
as well as maintaining the physical association between cells in adult organism [59, 
60].  Adherens junctions can involve typical cadherins (such as E-cadherin) or nectin 
which are different trans-membrane proteins. They mediate adhesive contacts through 
the extracellular region while their intracellular region interacts with the cytosolic 
proteins that connect them to the actin cytoskeleton (Figure 1.6). 
All 20 members of mammalian classical cadherins share a common domain 
structure: the extracellular region composed of five repeats called the EC 
(extracellular cadherin) domain that binds calcium. The adhesive function of cadherin 
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is dependent to its interaction with the calcium ions since this interaction is needed for 
conformational stability of the EC. Classical cadherins connect neighbouring cells 
through homophilic interactions of extracellular domains [61]. The cytoplasmic 
domain of classical cadherins interacts with two important catenins. Both beta-catenin 
and p120 catenin can bind simultaneously to cadherin 'tails'. The p120 catenin 
interacts with the juxta membrane domain of cadherin while β-catenin is associated 
with the carboxy terminal of the cytoplasmic domain [59, 60].  
Nectins are a family of four proteins with extracellular immunoglobulin 
related repeats. Nectins do not bind calcium and their interaction with the nectins of 
neighbouring cells can occur in either homophilic or heterophilic manner, though 
heterophilic interaction leads to stronger cell-cell adhesions [59]. The cytoplasmic 
domain of nectins bind an important adaptor called afadin, via its PDZ domain. 
Afadin also interacts with the small G-protein Rap1, and can interact with actin 
filaments [60]. Nectin and afadin complex may initiate adherens junction formation 






























Figure 1.6 Schematic diagram of key components of adherens junctions 
and tight junctions. (Adapted from the review by Kooistra, et al. 2007 [63]) 
 
1.2.6.2 Localization of group II PAKs at cell-cell junctions 
The association of group II PAKs with adherens junction has been shown. For 
example PAK4 is localized at cell-cell junctions of U2OS and MDCK cells in a 
Cdc42 dependent manner, where it plays role in cell polarity [64]. PAK6 forms a 
complex with IQGAP and E-cadherin at cell-cell contacts of DU145 cells, leads to 
disassembly of cell-cell junctions [65]. In addition, both PAK4 and PAK6 
phosphorylate Ser675 of β-catenin at cell-cell boundaries [62, 66]. P120-catenin has 
been reported as a binding partner and substrate for group II PAKs, although PAK5 
binding seems to be most efficient. Ectopic expression of PAK5 and p120 catenin in 


















catenin is a well-established component of adherence junction and regulates several 
processes such as cell adhesion, reorganization of the cytoskeleton and cell movement 
[67, 68]. Nucleocytoplasmic trafficking of p120-catenin plays role in gene expression 
[69].  
p120-catenin has four isoforms resulting from alternate translational start sites 
or post translational modifications [70]. The long isoform of p120-catenin is 
composed of four distinct functional regions, including a coiled-coil domain, a 
regulatory or phosphorylation domain, an armadillo domain containing ten armadillo 
repeats and a short C-terminal tail (Figure 1.7). The short isoform contains only the 
armadillo repeats and c-terminal tail. p120-catenin is ubiquitously expressed and 
despite the other members of the armadillo repeat proteins, it lacks the PDZ domain at 
C-terminal. P120-catenin interacts with cadherin and increases cadherin stabilization 
in cell surface by regulating endocytosis and degradation of this protein, thus 
increases cell adhesiveness. Furthermore, p120 regulates Rho family small GTPases 
signalling through different mechanisms: it binds to and suppresses RhoA activity; 
although different isoforms of p120 vary in this ability. The p120-RhoA interaction is 
further stabilized by p120 phosphorylation on Tyr217 and 228, or destabilized by its 
phosphorylation at Tyr 112. The other mechanism is through its association with Rho 
GAPs and Rho GEFs which leads to indirect regulation of downstream Rho GTP-
ases. For example p120 binding to Vav-2 activates Rac-1 and Cdc42. P120 and Rho 
GTPases signalling are involved in regulation of cell motility, however the function of 
p120 on regulation of Rho GTPases seems to be tissue dependent [70].   
 Besides its physiological function, p120 plays role in cancer progression and 
downregulation or mislocalization of p120 is shown in most of human cancers [70, 
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71]. For example translocation of p120-catenin from junctions to the cytoplasm or 
nucleus is observed in majority of breast cancers [72].   
 
 
               
 
Figure 1.7 Schematic overview of p120-catenin functional domain 
(Adapted from the review by Daniel. 2007 [69]). Armadillo domain is composed of ten 
42 amino acids armadillo repeats which mediate interaction with E-cadherin. The N-
terminal coiled domain is involved in protein-protein interactions. Asterisks represent 
phosphorylation domain involved in protein regulation.  
 
PAK5 has been shown to bind and phosphorylate p120 catenin mainly on 
Ser288; however the biological function of the PAK5-p120 complex has not been 
assigned. As mentioned above, p120 is complicated in cytoskeleton reorganization 
through inhibition of Rho-A [73-75] and overexpressed p120 induces dendrite-like 
processes in NIH-3T3 cells through the Rho-A inhibition [76]. On the other hand, 
PAK5 is also shown to inhibit Rho-A [33], although the underlying mechanism has 
not been completely understood. One suggestion is that p120 acts downstream of 















1.2.7 PAK5 and the regulation of apoptosis  
1.2.7.1 Background  
Apoptosis or programmed cell death is a physiological event which is applied 
for disposal of unwanted cells. It occurs as a normal process during development and 
aging and as a defence mechanism in a diseases condition [77]. Two major 
mechanisms of apoptosis have been identified including extrinsic or death receptor 
pathway and intrinsic or mitochondrial pathway [78] (Figure 1.8). The apoptosis 
mediated by the extrinsic pathway requires the binding of death receptor to the 
respective ligand on the cell surface. The death receptors are the members of the 
tumour necrosis factor (TNF) receptors family such as TNFR-1 and FasR that bind to 
their ligands TNF-α and FasL respectively. Ligand binding to its death receptor leads 
to recruitment of cytoplasmic adaptor proteins that are associated with the pro-
caspases such as pro-caspase 8 and 10, causing to formation of death-inducing 
signalling complex (DISC) that finally results to activation of caspase 3 [79]. The 
intrinsic pathway is activated by a variety of receptor-independent stimuli such as 
radiation or serum withdrawal that produce some intracellular signals. These signals 
mainly target the inner membrane of the mitochondria, leading to loss of the function 
of mitochondrial permeability transition (MPT) pore as well as mitochondrial trans-
membrane. This follows by release of pro-apoptotic proteins such as cytochrome c to 
the cytosol and subsequent formation of the 'apoptosome' that activates caspases such 
as caspase 9 and finally leads to the activation of caspase 3 [77, 79, 80]. Intrinsic and 
extrinsic pathways are linked and are concurrent in the same termination pathway 
which initiated with the cleavage of caspase 3. Caspase 3 cleavage subsequently leads 
to DNA fragmentation and cytoskeleton degradation.  
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The B-cell lymphoma-2 proteins (Bcl-2) family are a group of proteins 
involved in regulation of the intrinsic pathway by governing the permeabilization of 
mitochondrial outer membrane [81, 82]. They constitute BH (Bcl-2 homology) 
domains blocks and share homology in at least one of the four BH domains (Figure 
1.9). Bcl-2 family are basically divided to three groups based on the composition of 
homology domain. 1. The anti-apoptotic proteins such as Bcl-2 and Bcl-XL that 
possess four BH domains. 2. Pro-apoptotic members contain BH domain 1-3 
including Bax and Bak3. BH3 only domain proteins such as BAD, BID and BIM. 
Pro-apoptotic and anti-apoptotic members can form heterodimers and this interaction 
influences their function [83]. For example, heterodimerization of BH3-only protein 
BAD with Bcl-2, neutralizes anti-apoptotic function of Bcl-2.  Mutation of BH1, BH2 
and BH3 affect homo and hetero dimerization.  
Most members of Bcl-2 family contain a trans-membrane domain that seems 





Figure 1.8 Schematic overview of two main apoptotic pathways 
 (Taylor, et.al. 2008 [80]. Used with permission). Extrinsic pathway is activated by 
engagement of the death receptor to its ligand. This promotes recruitment of the Fas-
associated death domain protein (FADD) which in turn recruits and activates caspase 
8. Activated caspase 8 then activates caspase 3 and caspase 7 via proteolytic 
activity which finally leads to cell death. The extrinsic pathway can crosstalk with the 
intrinsic pathway through the proteolysis of BH3 only protein BID by caspase 8. 
Truncated BID (tBID) promotes release of mitochondrial cytochrome c. The intrinsic 
pathway is initiated by diverse receptor independent death signals such as serum 
withdrawal, which activates one or more BH3 only proteins. Activated BH3 only 
proteins can prevent anti-apoptotic activity of BCL-2 family members such as BCL-2. 
This promotes oligomerization of BAX and BAK proteins and formation of pores 
within the mitochondrial outer-membrane and releasing cytochrome c to the cytosol 
which promotes assembly of proteasome containing caspase 9. Caspase 9 can 






Figure 1.9 The Bcl-2 family of proteins 
(Danial NN. 2008 [85]. used with permission). Bcl-2 family members are divided to 
three groups based on the composition of the BH domains as indicated. They contain 
between 1-4 BH domains. Most of the members also contain trans-membrane 
domains (TM) and are therefore usually associated with the membrane. BH domains 
have crucial role for homo or hetero dimerization of the BCL-2 proteins.  
 
1.2.7.2 PAK5 plays a role in cell survival 
PAK family members are involved in apoptosis regulation through several 
pathways. There is evidence that PAK1, PAK2, PAK4, PAK5 and PAK6 promote cell 
survival [40, 52, 86, 87]. On the other hand, PAK2 is cleaved and activated by the 
caspase 3 activity during apoptosis and promotes certain morphological changes 
characteristic of apoptotic cells [88], therefore PAK2 is suggested to play antagonistic 
role in apoptosis [89]. One common pathway applied by PAKs to exert their role in 
cell survival is phosphorylation and inactivation of pro-apoptotic member of the BCL-
2 family, BAD. BAD triggers apoptosis by binding and neutralizing anti-apoptotic 
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partner BCL-2 which in turn promotes BAX-BAK oligomerization and formation of 
pore within mitochondrial outer membrane and release of cytochrome c [80]. The pro-
apoptotic function of BAD is latent until its activation. Phosphorylation by survival 
kinases inactivates BAD by promoting BAD interaction with 14-3-3 protein and thus 
its maintenance in the cytoplasm (Figure 1.10). Cytoplasmic BAD cannot bind and 
neutralize mitochondrial Bcl-2. BAD contains three major evolutionarily conserved 
serine residues S112, S136 and S155 (mouse BAD enumeration) and their 
phosphorylation regulates the anti-apoptotic activity of BAD [85].  To be inactivated, 
BAD requires phosphorylation in at least two of these residues.    
A sequential phosphorylation model has suggested in which Bad Ser136 is the 
apical phosphorylation site, leading to phosphorylation of Ser112 and Ser136 [90]. 
Phosphorylated Ser112 and Ser136 allow Bad to bind various isoforms of 14-3-3 [91]. 
A nearby site, Ser155, is located in the BH3 domain which interacts with the 
hydrophobic groove of anti-apoptotic partners like BCl-2. Ser155 phosphorylation can 
prevents this interaction, but may first require phosphorylation of Ser112 and 136 
[90]. This suggests that 14-3-3 binding to BAD induces conformational changes that 
expose Ser155 for phosphorylation. Binding to 14-3-3 also maintains BAD in the 
cytoplasm, so BAD phosphorylation not only influences its association with the 
mitochondrial partners, but also regulates its subcellular localization.  
Various kinases have been reported to phosphorylate BAD. AKT and p70S6 
target the Ser 136 residue [92, 93]. Ser 112 can be phosphorylated by different kinases 
such as protein kinase A (PKA), p90 ribosomal S6 kinase (p90RSK), Raf-1, PIM 
kinase and PAKs [86, 90, 94-97]. PKA and p90RSK are able to phosphorylate Ser155 
residue as well [98]. Unlike the survival effect of phosphorylated residues 112, 136 
and 155, phosphorylation of Ser128 abrogates 14-3-3 binding by interfering with 
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Ser136 phosphorylation. Cdc2 has been proposed to phosphorylate Ser128 of BAD 
and induces apoptosis in primary neurons [99].  
Group II PAKs directly phosphorylate BAD on Ser112, whereas this is mediates 
through activation of Raf-1 in group I PAKs (PAK1) [40, 52, 100].  PAK5 has been 
reported to phosphorylate BAD on Ser136 as well; however this might be an indirect 









Figure 1.10 schematic diagram of apoptosis regulation through the regulation 
of BAD phosphorylation.   
(Adapted from the review by Liu and Lin. 2005 [101] with some modifications). BAD 
contains three major conserved residues S112, S136 and S155 whose 
phosphorylation regulate pro-apoptotic effect of BAD. Phosphorylated BAD is bound 
to phospho-site adaptor protein 14-3-3 and retained in the cytoplasm. The de-
phosphorylation of BAD allows it to translocate to the mitochondria where it can form 
a complex with BCL-2 and Bcl-XL and finally leads to release of cytochrome c, thus 
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1.2.8 The role of PAK5 on MAPK pathway 
1.2.8.1 Overview of Raf-1 kinase  
The Raf family kinases act as an effectors of Ras to mediate the cellular effect 
of growth factor signals to their downstream effectors MEK and ERK to regulate 
some cellular processes such as cell proliferation, differentiation, apoptosis and 
migration (Figure 1.11).  The Raf family embraces three isoforms: A-Raf, B-Raf and 
C-Raf (Raf-1). Raf-1 is the most investigated isoform of this family, however despite 
the extensive studies; Raf-1 regulation seems a complex process that is not completely 
understood. Raf-1 contains three conserved regions (CR); CR1 comprises of Ras 
binding domain (RBS) and cysteine-rich domain (CRD), CR2 contains several 
Ser/Thr residues and CR3 that is the C-terminal kinase domain (Figure 1.12A). The 
Raf-1 C-terminal contains residues including Ser 491 and Thr 494 in activation loop 
and Ser338 and Tyr 341 near the kinase domain whose phosphorylations mostly 
stimulate Raf-1 activation [102, 103]. In contrast, most of the phosphorylated residues 
required for negative regulation of Raf-1 are located at the N-terminal. These residues 
comprising Ser43, 233 and 259 are phosphorylated by PKA or PKB to create 
additional sites for 14-3-3 binding [104, 105], as well as Ser 29, 43, 289, 296 and 301  
whose phosphorylation by ERK negatively regulate Raf-1 kinase activity [106]. The 
other ERK phosphorylation site, Ser 624, located at C-terminal. Negative regulation 
of Raf-1 by ERK phosphorylation suggests the existence of a negative regulatory 
feedback loop that is actually limiting the ERK activation in the cell.  
As illustrated in figure 1.12B, in the inactive conformation, Raf-1 is auto-
inhibited by binding of the N-terminal to the catalytic domain. 14-3-3 binding to the 
phosphorylated residues of the N-terminal and the C-terminal stabilizes this inactive 
conformation. The kinase activation of Raf-1 by growth factors requires 
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dephosphorylation of Ser259 by phosphatase PP2A and subsequent release of 14-3-3 
protein from the N-terminal which recruits Raf-1 to the membrane where it binds to 
active Ras and  becomes phosphorylated on at least four residues including Ser338, 
Tyr341, Ser491 and Thr494 [107-110]. Phosphorylation of these residues stabilizes 
the Raf-1 active conformation. [111]. Some recent papers have suggested Raf-1 
dimerization as a key part of activation. The mechanism is not clear but it is suggested 
that the active Ras induces Raf-1 dimerization through conformational changes. Raf-1 
dimerization then triggers trans-autophosphorylation of Ser338 that stabilizes Raf-1 
dimerization and its binding to the Ras.GTP [112, 113].  
A negative feedback loop terminates Raf-1 activation via phosphorylation of 
inhibitory residues by ERK and PKB (Figure 1.12B).  
 
1.2.8.2 PAK5 role on Raf-1 activation 
Serine residue 338 is one of the important regulatory residues as its 
phosphorylation has been proposed to be necessary for Raf-1 activity [114]. In 
addition to auto-phosphorylation of Ser338, other kinases have been shown to target 
this site. All the PAK isoforms have been reported to phosphorylate Raf-1 on Ser338; 
moreover, PAK1 and PAK5 have been shown to interact with and activate Raf-1 [51, 
115, 116]. The role of PAK4 in activating Raf-1 is not consistent; while one study has 
shown that PAK4 significantly activate Raf-1[116] another one has demonstrated that 
PAK5 is the only member of group II PAKs which is able to activate Raf-1 [51]. 
PAK1 and PAK5 are reported to translocate Raf-1 to the mitochondria. PAK1 kinase 
activity is required for interaction and translocation of Raf-1 to the mitochondria. 
Conversely, PAK5 interact with Raf-1 and translocate it to the mitochondria 
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independent of kinase activity [51, 117]. Mitochondrial Raf-1 is believed to protect 
cell from apoptosis either in a MEK dependent or MEK independent manner [117].  
Besides PAKs, calcium/calmodulin-dependent kinase II (CaMKII) has been 
reported to induce Raf-1 phosphorylation on Ser338 and subsequent activation in 
response to Ras activation [118].  
 
   






   
         
             
Figure 1.11 schematic of the classic MAPK kinase pathway 
 (Adapted from the review by Matallanas, et al. 2011 [109] with some modifications). 
Activated receptor tyrosine kinase (RTK) recruits GEF SOS to activate Ras protein. 
Ras-GTP binds to and phosphorylate and activate Raf. Activated Raf phosphorylates 
and activates MEK which in turn phosphorylates and activates the downstream 
effector ERK.  ERK has more than 150 substrates in the cytosol and nucleus; 
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Figure 1.12 Schematic overview of Raf-1 domains (A) and mechanism of 
regulation. (B). 
 A. (Adapted from a review from Baccarini. 2005 [111]). Raf-1 contains three 
conserved regions (CR); CR1, CR2 and CR3.  CR1 comprises of Ras binding 
domain (RBS) and cysteine-rich domain (CRD). CR2 contains several Ser/Thr 
residues that their phosphorylations negatively regulate Raf-1 activity (Red residues). 
CR3 is the C-terminal kinase domain and contains residues that their 
phosphorylation induces Raf-1 activity (Green residues). B. (Matallanas, et.al. 2011 
[109]. used with permission) Raf-1 phosphorylation on S259 and S621 stabilizes the 
inactive conformation of Raf-1 via binding to 14-3-3 protein in the cytosol of quiescent 
cells. Activated Ras recruits the inactive Raf-1 to the membrane where it is 
dephosphorylated on S259. This leads to the release of intermolecular bridge of 14-
3-3 protein. Subsequent phosphorylation on activation loop and C-terminal residues 
promotes Raf-1 homo-dimerization or hetero-dimerization (with B-Raf), leading to the 
full activation of Raf-1. Deactivation is initiated by de-phosphorylation of S338 as well 
as ERK-mediated negative feedback phosphorylation, which in turn leads to re-
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1.2.9 The role of PAK5 on cancer progression 
Enhanced cell proliferation, cell survival and motility are the important 
hallmarks of cancers. Since PAKs are involved in a number of oncogenic signalling 
pathways, they are widely considered as promoters of cancer progression. Among the 
group II PAKs, the importance of PAK4 in cancer development is well established 
[119-121]. PAK4 has the potential of cell transformation and its over-expression 
promotes anchorage independent of cell growth [122]. Moreover, PAK4 mRNA has 
been up-regulated in many types of cancers including breast, ovarian, colon, lung and 
skin. PAK4 plays role in migration and invasion of several types of cancer cells such 
as prostate and pancreatic cancer cells [47, 89, 123]. Up-regulation of PAK6 protein 
has been demonstrated in some prostate and breast cancer cell lines as well as the 
clinical samples from the patients with hepatocellular carcinoma [124, 125]. Down 
regulation of PAK6 in prostate cancer cell lines decreases cell proliferation and 
enhances sensitivity to the Docetaxel [126]. In lung cancer, high expression of PAK6 
is correlated with the poor survival of the patients [124].  
In recent years, PAK5 has also been implicated in progression of several types 
of cancers. One study indicates that among all the kinases, knockdown of PAK5 has 
the most effect on apoptosis induction of pancreatic cancer cell lines MiaPaCa-2 and 
another study by the same group shows that the combined inhibition of both PAK5 
and MAP3K7 slows down pancreatic adenocarcinoma progression in a mouse 
xenograft model [127, 128]. A gain of function mutation (GOF) in Tyr 538 (T538N) 
of PAK5 has been reported in lung cancer cell lines H2087 and H157. Overexpression 
of this mutated form of PAK5 increases Raf-1 and ERK phosphorylation versus the 
wild type protein. Consistent with this result, PAK5 suppression reduced cell 
proliferation and induced apoptosis in H2087 cells line [129].  
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High expression of PAK5 is contributed to development of colorectal cancer, 
breast cancer, ovarian cancer, osteosarcoma, and glioma [130-134] as well as 
resistance to Camptothecin and Paclitaxel treatment of colorectal and ovarian cancers 
respectively [132, 135].  
The mechanism underlying PAK5 role in cancer progression has not been 
investigated in details. Abolished expression of PAK5 in gastric cancer cell lines 
SGC-7901 and MGC-803 induced cell cycle arrest in G0/G1 phase which was in 
concordance with the down regulation of cell cycle’s regulator CDK2, CDC25A and 
cyclin D1; however the underlying molecular mechanism is yet to be addressed [136]. 
Similar to gastric cancer, PAK5 suppression in glioma cell lines U87 and U251 leads 
to G0/G1 cell cycle arrest as well as down regulation of cyclin D1 and increased 
expression of p21 [134].  
PAK5 up-regulation has been shown to increase cell migration through the 
PAK5-Egr1-MMP2 pathway in glioma and breast cancer cells [131, 134]. MMp2 is a 
matrix metalloproteinase that is involved in breakdown of extracellular matrix. MMp2 
activity is inhibited by binding of the transcription factor Egr1 to its promoter [137]. 
Egr1 expression is increased in glioma and breast cancer cells upon PAK5 
suppression. 
Two recent studies indicate the PAK5 role in epithelial-mesenchymal 
transition (EMT) through phosphorylation of cadherin transcriptional repressors E47 
and GATA1 in colon cancer and breast cancer respectively. EMT is involved in 
cancer metastasis which is characterized by the reduced expression of components of 
cell-cell adhesions such as cadherin.  
Under HGF (hepatocytes growth factor) stimulation, PAK5 phosphorylates 
E47 on Ser39. This phosphorylation increased cell migration and invasion in vitro and 
28 
 
promoted metastasis in colon cancer xenograft mice. Ser39 phosphorylation of E47 is 
shown to induce nuclear accumulation of E47 and its subsequent effect on cadherin 
suppression [138].  
Another study showed that GATA1 acts as a suppressor of E-cadherin. PAK5 
mediated phosphorylation of GATA1 decreased cadherin expression in breast cancer 
cells and induced cell migration in vivo [139].  
1.2.10 PAK5 role in neuronal vesicle trafficking 
PAK5 has been implicated in synaptic vesicle trafficking by binding to and 
phosphorylating the proteins synaptojanin-1 and pacsin-1 [140]. These two proteins 
were identified as PAK5 interacting partners in the murine brain extract using yeast 
two hybrid assay and indeed, they are the specific substrates for group II PAKs. 
Synaptojanin has phosphatase activity and dephosphorylates phosphatidylinositol 4,5-
bisphosphate (PIP2) that is required for un-coating and recycling of the synaptic 
vesicles [141]. Pacsin-1 is the brain specific isoform of pacsin family which plays role 
in endocytosis and vesicle trafficking. Pacsin-1 binds to proline rich domain of 
synaptojanin via its C-terminal SH3 domain and this interaction regulates vesicle 
dynamics at the synapse. Pacsin-1 and Synaptojanin phosphorylation by PAK5 
promotes their interaction in vitro and in vivo. This role of PAK5 is contributed to the 
PAK5/PAK6 knockout mice phenotype which shows cognitive deficits.  
 
1.3 Overview of the LZTS family   
The leucine zipper tumor suppressor (LZTS) proteins family is a group of 
related proteins termed LZTS1 (FEZ1), LZTS2 (LAPSER1) and LZTS3 
(ProSAPiP1). Mapped on human chromosomal region 8p22, LZTS1 was the first 
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member of this group to be identified that is ubiquitously expressed in normal tissues 
[142]. LZTS1 plays an important role in tumor suppression and its deletion 
significantly increases the rate of spontaneous or carcinogen induced tumors [143]. 
LZTS1 chromosomal region is frequently deleted and protein expression is reduced in 
human tumors [144].  
LZTS2, named also LAPSER1, was identified based on homology with 
LZTS1 gene [145]. It is located on human chromosome 10q24.3 near the PTEN gene 
and its deletion has been reported in various cancers [145]. LZTS2 contains three 
leucine zipper motifs at the C-terminal responsible for interaction with other proteins. 
The protein is ubiquitously expressed and high expression has been detected in 
prostate and testis. Northern blot analysis demonstrated the expression of multiple 
isoforms of LZTS2 that are differentially expressed in different tissues and cell lines 
[145]. LZTS2 expression is suggested to be regulated by NF-κB. Indeed, NF-κB 
directly binds to the LZTS2 promoter and regulates its transcription but this regulation 
differs among different cell lines. This might be the results of NF-κB interaction with 
different transcriptional co-regulators in different cell lines [146]. 
LZTS3 is the less investigated member of LZTS family which is 
predominantly expressed in the brain and kidney [147]. 
1.3.1 The role of LZTS2 on tumour suppression 
The sequences alignment of LZTS1 and LZTS2 shows significant conserved 
sequences in these proteins suggesting that they are functionally similar (Figure 1.13). 
Since LZTS1 is known as a tumour suppressor gene, several studies investigated the 
importance of LZTS2 as a tumour suppressor. The results of one study showed that 
overexpression of LZTS2 in several cell lines including human and Rat cancer cell 
lines slows down cell growth and its down regulation increases cell proliferation 
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[145]. Another study revealed that LZTS2 negatively regulates Wnt signalling 
pathway through modulating β-catenin localization [148]. They demonstrated that 
endogenous LZTS2 directly binds to β-catenin in colorectal cancer cell line SW480 
and prevents nuclear accumulation of β-catenin, thereby repressing β-catenin 
mediated transcription. In neurons, LZTS2 targets to the post synaptic compartment 
via its interaction with the PDZ domain of ProSAP-Shank proteins. In this 
compartment LZTS2 interacts directly with β-catenin and regulates nuclear 
translocation and export of β-catenin in response to N-methyl-D-aspartate (NMDA) 
[149]. However, the interaction of LZTS2 and β-catenin was not observed in lung 
cancer cell lines H1299 and A549, though overexpression of LZTS2 reduced the rate 
of cell proliferation in these cell lines. [150]. LZTS2 was shown to negatively regulate 
AKT phosphorylation in these cells which could enhance the ability of Gsk3β to 
phosphorylate and promote β-catenin degradation (Figure 1.14).  
In addition, LZTS2 mediates the crosstalk of β-catenin/Tcf and NF-κB 
pathways, however the effect differs in various cell lines [151]. LZTS2 inhibition 
consistently promotes β-catenin/Tcf pathway in various cancer cells but its 
suppression inhibits NF-κB activation in breast, colon and prostate cancers whereas 
increases it in glioma. This suggests that LZTS2 expression modulates tumorigenicity 
differently in different cell lines. However, it has been shown that LZTS2 repression 
increases tumour volume regardless of its effect on NF-κB activity in nude mice 
subcutaneously injected with colon cancer, prostate cancer or glioma cells [146]. 
Therefore, the function of LZTS2 on NF-κB pathway is ambiguous.  
LZTS2 deficient mice are susceptible to spontaneous and carcinogen induced 
tumour development [152]. However, compared to LZTS1, LZTS2 knockout induces 
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lower rate of tumorigenicity. This suggests that additional genetic or epi-genetics 
changes are required to drive LZTS2 mediated tumorigenesis.  
 
hLZTS1 -------------------------MGSVSSLISGHSFHSKHCRASQYKL 25 
hLZTS2 MAIVQTLPVPLEPAPEAATAPQAPVMGSVSSLISGRPCPGGPAPPRHHGP 50 
                                **********:.  .  . . ::   
 
hLZTS1 RKSSHLKKLNRYSDGLLRFGFSQDSGHGKSSSKMGKSEDFFYIKVSQKAR 75 
hLZTS2 PGPTFFRQQ----DGLLRGGYEAQEPLCPAVPPRKAVPVTSFTYINEDFR 96 
         .:.:::     ***** *:. :.    : .         :  :.:. * 
 
hLZTS1 GSHHPDYTALSSGDLGGQAGVDFDPSTPPKLMPFSNQLEMGSEKGAVRPT 125 
hLZTS2 TESPPSPSSDVEDAREQRAHNAHLRGPPPKLIPVSGKLEKNMEKILIRPT 146 
        .  *. ::  ..    :*   .  ..****:*.*.:** . **  :*** 
 
hLZTS1 AFKPVLPRSG------------------------AILHSSPESASHQLHP 151 
hLZTS2 AFKPVLPKPRGAPSLPSFMGPRATGLSGSQGSLTQLFGGPASSSSSSSSS 196 
       *******:.                          :: ....*:* .  . 
 
hLZTS1 APPDKPKEQE-LKPGLCSGALSDSGRNSMSSLPTHSTSSSYQLDPLVTPV 200 
hLZTS2 SAADKPLAFSGWASGCPSGTLSDSGRNSLSSLPTYSTGGAEPTTSSPGGH 246 
       :..***   .   .*  **:********:*****:**..:    .      
 
hLZTS1 GPTSRFG-----GSAHNITQGIVLQDSNMMSLKALSFSDGGSKLG----- 240 
hLZTS2 LPSHGSGRGALPGPARGVPTGPSHSDSGRSSSSKSTGSLGGRVAGGLLGS 296 
        *:   *     *.*:.:. *   .**.  * .  : * **   *      
  
hLZTS1 -------HSNKADKGPSCVRSPISTDECSIQELEQKLLEREGALQKLQRS 283 
hLZTS2 GTRASPDSSSCGERSPPPPPPPPSDEALLHCVLEGKLRDREAELQQLRDS 346 
               *. .::.*.   .* * :      ** ** :**. **:*: * 
 
hLZTS1 FEEKELASSLAYEERPRRCRDELEGPEPKGGNKLKQASQKSQRAQQVLHL 333 
hLZTS2 LDENEATMCQAYEERQRHWQREREALR----EDCAAQAQRAQRAQQLLQL 392 
       ::*:* : . ***** *: : * *. .    :.    :*::*****:*:* 
 
hLZTS1 QVLQLQQEKRQLRQELESLMKEQDLLETKLRSYEREKTSFGPALEETQWE 383 
hLZTS2 QVFQLQQEKRQLQDDFAQLLQEREQLERRCATLEREQRELGPRLEETKWE 442 
       **:*********:::: .*::*:: ** :  : ***: .:** ****:** 
 
hLZTS1 VCQKSGEISLLKQQLKESQTEVNAKASEILGLKAQLKDTRGKLEGLELRT 433 
hLZTS2 VCQKSGEISLLKQQLKESQAELVQKGSELVALRVALREARATLRVSEGRA 492 
       *******************:*:  *.**::.*:. *:::*..*.  * *: 
 
hLZTS1 QDLEGALRTKGLELEVCENELQRKKNEAELLREKVNLLEQELQELRAQAA 483 
hLZTS2 RGLQEAARARELELEACSQELQRHRQEAEQLREKAGQLDAEAAGLREPPV 542 
       :.*: * *:: ****.*.:****:::*** ****.. *: *   **  .. 
 
hLZTS1 LARDMGPPTFPEDVPALQR------------ELERLRAELREERQGHDQM 521 
hLZTS2 PPATADPFLLAESDEAKVQRAAAGVGGSLRAQVERLRVELQRERRRGEEQ 592 
        .   .*  :.*.  *  :            ::****.**:.**:  ::  
 
hLZTS1 SSGFQHERLVWKEEKEKVIQYQKQLQQSYVAMYQRNQRLEKALQQLARGD 571 
hLZTS2 RDSFEGERLAWQAEKEQVIRYQKQLQHNYIQMYRRNRQLEQELQQLSLEL 642 
        ..*: ***.*: ***:**:******:.*: **:**::**: ****:    
 
hLZTS1 SAGEPLEVDLEGAD--IPYEDIIATEI 596 
hLZTS2 EARELADLGLAEQAPCICLEEITATEI 669 
       .* *  ::.*      *  *:* **** 
 
 
Figure 1.13 ClustalW sequence alignment of human LZTS1 and LZTS2  
 ClustalW alignment depicts significant conserved sequences in LZTS1 and LZTS2. 
Asterisks show the identical sequences and dots indicate the conservative amino 




















Figure 1.14 Schematic view of LZTS2 mediated regulation of β-catenin/Tcf 
pathway 
 (Adapted from van wauwe and Haefner. 2003 [153]. with some modifications). In 
resting cells, β-catenin is targeted for ubiquitination and degradation through 
formation of the destruction complex. Destruction complex including 
APC/Axin/GSK3β binds to β-catenin and leads to phosphorylation of β-catenin by 
GSK3β and subsequent degradation. In stimulated cells, Wnt binding to its receptor 
disrupts degradation complex and prevents β-catenin degradation. Thus, β-catenin 
accumulates in the nucleus and drives its transcriptional activity by binding to 
transcription factor TCF/LEF. LZTS2 interferes with β-catenin function via two 
reported mechanisms: 1. LZTS2 binds to β-catenin and exports it to the cytoplasm 
through CRM1/exportin-regulated NES sequences located at the C terminus of the 
LZTS2. Thus, LZTS2 prevents β-catenin accumulation in the nucleus. 2. LZTS2 
prevents AKT mediated accumulation of β-catenin in the nucleus. Activated AKT 
leads to phosphorylation and inactivation of GSK3β and subsequent accumulation of 
β-catenin in the nucleus. LZTS2 has been suggested to negatively regulate AKT 
activity via an unknown mechanism and prevents β-catenin mediated transcriptional 

































1.3.2 LZTS2 and regulation of the cytoskeleton 
A previous study has shown that LZTS2 localizes in either centrosome or 
midbody of osteosarcoma cell line Saos-2 depending to the cell cycle phase [154]. 
During interphase, metaphase and anaphase, LZTS2 co-localizes with γ-tubulin in the 
centrosome and then translocates to the centre of the mid-body during cytokinesis. 
Ectopic expression of LZTS2 abrogates central spindle formation during cytokinesis 
and induces bi-nucleation in Saos-2 cells [154]. This effect is the consequence of 
LZTS2 interaction with the microtubule severing protein katanin.  
Katanin is composed of two subunits: 1. Catalytic P60 subunit (P60 katanin) 
and regulatory P80 subunit (P80 katanin). P80 katnin enhances the P60 severing 
activity [155, 156]. P80 Katanin localizes in the centrosome in prometa/metaphase 
and in the mid body during cytokinesis. LZTS2 has been shown to interact with the 
P80 katanin via its C-terminal and inhibits severing activity of the katanin, therefore 
LZTS2 disrupts central spindle formation which leads to bi-nucleation [157]. This is 
contributed to the tumour suppression activity of LZTS2, because bi-nucleated cells 
have the reduced ability of proliferation.  
An shRNA screen suggested that LZTS2 knockdown decreases cell survival 
and sensitizes A549 cell line to paclitaxel treatment [158]. In agreement with this 
result, another study has shown that stable expression of LZTS2 in Rat-1 cells 
decreases sensitivity to the paclitaxel. This effect is contributed to the LZTS2 
induced-cell arrest in prophase which prevents cells from entering into the metaphase 






1.3.3 LZT2 and cell migration 
LZTS2 suppression increases cell migration in Rat-1 and SaOs-2 cells [157]. 
LZTS2 is suggested to negatively regulate cell migration through inhibition of katanin 
mediated microtubule severing [157] because inhibition of microtubule dynamics 
attenuates cell migration [159]. These results are controversial because wound healing 
assay in breast cancer, colon cancer and glioma cell lines showed that LZTS2 
expression has no effect on cell migration [146],  
 
1.3.4 The role of LZTS2 in development 
LZTS2 and LZTS1 are expressed in mice embryo at stage E9.5 and E11.5 
respectively [160]. LZTS2 knockout mice show sever defects in kidney and urinary 
tract development such as renal/ureteral duplication, hydroureter and hydronephrosis 
[160]. Such a defects are very similar to the abnormalities detected in β-catenin loss 
of functions or gain of functions mutations [161]. LZTS2 is expressed in ureteric bud 
and developing nephron structure which is similar to the expression pattern of β-
catenin. This suggests that LZTS2 acts as a β-catenin regulator in nephrogenesis. In 
addition, β-catenin subcellular localization is affected in LZTS2 null mice. In wild 
type kidney, β-catenin is expressed in the cell junctions of the collecting duct 
epithelium as well as basolateral side of the renal tubule epithelium, while β-catenin is 
mainly cytoplasmic in LZTS2 null mice [160].  
LZTS2 has also been implicated in PSD (post synaptic density) through 
interaction with the ProSAP/Shank family [162]. One study demonstrated the spatio-
temporal expression of ProSAP/Shank family during xenopus laveis development and 
highlighted the similar expression pattern of LZTS2. They showed the co-localization 
of LZTS2 with the all three members of proSAP/Shank family when they were 
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overexpressed in COS-7 cells.  Co-expression of LZTS2 with ProSAP/Shank family 
in forebrain, isthmus, nerves, Hypochord, Somites, pronephros and proctodeum 
suggests that LZTS2 plays role in PSD formation as well as embryonic development 
in xenopus laveis. [161]. Nevertheless, the function of the interplay of LZTS2 with 
ProSAP/Shank family members has not been investigated.  
 LZTS2 is required for the specification of organ precursors of heart, pancreas 
and liver in zebrafish and negatively regulates the midline convergence. LZTS2 exerts 
this function through direct interaction with β-catenin and regulation of several 
marker genes that are implicated in regulation of convergence and extension 
movements in zebrafish [163].  
 
1.4 Aims of the study 
The identification of a conserved auto-inhibitory domain (AID) in group II PAKs 
(isoforms 4-6) uncovered the mechanism of regulation of this group by the polarity 
protein Cdc42 [28, 29]. However, an outstanding question regarding PAK5 (and 
PAK6) remained - why is PAK5 then constitutively active?  Since its discovery in 
2002, it was clear that PAK5 has much higher activity relative to PAK4 when isolated 
from mammalian cells whether or not it was bound to Cdc42 [33].  One object of my 
study was to identify the differences between the regulation of PAK4 and PAK5, and 
the mechanisms that are responsible for human PAK5 being basally active.  
 PAK5 is predominantly expressed in the brain:  knockout studies in mice 
suggested it acts in a redundant pathway with PAK6 in brain development [49]. The 
kinase has received more attention because PAK5 is linked to cancer progression in a 
variety of situations [130-132, 135], however the basis for such activities are unclear. 
One reason is that a few targets of PAK5 have been discovered. These targets are 
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likely to overlap with PAK4 given the high degree of conservation in the kinase 
domain [37].  In order to find valid kinase target for PAK5, I have sought to identify 
proteins which are closely associated with PAK5 in cancer cells. By identifying such 
a network it should now be possible to establish the protein network acting 


















Chapter 2: Materials and methods 
 
2.1 Materials 
2.1.1 Plasmids and siRNAs  
The pXJ-40 mammalian expression vector [164] was applied as the base 
vector for generation of most of the constructs. The vector contains a CMV promoter 
and Amp
R 
gene with N-terminal Flag, HA, GST and GFP tag. Furthermore, pXJ-GFP-
BirA
* 
containing the mutated version of biotin ligase gene (R118G) was utilized to 
generate pXJ-GFP-BirA
* 
-PAK5 that used for the BioID assay and GFP-pull down 
analysis. The pBABE.puro and pSUPER.neo contains puromycin and neomycin 
resistance genes respectively and were co-transfected with the target gen for 
establishing stable lines. The pGEX4T1 (GE Healthcare) was used for bacterial 
expression. 
Smart-pool human PAK5 siRNA was purchased from Dharmacon. In other 
cases, the siRNAs (Table 2.1) were designed by siRNA design tool from Dharmacon 
(http://dharmacon.gelifesciences.com/design-center). The oligos were synthesized by 
Sigma.   
Table 2.1 List of siRNAs 
siRNA Sequences (5'-3'), Sense 
siLZTS2-ORF CAACCUGUGGUCCAUAAACAAUU 
siLZTS2-3' UTR-1 CAAAGGAAGAACYCAGAAAUU 





2.1.2 Antibodies and reagents 
Mouse monoclonal and rabbit polyclonal antibodies against Flag and HA were 
from Sigma. Mouse anti GFP obtained from Santa Cruz and rabbit GFP was from 
Invitrogen. Mouse and rabbit anti GST obtained from Santa Cruz. Mouse monoclonal 
anti-Raf-1 and anti-p120 antibodies were from Upstate and Santa Cruz respectively. 
Rabbit poly-clonal antibodies against phosphoS338 Raf-1, p44/42 ERK and BAD 
were purchased from Cell Signaling. The rabbit polyclonal antibodies against 
phosphoS112-BAD and phosphoS474, phosphoS602, phosphoS560 of PAK4/5/6 
were from Epitomics. The anti-LZTS2 and anti-afadin rabbit polyclonal antibodies 
were from Protein Tech Group and Sigma Respectively. Secondary horse radish 
peroxidase conjugated antibodies were from Dako.   
Restriction enzymes and DpnI were obtained from NEB. PFU enzyme was 
from Promega and T4 ligase from Thermo Scientific.  
The PKA inhibitor (H89), pan Raf inhibitor (TAK-632) and Akt inhibitor 
(MK-2206) purchased from “Selleck Chemicals”. PI3 kinase inhibitor (LY 294002) 
obtained from “Calbiochem”.  
Puromycin and neomycin were obtained from Sigma.  
2.2 DNA manipulation methods 
2.2.1 Plasmid DNA purification 
Plasmid DNA was extracted from transformed bacterial pellet using the 
QIAprep (QIAGEN) columns according to the manufacture’s protocol. Briefly, the 
bacterial cells were lysed under alkaline condition and the released DNA was 
adsorbed on a silica matrix of the provided column under high salt conditions. DNA 
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washed with ethanol and then recovered from the column by elution in low salt buffer 
TE. 
2.2.2 Polymerase Chain Reaction (PCR) and gel electrophoresis 
The standard PCR reaction mixture was provided as following: 
10X PFU buffer+MgCl2 5μl (1X) 
dNTP Mix  200μM 
Foreword and reverse primers 0.5μM 
Template DNA 0.1μg 
PFU 1U 
Distilled water Up to 50μl 
 
The standard PCR performed in these conditions: 
Step Temperature 
(°C) 
Time (min) Number of cycles 
Initial denaturation 95 2 1 
Denaturation 95 0.5-1  
25-30 Annealing Tm-5 0.5-1 
Extension 72 2min/kb 
Final extension 72 10 1 
 
Quick-change (QIAGEN) PCR performed in these conditions: 
Step Temperature 
(°C) 
Time (min) Number of cycles 
Initial denaturation 95 5 1 
Denaturation 95 1  
20 Annealing 55 1 
Extension 68 1.5min/kb 
Final extension 68 10 1 
 
After PCR, the samples were subjected to agarose gel electrophoresis. DNA 
was separated on an agarose gels (1-1.5% w/v) containing ethidium bromide 
(0.5μg/ml) or gel green (1/10000v/v) by electrophoresis in TAE buffer and the 
separated bands were visualized by UV illumination. Electrophoresis was carried out 
at a constant voltage of 90-110 V for 1-1/5 h. 
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Quick-change PCR with 50 µl reactions was followed by DpnI digestion. 10 
units of DpnI enzyme was added to 25μl of PCR sample and incubated in 37°C for 
1h. 10μl of sample was used to transform 50μl of competent cells.  
2.2.3 Preparation of competent cells for transformation via heat shock method 
E.coli strains XL-1 Blue and BL-21 were used for DNA amplification and 
protein production respectively. A single fresh colony of E.coli was inoculated in 10 
ml of LB agar and incubated in 37°C for overnight. The following day, the starter 
culture was diluted in 400 ml of LB media and incubated in shaker incubator at 37°C 
for around 2h till the OD600 reached to 0.4-0.6. The cells were collected with 
centrifugation at 2500 rpm for 15 min at 4°C and re-suspended in 60 ml of ice-cold 
CCMB and incubated on ice for 20 min. The cells were recovered by centrifugation 
and re-suspended in 16 ml of CCMB buffer and aliquoted into 1.5ml Eppendorf tubes 
and stored at -80°C.  
For DNA transformation, the frozen competent cells were thawed on ice and 
then mixed with the either plasmid DNA or ligated DNA reaction and incubated on 
ice for 10 minutes. The cells were heat shocked by incubating at 42 °C for 90s 
followed by chilling in 4 °C for 5 minutes. Transformed cells then were grown in LB 
media for 1h at 37°C and then plated on LB agar supplemented with the appropriate 
antibiotics. 
2.2.4 Cloning 
To clone a gene of interest in a plasmid with particular restriction sites, the 
gene was amplified using primers containing the sequence of suitable restriction 
enzymes. This allows adding the desired restriction sites to flank the insert. The PCR 
products as well as recipient plasmid were digested with appropriate restriction 
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enzymes for 2-4h at 37 °C. Digested samples were run in an agarose gel (0.5 -1.0%) 
electrophoresis and the band of the correct size was excised and the DNA was 
recovered using QIAquick gel extraction kit according to the manufacture’s protocol. 
The concentration of purified plasmid and insert were calculated by NanoDrop 1000 
and a molar ratio of 1:3 or 1:5 of vector to insert was used in a 10μl of ligation 
mixture containing T4 DNA ligase buffer and T4 ligase (New England BioLabs) and 
incubated overnight at 16 °C for ligation.  
The following day, 5-7μl of ligation mixture was transformed to the E.coli 
XL-1Blue via heat shock method and then plated in LB agar containing Ampicillin 
(100μg/ml). The plate was then incubated in 37 °C for overnight and the next day 10-
15 colonies were selected and inoculated in LB media containing 100μg/ml of 
ampicillin. After overnight growing of bacteria in shaker incubator at 37 °C, the 
plasmids were purified after recovering the cells with centrifugation. Purified 
plasmids were subjected to digestion with the same restriction enzyme and the 
products were analyzed with gel electrophoresis to observe whether gene of interest 
ligated to the recipient plasmid.  
To confirm the success of ligation and assess the accuracy of manipulated 
gene of interest, DNA sequencing was performed using a primer flanking the 5’ or 3’ 
end of the insert in a mixture containing BigDye (composed of DNA polymerase and 
tagged nucleotides) and the purified plasmid. The reaction was performed as 
following:  
step Temperature (°C) Time (second) cycle 
1 96 30 1 
2 96 10 
 
30 
3 50 5 
4 60 240 (4 mins) 
5 4   
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2.3 Protein analysis methods 
2.3.1 SDS polyacrylamide gel electrophoresis (SDS-PAGE) 
8-12% acrylamide gel were prepared in mini gel cast and used for protein 
electrophoresis in BioRad mini-protean system. Protein samples mixed with the SDS 
sample buffer before loading. Electrophoresis was performed in SDS Running buffer 
at a constant voltage of 100-120 V for 1-2h.  
2.3.2 Western blotting 
SDS-PAGE separated proteins were transferred to PVDF membrane using 
tank blotting or BioRad semi-dry trans-blotting system. In most cases the membrane 
was stained in 0.05% Coomassie Blue before pre-blocked with 5% milk for 30 
minutes. The membrane then was incubated with diluted primary antibody (1/100-
1/5000 dilution from 1mg/ml stock solution) in 3% milk or 1% BSA/PBS(or TBS) for 
1-2h at room temperature or overnight at 4 °C and then washed 3 times in 0.1% 
Tween 20/PBS (or TBS) for 30 minutes. The membrane was then incubated with 
diluted horse radish peroxidase (HRP) conjugated secondary antibody for 30-45 
minutes. After washing the membrane for 20-30 minutes, signals were visualized with 
enhanced chemiluminescence reagents.  
2.3.3 Expression and purification of bacterial expressed recombinant proteins 
Bacterial expression vector pGEX4T1 containing the gene of interest was 
transfected into E.coli BL-21. A fresh single colony of recombinant bacteria was 
inoculated in 10ml of LB media containing 100μg/ml ampicillin and incubated 
overnight at 37 °C. The following day, the starter culture was diluted in 200ml of LB 
containing ampicillin and incubated in 37 °C till the OD 600 was 0.6. The culture was 
then induced with 0.5mM IPTG for 5h at room temperature. Cells were pelleted by 
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centrifugation at 4000 rpm for 20 minutes and re-suspended in ice-chilled bacterial 
lysis buffer contains lysozyme and allowed to equilibrate for 10 minutes on ice. The 
samples were then sonicated at 4°C in a triple cycle of 20 seconds pulse and 10 
seconds interval and centrifuged at 35000rpm for 30 minutes at 4 °C. Clarified lysate 
was passed through the glutathione Sepharose beads column to purify GST tagged 
protein. The protein was then eluted using reduced glutathione containing buffer. 
2.3.4 Antibody production 
Two polypeptides were chosen from N-terminal (amino acids 7-15) and 
central region (amino acids 142-159) of PAK5. The synthesized peptides (Genemed) 
used as a source of antigen for production of polyclonal rabbit antibodies (Genemed). 
The crude sera were obtained and affinity purification was performed to gain the 
purified antibody against PAK5.   
2.3.4.1 Coupling peptide to Cyanogen Bromide-Activated agarose for Antibody 
purification 
Cyanogen bromide-activated resin was used for coupling to peptide according 
to the manufacture’s protocol. Briefly, 2 mg of peptide was dissolved in coupling 
buffer. Cyanogen bromide-activated resin was swelled and washed in cold 1mM HCl 
for 30 minutes, followed by washing with distilled water and then equilibrating with 
coupling buffer. The resin was mixed with dissolved peptide immediately and 
incubated at 4 °C overnight. The next day, un-reacted ligand was washed away using 
coupling buffer before blocking the resin with 0.2M glycine for 2 hours. The resin 




2.3.4.2 Affinity purification of antibody 
5 ml of serum was centrifuged for 5 minutes at 13000 rpm, the supernatant 
then diluted with 5 ml of PBS and pre-cleared by rolling with Sepharose 4B beads for 
1h at 4ºC. The serum passed through the column to remove the beads and flow 
through was collected. 500μl of peptide coupled resin was added to the serum and 
rolled at 4°C overnight. The suspension was passed through the column and washed 
with 5ml of cold PBS. Four tubes of 15 ml conical tubes were prepared by adding 30 
μl of 1M Tris Ph 8.5 to the first tube and 50 μl to tubes 2-4. 500 μl of elution buffer 
added to column and flow through was collected in tube 1. This step was repeated for 
the tubes 2-4 very quickly. Then the pH of the collected fractions was checked by 
litmus paper. The ideal pH should be around 7-8. The specificity and sensitivity of the 
purified fractions of antibody were analyzed using Western blotting and antibodies 
with good immune-reactivity were mixed with 30-40% glycerol and kept in -20°C. 
2.4 Cell culture techniques and manipulations 
2.4.1 Cell culture 
COS-7, HEK-293, MDCK and U2OS cells were grown in Dulbecco’s 
modified eagle’s medium (DMEM) supplemented with 10% fetal bovine serum (FBS) 
and penicillin-streptomycin (100I.U/ml and 100μg/ml respectively) (Pen Strep). HeLa 
cells were grown in DMEM supplemented with L-glutamine (2mM), sodium pyruvate 
(1mM), sodium bicarbonate (1.5g/liter), non-essential amino acids (1X from 100X 
stock), FBS and Pen Strep. NCI-H446 cells were grown in RPMI 1640 medium 
supplemented with D-glucose (4.5g/liter), L-glutamine (2mM), Sodium pyruvate 
(1mM), sodium bicarbonate (1.5g/liter), FBS (10%) and Pen Strp. The other 
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mammalian cancer derived cell lines were grown in RPMI 1640 medium 
supplemented with 10% FBS.  All cell lines were grown in 37°C and 5% CO2 
2.4.2 Transient transfection 
COS-7, HEK 293 and HeLa cells were transfected with GeneJuice (Novagen) 
reagent and U2OS, MDCK and NCI-H446 cells were transfected with Lipofectamine 
2000 (Invitrogen) according to the manufacture’s protocol. 2-5μg of DNA was used 
to transfect cells with 70-90% confluency in 6cm plates. Cells were incubated for 16-
20 hours before harvesting.   
2.4.3 siRNA transfection  
Typically reverse transfections were used to transfect cells with 40-60nM of 
siRNAs using Lipofectamine 2000. Briefly siRNA and Lipofectamine 2000 diluted in 
serum free DMEM media separately and after 5minutes incubation the content of two 
tubes were combined and incubated for additional 20 minutes. Meanwhile the cells 
were trypsinized and the appropriate volume of cell solution in complete growing 
media was added to 35mm plates. The siRNA mixture then was added dropwise to the 
cells and cells were incubated for 48h at 37°C.   
2.4.4 Establishing stable lines 
Two types of stable lines were established: 1. U2OS cells that stably 
expressing GFP PAK5 and GFP-BirA
*
-PAK5 as well as corresponding controls 2. 
NCI-H446 with stable knockdown of endogenous PAK5. 
U2OS cells were grown in 35mm plate to around 70% confluency and then co-
transfected with 2μg of target plasmid ( pXJ-GFP-PAK5 or pXJ-GFP-BirA*-PAK5) 
or control plasmids (pXJ-GFP or pXJ-GFP-BirA
*
) and 0.04μg of pBABE-puro using 
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Lipofectamine 2000 and were incubated for 48 hours. The expression of GFP PAK5 
and GFP vector were analyzed using fluorescence microscope. Cells then were 
trypsinized and split in four 10cm plates with low density. After overnight incubation, 
the media were changed with the complete media containing 0.8μg/ml puromycin and 
cells were incubated for two weeks in the presence of puromycin. During this period, 
culture media were changed with a fresh media containing puromycin every 4-5 days 
to remove the dead cells. Cells which have integrated the resistance gene forms clones 
after 2-3 weeks which were examined for GFP expression with fluorescence 
microscope. Colonies with different intensity of GFP expression were selected and 
transferred using sterile whatman filter papers separately to media containing 
puromycin in 6cm plates. Confluent cultures then were used for further analysis using 
immunofluorescence staining to analysis protein localization and Western blotting to 
assess the protein expression. 
To stably knockdown PAK5 in NCI-H446 cells, I used the pSUPER RNAi 
system. A siRNA sequence which specifically targets PAK5 and siScramble sequence 
were obtained from previously published data [132]. The oligos were purchased from 
sigma and cloned to the pSUPER.neo vector according to pSuper RNAi System 
manual (OligoEngine) to generate shRNAs. NCI-H446 cells were plated in 35mm 
plate and transfected with sh-PAK5 or sh-scramble using Lipofectamin 2000. Cells 
then were trypsinized in 48h and split with low confluency in several 10cm plates.  
The following day, the media were changed with a fresh media containing 300μg/ml 
G418. The remaining steps were identical to establishing U2OS stable line.  
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2.4.5 Immuno-precipitation  
Cells were harvested and lysed in lysis buffer (Appendix) and then centrifuged 
in 13000 rpm for 15 minutes at 4°C. The appropriate volume of clarified supernatant 
were incubated with M2-Flag beads (Sigma), glutathione beads or streptavidin 
conjugated beads and rolled for 2h at 4°C. The beads then washed three times with 
lysis buffer and then either used for in vitro kinase assay or mixed with SDS sample 
buffer to use directly for Western blotting.  
2.4.6 In vitro kinase assay 
The immunoprecipitated kinase was subjected for in vitro kinase assay. 30μl 
of kinase mixture containing kinase buffer (1X), substrate (5-10μg/reaction), cold 
ATP (500μM) and distilled water was added to the beads and incubated in 30°C for 
20 minutes. For radioactive in vitro kinase assay, I used 10μg/reaction substrate, 
40μM cold ATP and 2µCi 32P-γATP in 1X kinase buffer. The reaction was terminated 
by addition of hot SDS sample buffer (2X). In most of the cases, cold ATP was used 
and the samples were subjected to SDS-PAGE and Western blotting to detect 
phosphorylated substrate using specific antibody. When 
32
P-γATP was used for the 
kinase assay, the intensity of radiation detected by exposure to photographic film.  
2.4.7 Immunostaining 
Cells were seeded on cover slip and transfected with 0.5μg of desired gene for 
overnight. Cells were then fixed with either paraformaldehyde (PFA) 4% for 20 
minutes at room temperature or cold methanol for 5 minutes at -20°C followed by 
washing with PBS for 10 minutes. Cells were permeabilized using PBS containing 
0.2% Triton X-100 for 10 minutes and then blocked with 5% BSA in 0.1% Triton X-
100/PBS for 10 minutes and then incubated with relevant primary antibody diluted in 
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0.1% Triton X-100/PBS for 1-2 hours. The cells then were washed 3 times with 0.1% 
Triton X-100/PBS for 30 minutes before incubating with the appropriate Alexa fluor 
conjugated secondary antibody (Alexa 488, 546 and 635) and DAPI (1.5μg/ml) for an 
hour. Cells were finally washed 3 times and coverslips were dried and mounted on 
glass slides using mounting solution.  
For visualization of mitochondria, transfected cells were incubated with 
Mitotracker CMXRose (life technologies) (150nM final concentration) for 20-30 
minutes before fixation. 
2.5 Methods for detections of protein-protein interactions 
2.5.1 Establishing stable lines for BioID and GFP pull down analysis 
PAK5 was cloned in pXJ-GFP-BirA
* 
vector and this vector along with empty 
vector were used to generate U2OS stable lines under puromycin selection as 
described in section 2.4.3. Several clones of each line were analyzed using 
immunofluorescence staining and Western blotting for proper localization and 
expression of protein. Finally, two clones of each line with low expression of proteins 
were selected for BioID and GFP pull down (GFP-PD) analysis.  
2.5.2 Adapting cells in SILAC media 
To increase reliability of the results and reduce the rate of false positive data in 
mass spectrometry, SILAC strategy was adapted to isotopically label PAK5 lines. To 
this end, GFP-BirA
*
PAK5 lines were grown in SILAC DMEM media (deficient in 
both L-lysine and L-arginine, Thermo Scientific) supplemented with heavy isotopes 
(13C,15N) of arginine and lysine (Cambridge Isotope Laboratories) and 10% dialyzed 
serum (Thermo Scientific) for two weeks. The control lines were adapted in the 
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identical media that was supplemented with the normal isoforms of arginine and 
lysine for a few days. The cells then were used for immuno-precipitation with 
Neutravidin beads (Thermo Scientific) or GFP-Trap beads (ChromoTek).   
2.5.3 Purification of biotin-labelled proteins from stable GFP-Bir*A cells   
Two different clones of U2OS stable cells expressing GFP-Bir
*
A-PAK5 along 
with two clones of GFP-Bir
*
A stable cells were adapted in SILAC media for two 
weeks. The confluent culture of cells in 10cm plates were then grown in SILAC 
media containing 100μM of Biotin (Invitrogen) for 5 hours before they were used for 
immune-precipitation. Cells were rinsed with PBS and harvested in 500 µl of lysis 
buffer containing 100mM KCl, 25mM Tris pH 8, 0.5% Triton X-100, 0.5% sodium 
deoxycholate (DOC) and protease cocktail containing EDTA(Roche). Cells were spun 
for 20 seconds at 13000 rpm to pellet nuclei. The supernatants were collected and 
protein concentrations assessed using Bradford assay (40µl of the lysates were kept 
for further analysis). The supernatants were then mixed with SDS (final concentration 
of 0.2%) and sonicated briefly (14% power for 20 Sec) before centrifugation at 13000 
rpm for 10 minutes at 4°C. The cleared lysates of the target (Heavy) and control 
(Light) were pooled in one tube. Neutravidin agarose beads were pretreated with lysis 
buffer+0.2% SDS and then incubated with the clarified lysate at 4°C for overnight by 
rolling. The following day, the `flow through` was removed (50µ of `flow through` 
was kept for further analysis) and beads were washed in buffer comprising 25mM 
Tris pH 8, 1% SDS and proteases cocktail for 5 minutes at room temperature and then 
in buffer containing 25mM Tris pH 7.4, 0.5% deoxycholate, 0.5% triton X-100, 
100mM KCl and protease cocktail for additional 10 minutes at 4°C. 80μl of elution 
buffer (1X LDS sample buffer from novex) was added to the sample and incubated 
for 5 minutes at 100°C. Supernatant was collected and this step was repeated with 
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40μl of dH2O. The supernatants then were pooled in one tube (120μl total) and the 
tube was vacuumed to reduce the volume to 50μl. 40μl of the sample was run on 1mm 
10% SDS-PAGE for 30 minutes till the dye front moved half way down the gel and 
remaining 10μl was kept for further analysis. The gel was submitted for mass 
spectrometry analysis.  
2.5.4 GFP Purification of proteins from stable GFP-Bir*A cells   
Two different clones of U2OS GFP-Bir
*
A-PAK5 along with two different 
clones of GFP-Bir
*
A vector lines (the identical clones that were used for BioID) were 
adapted in heavy media and light media respectively as previously described in 
section 2.5.1. The cells then harvested in 500µl of lysis buffer containing 100mM KCl 
, 25mM Tris pH 8, 0.5% Triton X-100, 5mM MgCl2, 5mM DTT and protease 
cocktail (Roche) and then were cleared by centrifuge at 13200 rpm for 15min at 4°C. 
The two Heavy lysates and the two light lysates were combined in the separate 
microtubes and protein concentration was assessed using Bradford assay (OD
595
 
should be ~ 0.3) (50µl of the heavy lysate and 50µl of the light lysate were kept and 
maked up with 50µl 2x SDS buffer for further analysis). GFP-Trap beads were 
washed with 1ml of 0.1% Triton X-100 in PBS and incubated with the cleared lysate 
of the target (H) sample or control sample (L) in 4 °C for 3 hours by rolling.  The 
'flow-through' lysates were removed (50µl was kept for further analysis) and the 
beads were washed with 1 ml of lysis buffer, 3 times (5 minutes each). The proteins 
were eluted by addition of 40μl elution buffer (1X LDS sample buffer from novex) 
and incubation for 5 minutes at 100°C. This step was repeated with 20µl of H2O and 
the supernatants then were combined (60µl) and 10µl of each of heavy and light 
samples were kept for further analysis. The remaining 50µl of H sample and 50 µl of 
L sample (total = 100µl) were combined and concentrated to 50µl in a Speed 
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Chapter 3: Regulation of PAK5 activity 
3.1 Introduction 
Previously a PAK4 auto-inhibitory domain (AID) was identified through 
biochemical and structural analysis [28, 29].  This AID sequence which is located C-
terminal to the Cdc42 binding domain is conserved across group II PAKs (Figure 3.1). 
These sequences can adopt a pseudo-substrate like conformation in which a conserved 
proline (P52) occupies the position that the substrate serine would bind. The AID 
binding to the substrate binding site of the catalytic domain prevents access of 
substrate(s) and although the activation loop Ser474 is constitutively phosphorylated, 
the kinase is thus inactive. When expressed in mammalian cells, full length PAK4 has 
low activity compared to that of the catalytic domain [40] and this situation seems to 
prevail when the kinase is purified from E.coli [28]. In contrast to PAK4, PAK5 has 
much higher activity when isolated from mammalian cells [33]. Given that the PAK5 
AID is 90% identical to that of PAK4 (Figure 3.1), it seems puzzling as to why the 
kinase is apparently constitutively active. In this chapter, I show that the PAK5 AID is 
indeed functional with respect to its ability to inhibit the kinase domain of PAK4, and 
show how sequences outside this region are responsible for the pronounced difference 






   
   hPAK4 –MFGKRKKRVEISAPSNFEHRVHTGFDQHEQKFTGLPRQWQSLIEESARR 49 
   hPAK5 –MFGKKKKKIEISGPSNFEHRVHTGFDPQEQKFTGLPQQWHSLLADTANR 49 
   hPAK6 MFRKKKKKRPEISAPQNFQHRVHTSFDPKEGKFVGLPPQWQNILDTLR-R 49 
          :  *:**: ***.*.**:*****.** :* **.*** **:.::     * 
 
   hPAK4 PKPLVDPACITSIQPGAPKTIVRGSKGAKDGALTLLLDEFENMSVTRSNS 99 
   hPAK5 PKPMVDPSCITPIQLAPMKTIVRGNKPCKETSINGLLEDFDNISVTRSNS 99 
   hPAK6 PKPVVDPSRITRVQLQPMKTVVRGSAMPVDGYISGLLNDIQKLSVISSNT 99 




   hPAK4 -----ACTPAAPAVPGPPGPRSPQREPQRVSHEQFRAALQLVVDPGDPRS 314 
   hPAK5 ASYLSSLSLSSSTYPPPSWGSSSDQQPSRVSHEQFRAALQLVVSPGDPRE 442 
   hPAK6 -----TSNLYLPQDPTVAKGALAGEDTGVVTHEQFKAALRMVVDQGDPRL 400 
              : .   .  *  .    . .:.  *:****:***::**. ****  
 
   hPAK4 YLDNFIKIGEGSTGIVCIATVRSSGKLVAVKKMDLRKQQRRELLFNEVVI 365 
   hPAK5 YLANFIKIGEGSTGIVCIATEKHTGKQVAVKKMDLRKQQRRELLFNEVVI 493 
   hPAK6 LLDSYVKIGEGSTGIVCLAREKHSGRQVAVKMMDLRKQQRRELLFNEVVI 451 
          * .::***********:*  : :*: **** ****************** 
 
   hPAK4 MRDYQHENVVEMYNSYLVGDELWVVMEFLEGGALTDIVTHTRMNEEQIAA 416 
   hPAK5 MRDYHHDNVVDMYSSYLVGDELWVVMEFLEGGALTDIVTHTRMNEEQIAT 544 
   hPAK6 MRDYQHFNVVEMYKSYLVGEELWVLMEFLQGGALTDIVSQVRLNEEQIAT 502 
         ****:* ***:**.*****:****:****:********::.*:******: 
 
   hPAK4 VCLAVLQALSVLHAQGVIHRDIKSDSILLTHDGRVKLSDFGFCAQVSKEV 467 
   hPAK5 VCLSVLRALSYLHNQGVIHRDIKSDSILLTSDGRIKLSDFGFCAQVSKEV 595 
   hPAK6 VCEAVLQALAYLHAQGVIHRDIKSDSILLTLDGRVKLSDFGFCAQISKDV 553 
         ** :**:**: ** **************** ***:**********:**:* 
 
   hPAK4 PRRKSLVGTPYWMAPELISRLPYGPEVDIWSLGIMVIEMVDGEPPYFNEP 518 
   hPAK5 PKRKSLVGTPYWMAPEVISRLPYGTEVDIWSLGIMVIEMIDGEPPYFNEP 646 
   hPAK6 PKRKSLVGTPYWMAPEVISRSLYATEVDIWSLGIMVIEMVDGEPPYFSDS 603 
         *:**************:***  *..**************:*******.:. 
 
   hPAK4 PLKAMKMIRDNLPPRLKNLHKVSPSLKGFLDRLLVRDPAQRATAAELLKH 569 
   hPAK5 PLQAMRRIRDSLPPRVKDLHKVSSVLRGFLDLMLVREPSQRATAQELLGH 696 
   hPAK6 PVQAMKRLRDSPPPKLKNSHKVSPVLRDFLERMLVRDPQERATAQELLDH 654 
         *::**: :**. **::*: ****. *:.**: :***:* :**** *** * 
 
   hPAK4 PFLAKAGPPASIVPLMRQNRTR---- 591 
   hPAK5 PFLKLAGPPSCIVPLMRQYRHH---- 719 
   hPAK6 PFLLQTGLPECLVPLIQLYRKQTSTC 681 


























Figure 3.1. Comparison of N-terminal and C-terminal sequences of
human group II PAKs. An alignment of human PAK4, PAK5 and PAK6
sequences using ClustalW. This highlights the N-terminal regulatory domain
that contains a p21(Cdc42) binding domain (PBD) and auto inhibitory domain
(AID). Identical residues are marked (*) while conservative residues are
indicated as (:) or (.). The pseudo-substrate like sequence which binds the
PAK4 substrate binding pocket and forms the major AID contact with the




3.2 PAK5 contains a functional auto inhibitory domain  
Both PAK4 and PAK5 which belong to the group II (non-conventional) PAKs 
are highly related at their N-terminal regulatory domain and C-terminal kinase 
domain. As illustrated in Figure 3.1, the p21 binding domain (PBD), which binds 
Cdc42, and the auto inhibitory domain (AID) lie within the first 60 residues.  The 
critical contact of the AID with the kinase domain involves residues 49-52 (Figure 
3.1, green mark). Constructs of PAK4 lacking residues 1-50 or mutated in the AID 
show >10 fold increase in activity relative to the wild type kinase [28].  
To test if the PAK5 N-terminal similarly regulates kinase activity, I generated 
a series of deletion constructs (removing 20, 30, 40, 50 residues from the N-terminus). 
These proteins were expressed in mammalian cells and immuno-precipitated to test 
their activity (Figure 3.2A). In vitro kinase assays were carried out in the presence of 
ATP (0.5mM) and recombinant GST-BAD, which has been shown previously as a 
substrate for PAK5 [52]. As can be seen in Figure 3.2B, the PAK5 lacking residues 1-
50 (PAK5 Δ50) was several-fold more active than the full-length kinase. Comparing 
the kinase activity of PAK5 with PAK4 clearly indicates that PAK5 is indeed 
constitutively active (Figure 3.2D) and as previously reported [33]. Thus, although 
PAK4 and PAK5 contain conserved regulatory and catalytic domains, the behaviour 
of PAK5 is quite different.  
3.3 PAK5 is likely a Cdc42-specific effector 
In the group I PAKs, Cdc42 binding to the PBD is thought to induce a large 
change in the conformation of the AID; thus displacing it from the kinase domain [8, 
19]. Previously it has been shown that PAK5 binds preferentially to Cdc42 rather than 
Rac1 [45], unlike PAK1 [8]. The higher activity of PAK5 relative to PAK4 might be 
explained by a different sensitivity to the different Cdc42 related GTPases. Therefore, 
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I tested the ability of PAK5 to interact with Cdc42 related GTPases (mutationally 
activated) when co-expressed in COS-7 cells. Surprisingly, although TCL (RhoJ) and 
TC10 (RhoQ) are highly related to Cdc42, they could not efficiently bind PAK5 
(Figure 3.3A). Next, using an in vitro kinase assay I examined whether binding to 
Cdc42 can regulate PAK5 activity. Indeed, Cdc42 could bind to and enhances PAK5 
activity ~2.5 times; confirming that in-vivo PAK5 is likely to be regulated by Cdc42 
(Figure 3.3B,C), as was reported for PAK4 [28]. It should be noted that this kinase 














































































in vitro kinase assay

























































Figure 3.2 N-terminal deletion induces PAK5 activity. A. Schematic of 
PAK5 constructs used for expression in COS-7 cells B. The various Flag-
PAK5 constructs were purified and tested in vitro for their kinase activity 
toward BAD Ser-112. Kinase activity was assayed in vitro using full-length 
recombinant GST-BAD (5μg) and 0.5mM ATP in 30ul kinase buffer. 
Phosphorylated BAD was detected using anti-pS112 BAD antibody that 
detects the major site of PAK5 phosphorylation [52]. C. The relative in vitro
kinase activity of purified PAK5 constructs averaged in three independent 
experiments. The data were normalized relative to full-length PAK5 (FL = 1).
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DFigure 3.2 N-terminal deletion induces PAK5 activity. D. COS-7 cells
were transfected with the indicated constructs and immunoprecipitated
constructs were subjected to in vitro kinase assay ( in Sepharose.)
Input: anti-HA

















































Flag constructs     
Figure 3.3 Co-transfection of Cdc42 (G12V) increases the in vitro
activity of PAK5. A. HA-PAK5 was co-expressed with the mutationally
activated form of GTPases most closely related to Cdc42. Rac1 used as a
negative control. The interaction was examined by anti-Flag pull-down.
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Figure 3.3 Co-transfection of Cdc42 (G12V) increases the in vitro
activity of PAK5. B. Co-immunoprecipitation was performed using anti-
Flag beads and Flag-PAK5 was directly immune-precipitated and HA-
PAK5 was indirectly recovered using Flag-Cdc42 V12. The activity was
assessed using an in vitro kinase assay of the immobilized kinase in
Sepharose. C. The relative in vitro kinase activity of PAK5 or the
PAK5:Cdc42 complex were tested in three independent experiments.
The relative activity is shown. Cdc42V12 by itself did not pull-down




3.4 PAK5 auto-regulatory domain can inhibit PAK4 
Full-length PAK5 cannot be expressed in E.coli (data not shown) and the 
mammalian expressed kinase is clearly very active (Figure 3.2D). Since PAK4 and 
PAK5 have highly conserved catalytic and regulatory domains, why is PAK5 already 
active when expressed in mammalian cells? One study has shown that mutationally 
activated MKK6 (EE) phosphorylates PAK5 on Tyr 608 and up-regulates the basal 
activity of PAK5 as shown for PAK4 and PAK6 as well [36]; however, I found no 
change on activity of PAK4 and PAK5, when co-expressed with constitutive active 
MKK6(EE)  (data not shown). Another untested possibility is that the PAK5 auto-
inhibitory domain has become ineffective because of the differences in amino acids 
residues (Figure 3.1). The best way to test this seemed to exchange the regulatory 
domain of the two kinases, since the region on the catalytic domain to which the AID 
is bound [29] is essentially identical. I therefore created two chimaeras in which the 
regulatory domains (residues 1-72) were exchanged (Figure 3.4A). The results shown 
in figure 3.4B demonstrate that the ‘PAK4(72)-PAK5’ chimaera was equally active to 
wild type PAK5 and conversely ‘PAK5(72)-PAK4’ was fully inhibited relative to 
wild type PAK4. Thus PAK5 AID is fully functional and the determinant responsible 



































































Figure 3.4 The PAK5 auto-inhibitory domain is functionally active
towards PAK4 catalytic domain. A. Schematic diagram of two PAK4
and PAK5 chimaeras. The first 72 amino acids of PAK4 and PAK5
contains PBD and AID were exchanged to make a chimaera of PAK5
contains PAK4 regulatory domain Flag-PAK4(72)-PAK5 or Flag-
PAK5(72)-PAK4 B. The indicated Flag tagged constructs were
expressed in COS-7 cells and the fusion proteins recovered by
immunoprecipitation. in vitro kinase assay was performed using GST-
BAD as a substrate in the presence of 0.5mM ATP. The GST-Bad (10μg





3.5 Different cellular distributions of PAK4 and PAK5 
Could the differences in activities of PAK4 and PAK5 relate to their intra-
cellular location?  For example there are reports that PAK4 and PAK5 can be found in 
the nucleus [50, 165]. Epitope tagged versions of PAK4 localize to the cytoplasm, at 
cell-cell junctions and in the nucleus [26, 66]; the situation with PAK5 is less clear 
[50, 52, 53]. Some studies have suggested that the kinase is found in clusters that 
mainly co-localizes with mitochondria [31, 52], while this punctate distribution of 
PAK5 in other circumstances does not appear to be mitochondrial [53, 54]. In my 
hands, the PAK4 and PAK5 clearly have very different basal level of activity, and I 
was interested to investigate whether this might relate to their compartmentalization. 
In COS-7 cells, Flag-PAK4 showed diffused cytoplasmic distribution whereas Flag-
PAK5 demonstrated a punctate distribution even when cells were transfected with 
0.2μg of Flag-PAK5 plasmid for 8 hours (Figure 3.5). These puncta are regular in size 
and do not resemble aggregates that typically form by unfolded proteins [53, 166]. 
Therefore, I hypothesized that PAK5 contains sequences that promote self-assembly. 
Comparison of the primary sequence of PAK4 and PAK5 indicates the presence of a 
central region in PAK5 which is evolutionary conserved and is not found in PAK4 
(Figure 3.6).  
To test which PAK5-specific region is involved in targeting the protein to 
puncta, I generated a series of N-terminal deletion PAK5 constructs which were 
expressed at low level in COS-7 cells (Figure 3.7A). The removal of the N-terminal 
109 residues clearly has two effects; firstly I noticed that in contrast to PAK5∆50 
construct, the protein was not completely excluded from the nucleus, suggesting that 
residues 50-109 contain a nuclear export signal.  Secondly, the puncta formed by 
Flag-PAK5∆109 were more diffuse (Figure 3.7B). This suggested that this N-terminal 
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region, which is well conserved in PAK4, participates in puncta formation although it 
is unlikely to be responsible for this phenomenon. Only by removing residues 1-236 
from PAK5, I was able to completely alter the distribution of PAK5 such that it 
remained largely cytoplasmic, with some accumulation at peripheral membrane ruffles 
(which is typical for this cell type). By contrast PAK5∆178 construct was relatively 
punctate. This data suggested the importance of region 178-236 in puncta formation. 
To test this, I generated flag-PAK5 lacking the region 178-268. The protein 
PAK5∆178-268 showed more diffuse cytoplasmic distribution with a few puncta but 
was not distributed as evenly as PAK4 (Figure 3.7B).  
 
3.6 The non-catlytic domain of PAK5 is sufficient for puncta formation 
An inactive version of PAK5 (PAK5 S602M/T606M) was found to localize 
similar to the active kinase (data not shown). Removal of the catalytic domain 
(PAK5(1-418) construct) did not disrupt the ability for puncta formation of PAK5 but 
resulted in ir-regularly sized punctate (Figure 3.8B) suggesting the participation of the 
kinase domain in formation and stabilization of the normal puncta. I therefore, 
generated smaller N-terminal constructs to establish the limits required for this 
process given that PAK5 residues 109-425 either are not found or not conserved in 
PAK4 (Figure 3.6). This data suggested that the whole central region of PAK5 is 












Figure 3.5 Subcellular distribution of PAK4 and PAK5 in COS-7
cells. A. COS-7 cells were transiently transfected with 0.5μg of either
Flag-PAK4 or Flag-PAK5 constructs in 35mm culture dishes containing
glass coverslips; At 16h the cells were fixed in 4% paraformaldehyde (20
min, RT) and immunostained with mouse anti-Flag antibody. B. COS-7
cells were transfected with 0.2μg of Flag-PAK5 and after 8h expression
the cells were fixed and processed for staining with anti-Flag antibody.
(Scale bar = 10 μM)
PAK5
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Figure 3.6 ClustalW sequence alignment of the central region of
PAK4 and PAK5. The central region of PAK5 is moderately conserved
across vertebrates, however this sequence is not found in human PAK4.
Identical sequences are marked (*) and conserved amino acids are
shown with (.) or (:). In PAK5 species, dark grey and light grey
highlights the identical amino-acids or conserved amino-acids
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Figure 3.7 The central region of PAK5 is involved in puncta
formation. A. The diagram indicates the various constructs of PAK5
were used to test cellular localization by immunostaining. B, C. COS-7
cells were transfected with 0.5μg of the indicated constructs for overnight
then fixed in 4% PFA and processed for indirect immunostaining using
mouse anti-Flag antibody. Removal of residues 1-236 significantly
























PAK5 (1-268) PAK5 (1-310)
PAK5 (1-418) PAK5–FL (1-719)
Figure 3.8 The PAK5-specific central region is primarily involved in
puncta formation. A. A schematic of C-terminal truncated constructs of
PAK5 used to test cellular localization. B. Plasmids encoding tagged
versions of PAK5 (1-268), PAK5(1-310) and PAK5(1-418) were







3.7 Establishing the regions of PAK5 involved in self-association 
Puncta distribution of a protein is contributed to its oligomerization in some 
reports. For instance, overexpressed dishevelled (dvl), one of the component of the 
Wnt signalling pathway, form puncta that represents its oligomerization [167]. Given 
that PAK5 contains residues not found in PAK4 and are conserved across evolution 
(Figure 3.6), it seemed possible that these play an important role in self-association. 
To examine this hypothesis and map the possible self-interaction site of PAK5, co-
transfection experiments were carried out using HA-PAK5 and testing if this protein 
could be co-immunoprecipitated with Flag N-terminal truncated constructs of PAK5. 
These experiments suggested the PAK5 kinase domain was not involved in PAK5 
self-association (Figure 3.9B) and that residues 268-420 in this context seem critical 
for PAK5 self-association. To determine whether the residues 1-108 of PAK5, which 
are largely conserved in PAK4, play a key role in self-association of PAK5, the 
similar experiment was performed using HA-PAK5∆109. The results demonstrated 
that HA-PAK5∆108 co-immunoprecipitated with various truncated PAK5 constructs 
with roughly the same efficiency (Figure 3.9C). Further experiments were then carried 
out to further assess region required for PAK5 self-interaction. N-terminal truncated 
constructs of PAK5 were tested for their ability to interact with HA-PAK5(1-268). 
This contains approximately 50% of the PAK5-specific central region and yet retained 
the ability to self-associate albeit not as efficiently as the full length protein (Figure 
3.10A). The results showed that although HA-PAK5(1-268) interacts with Flag-
PAK5∆108, it could not be co-immunoprecipitated with Flag-PAK5∆236 implicating 
the importance of 109-236 region in self-interaction (Figure 3.10A).  
Taken together the immuno-precipitation analysis suggested two critical 
regions in PAK5 self-association: residues 109-236 and residues 268-420. To test 
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more directly the importance of central region of PAK5 in self-association, I 
generated PAK5 lacking residues 268-420 (Figure 3.10B). As can be seen in figure 
3.10C, Flag-PAK5(∆268-420) failed to co-immunoprecipitate HA-PAK5(∆268-420). 
Thus the biochemical data support the model that residues in the PAK5-specific 
region play key role to promote PAK5 self-association. In agreement with these 
results, gel filtration analysis in our lab has suggested that despite monomeric PAK4, 
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Flag constructs   
Figure 3.9. Biochemical experiments show PAK5 has the ability of
self-interaction. A. Schematic of N-terminal deletion constructs of
human PAK5 that used for co-immunoprecipitation. B. HA tagged PAK5
were co-expressed with the indicated Flag tagged N-terminal deletion
constructs of PAK5. Anti-Flag immunoprecipitation was performed after
cell lysis and clarification. The bound proteins were eluted from
sepharose by adding SDS sample buffer. These were subjected to

















Figure 3.9. Biochemical experiments show PAK5 has the ability of
self-interaction. C. HA-PAK5 ∆108 was co-transfected with Flag tagged
N-terminal truncated constructs of PAK5. Cell lysate were harvested and
Co-immunoprecipitation was performed using anti-Flag Sepharose.







































































































Figure 3.10 The central PAK5-specific region is required for self-
interaction. A. The Flag tagged N-terminal truncated construct of PAK5
were co-transfected with HA-PAK5(1-268). Cell lysates were harvested
and immuno-precipitation was performed using anti-Flag Sepharose. The






































Figure 3.10 The central PAK5-specific region is required for self-
interaction. B. A PAK5(∆268-420) construct lacking the region involved
in self-assembly was generated. C. COS-7 cells were transfected with
constructs of PAK5(∆108) or PAK5(∆268-420) and tested for co-
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Figure 3.11. Gel-filtration chromatography of Flag-tagged PAK1,
PAK4, PAK5 proteins. PAK1, PAK4 and PAK5 were expressed in
HEK293 cells by transient transfection from pXJ-Flag vectors.
Transfected cells were lysed with lysis buffer containing 25mM HEPES
pH=7.3, 100mM KCl, 5mM DTT, 10% glycerol +protease inhibitor
cocktail (Roche). Cell lysates was clarified at 60,000rpm (30min, 4oC)
using a TLA-100 rotor in a Beckman TL-100 ultracentrifuge (~100,000g).
Fractions of 50ul were injected in a Superdex™ 200 column on a
SMART system (Pharmacia) pre-equilibrated with running buffer (25mM
HEPES pH=7.3, 100mM KCl). A total of 30 fractions (50ul) were
collected for each sample. Fractions collected were assessed by anti-
Flag western blotting. Molecular weight standards as shown were run





3.8 PAK5 self-association contributes to its high basal activity  
Based on the localization of various truncated versions of PAK5 (Figures 3.7, 
3.8) and the results of co-immunoprecipitation experiments (Figures 3.9, 3.10), I 
suggested that a key role of the PAK5-specific domain is self-interaction. In a number 
of other contexts, dimerization or oligomerization of protein kinases is associated with 
their (auto) activation [168-171]. The construct PAK5(∆268-420), with ~50% of the 
PAK5-specific sequences deletion, showed a fully dispersed protein in the cytoplasm 
(Figure 3.12B). The construct has lost the ability of self-interaction (Figure 3.10C) 
and can be considered essentially monomeric (ie. like PAK4).  I therefore tested the in 
vitro kinase activity of this truncated kinase versus the full-length PAK5 (Figure 
3.12C). This smaller protein had much lower activity showing a correlation between 
self-association and a high basal activity of PAK5 constructs (Figure 3.12C, lane 4 
versus lane 2). Other mechanisms could be responsible however; for example the 
deleted region might contain sequences required for interaction with cellular activators 
(protein or otherwise), or this region could promote binding of substrates, and thereby 
affect the efficiency of the catalytic domain to target substrates as has been reported 
for other protein kinases [172-174].  To test these possibilities, I also generated a 
PAK5(∆116-260) construct (Figure 3.12A) that lacks the remaining ‘PAK5-specific’ 
sequences (ie not present in PAK4). Immuno-fluorescence staining showed diffuse 
pattern of cytoplasmic localization of this protein in COS-7 cells (Figure 3.12B). In 
vitro kinase assay indicated this protein exhibited a reduced activity versus the wild 
type protein (Figure 3.12C, lane 3 versus lane 2). These results further support the 
notion that PAK5 oligomerization can be abolished by removing all or part of the 
PAK5-specific region which in turn affects basal activity.  
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How might PAK5 self-association lead to elevated kinase activity? The first 
issue was whether all these constructs were constitutively phosphorylated on 
activation loop Ser602 as was suggested previously for group II PAKs [28].  
Therefore, I tested the phosphorylation status of this residue for PAK5(∆116-260) and 
PAK5(∆268-420) compared to wild type PAK5, using a phospho-specific antibody 
that recognizes the sequence around the unique phosphorylated serine in activation 
loop of group II PAKs. The result showed the activation loop is phosphorylated with 
the same extent in all PAK5 constructs (figure 3.13A). A second possibility is that 
PAK5 self-interaction interferes (in trans) with the AID binding to the catalytic 
domain. This hypothesis would be consistent with reduced activity of ‘monomeric’ 
PAK5(∆268-420). To test this, I investigated the effect of mutating the AID at 
equivalent residues to those in PAK4 that cause activation [28] (Figure 3.13B). This 
PAK5(∆268-420)-mAID protein exhibited elevated activity relative to the non-
mutated version, indicating that this shorter PAK5(∆268-420) is indeed auto-inhibited 
by the functional AID (Figure 3.12C).  This data also corroborates the original domain 
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Figure 3.12. The central PAK5-specific region is responsible for its
elevated activity. A. Schematic diagram of PAK5 constructs with
deletion in 50% of the central region. B. Indirect Immuno-fluorescence
staining of PAK5 deletion constructs in COS-7 cells. C. Immuno-
precipitation and subsequent in vitro kinase assay was performed (as in
Fig 3.2) in the lysate of COS-7 cells expressed Flag-PAK5(FL) or















































Figure 3.13. The PAK5 specific central region may interfere with the
AID function. A. COS-7 cells were transfected with the indicated
plasmid constructs for 16h. Cells were then lysed and processed for



























































































































Figure 3.13. The PAK5 specific central region may interfere with the
AID function B. The position of the point mutations generated in the
PAK5 AID sequence are indicated and as described previously [28]. C.
COS-7 cells were transfected with the indicated constructs of PAK5 and
PAK4. The in vitro kinase assay was performed directly on the anti-Flag
Sepharose beads with recombinant GST-BAD. The relative in vitro
kinase activity of the purified PAK5 constructs tested in three
independent experiments. The data were normalized and Flag-PAK5(FL)








Identification of a conserved AID domain at N-terminal of group II PAKs [28, 
29], has suggested that the activity of group II PAKs are regulated in a similar manner 
to group I PAKs.  In its auto-inhibited conformation, a key region of N-terminal AID 
(amino acids 49-52), which acts as a pseudo-substrate bound to catalytic domain, 
prevents kinase activity. Binding to Cdc42 induces conformational changes results in 
relief from auto-inhibition. Although this mechanism applies to PAK4, Cdc42 itself 
cannot interfere with pseudo-substrate binding and the mechanism by which PAK4 is 
activated remains to be addressed. It has been suggested that the proline-rich sequence 
in PAK4 could interact with SH3 domains [29] which would allow substrate access. 
Another complexity is that although the regulatory domain of group II PAKs 
(including AID) is conserved (Figure 3.1), PAK5 is clearly much more active than 
PAK4 when expressed and purified from  mammalian cells (Figure 3.2D) [45]. Ching 
et al, suggested that an alternate AID exists in PAK5 (amino acids 60-180) which is 
not conserved among other members of group II PAKs [30], however this observation 
does not explain the enhanced activity of PAK5 relative to PAK4. One of the 
questions I wished to address in my studies was, if PAK5 contains an active and 
functional AID, why is it much more active? 
 
3.9.1 PAK5 activity is partially regulated by the presence of a functional AID at 
N-terminal 
The presence of a conserved sequence in group II that serves as an AID in 
PAK4 has been noted [29]. Removal of 50 amino acids of PAK4 N-terminal, which 
contains the AID, leads to ~10 fold increased activity [28]. Since PAK5 is much more 
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active than PAK4, when purified from mammalian cells (Figure 3.2D), the 
outstanding question is whether the PAK5 indeed contains a functional AID? I have 
been able to show here that human PAK5 does contain an AID which has strong 
similarities with that found in PAK4.  These issues are discussed further in the next 
section: 
1.  Removal of 50 amino acids of PAK5 N-terminal increased the basal activity 
of the protein ~3 times (Figure 3.2B, C) which is significant though less dramatic than 
that seen with activity of PAK4 [28].  
2. Binding to activated Cdc42(G12V) in vivo can increase kinase activity > 2.5 
times (Figure 3.3B, C). Because the group II PAKs activity is not regulated in-vitro 
by binding to Cdc42(G12V), literatures regarding PAK5 regulation by Rho-GTPases 
is confusing [31, 33]. Certainly the ability of Cdc42 to regulate PAK5 localization 
(for example at filopodia) might provide the right cues to drive kinase activation - say 
by lipids. The suggestion that RhoD is a partner for PAK5 at mitochondria [31] is not 
borne out in my studies (Table 5.2). 
3. Swapping the first 72 amino acids of PAK4 and PAK5 was informative (Figure 
3.4). Firstly, a chimaera of PAK4 replacing with the PAK5 N1-72 was clearly fully 
inhibited, indicating that the conserved PAK5 AID is likely to bind tightly to the 
PAK4 catalytic domain. Secondly, in the context of the full-length PAK5 protein, 
PAK4 AID was not effective in suppressing catalytic activity to the level seen with 
full-length PAK4. This suggests these kinases may have diverse mechanisms of 
regulation. I conclude that human PAK5 contains a sequence that can act as a 




3.9.2 The punctate distribution of PAK5 reflects kinase oligomers 
In multiple cell types, GFP-PAK5 or Flag-PAK5 show unusual puncta 
distribution in the cytoplasm, but not PAK4 which is  diffuse (Figure 3.5) or presents 
in cell-cell junctions [175]. Other studies have also demonstrated such a distribution 
for PAK5 using various tags in mammalian cell lines such as CHO, HeLa, HEK293 
and NIH-3T3 cells [31, 51, 53, 54]. One hypothesis I developed was that puncta 
observed with PAK5 were connected to its elevated activity. A trivial explanation for 
puncta formation is aggregation as an unfolded protein [166]. Matenia et al [53] 
indicated an absence of the Vimentin cage-like structure typical under these 
conditions [53]. Thus, such aggresome formation is unlikely in the case of PAK5.  I 
was able to show that puncta formation requires the presence of a specific sequences 
(residues 109-420) mapped in the central region of PAK5 which are largely conserved 
in PAK5 in vertebrates  but  not present in PAK4 (Figures 3.6). My results suggest 
that most of the central region is required for puncta formation as PAK5(1-310) is 
unable to form the puncta (Figure 3.8). In addition, immuno-fluorescent staining of 
the truncated constructs of PAK5 suggests that neither the conserved N-terminal 
regulatory nor catalytic region is critical for puncta formation (Figures 3.7 and 3.8) 
suggesting they may play role to stabilize puncta.  
 Most interestingly, my studies show that PAK5 has the ability to self-associate 
(Figures 3.9 and 3.10). Co-immunoprecipitation experiments demonstrated that the 
full length PAK5 can bind to N-terminal truncated constructs of PAK5 but not the 
catalytic domain (Figure 3.9B). The removal of residues 1-109 did not affect PAK5 
self-interaction (Figure 3.9C), whereas removing the central region disrupted PAK5 
dimerization (Figure 3.10C). This region has no homology to other proteins in the 
database, and does not resemble coiled-coil sequences which are often used for self-
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association [176]. Thus, the regions of PAK5 that are conserved in PAK4 are clearly 
not critical for PAK5 dimerization, although we would expect the AID at the N-
terminus to bind the catalytic domain (in cis or trans).  
 Here, PAK5 has clearly been shown to undergo self-association and/or 
oligomerization, as noted for a number of other proteins [177, 178]. For example 
Dishevelled (Dvl) protein, a critical adaptor for Wnt signaling pathway, shows 
punctate distribution in endogenous or ectopic expression which is contributed to its 
oligomerization and subsequent induction of Wnt pathway [179]. The result of gel 
filtration analysis suggests PAK5 exhibits both dimeric and oligomer states after 
extraction without detergent (Figure 3.11). However, I do not exclude this possibility 
that a portion of PAK5 might be presented in monomeric state.   
3.9.3 The central region of PAK5 plays role in elevated activity of the protein   
Protein dimerization or oligomerization could have physiological outcomes: it 
places proteins in proximity to each other, perhaps to allow regulation of kinase 
activity or enhancing the specific protein-protein interaction site [180, 181]. Based on 
the experiments conducted in section 3.7, it appears PAK5 self-association is the key 
event that regulates the observed increased kinase activity. For example PAK5(∆268-
420) which lacks self-interaction (Figure 3.10C) has much lower in vitro kinase 
activity than the full-length protein (Figure 3.12C). One possible mechanism is that 
these residues increasing binding with substrates as reported for the other proteins 
[14, 182]. However this model is complicated by the fact that PAK5(∆116-260), has 
also lower kinase activity compared to the full length protein. (Figure 3.12C). The 
phosphorylation status of Ser602, likely the only residue modified in the activation 
loop, is not influenced by deletion of central region (Figure 3.13a). Given that this 
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residue is constitutively phosphorylated [28], changes in activity are unlikely to be 
regulated through A-loop phosphorylation.  
Interestingly PAK5(∆268-420) activity can be increased through an established 
mutation in the AID that prevents its binding to the catalytic domain (Figure 
3.13.B,C).  The significant lower activity of PAK5(∆268-420) coupled to its loss of 
oligomerization shows a good correlation between these two properties. Examples of 
similar phenomena include the Raf-1 homo- or hetero dimerization that is required for 
Raf-1 signaling in several cellular contexts [183]. Similarly most receptor tyrosine 
kinases such as epidermal growth factor receptor (EGFR) undergo oligomerization 
that leads to enhanced activity of the kinase [169, 184]. 
 Interestingly, PAK5 activity is increased a few-fold by preventing the AID 
function through different strategies (Figures 3.2, 3.3).  For example, removal of the 
first 50 amino acids or binding to Cdc42 increases PAK5 activity ~ 3-fold. There are 
two hypotheses that could explain this observation: 1. The PAK5 is in equilibrium 
between monomeric and oligomeric kinase, and therefore the mutation selectively 
activates the monomeric pool. 2. Oligomerization could partially interfere with the 
function of the AID; therefore removal of the AID would give higher activity.  The 
second hypothesis is supported by the observation that both PAK5Δ50 (Figure 3. 2B) 
and PAK5 bound to Cdc42(G12V) (Figure 3.3C) showed a mobility shift on SDS-
PAGE indicating additional phosphorylation (at as yet unidentified sites) after full 
loss of the AID function.  
Overall, the elevated activity of PAK5 clearly correlates with its oligomerization. In 
this proposal a previous study found that PAK5 activity could be suppressed by a 
fragment from the central region of PAK5 [30]. Here, GST-PAK5 was incubated with 
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the N-terminal fragment (N180) and there was reduced auto-phosphorylation and 
activity towards MBP however, the N60 fragment had no effect. The interpretation 
suggests that residues 60-180 (not conserved in other members of group II PAKs) are 
inhibitory. This suggestion can also be explained if the N180 fragments can interfere 




Chapter 4:  Analysis of potential PAK5 substrates BAD and Raf-1 
4.1 Introduction 
In general protein kinases are activated at specific cell locations, for example 
PKA acts at specific sites in the cell because it binds to AKAPs (A kinase anchor 
proteins) [185, 186]. It is not clear if PAK5 is targeted through intrinsic signals or 
requires specific adaptor proteins for its subcellular localization. In common with 
PAK4, it has been reported that PAK5 shuttles between the cytoplasm and nucleus 
due to the presence of nuclear localization sequences (NLS) and nuclear export 
sequence (NES) [50]. The NES seems to be dominant over NLS and the protein is 
observed primarily in the cytoplasm. Previously it had been suggested that 
'mitochondrial localization sequences' are present at the N-terminal region (residues 
30-83 and 400-411) [50] and within the kinase domain of PAK5 [31] .The 
underlying mechanism to establish mitochondrial targeting has not been explored in 
detail. Nonetheless, given the low level of PAK5 expression in cell lines 
(http://www-test.ebi.ac.uk/) and the poor quality of commercial anti-PAK5 
antibodies (my observations) it is unclear where endogenous PAK5 is localized.  
When tagged PAK5 was expressed stably in CHO cells or transiently in neuronal cell 
line HMN1, the protein was found to be mitochondrial [52]. In agreement with this 
report another study showed mitochondrial localization of overexpressed PAK5 in 
HeLa cells [31]. However, a number of studies have failed to detect mitochondrial 
PAK5 [53, 54]. 
Mitochondrial localization of PAK5 could be important for its observed anti-
apoptotic activity through phosphorylation of BAD [50] and indeed PAK5 was 
suggested to translocate Raf-1 to the mitochondria [51], where it is known to 
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promote pro-survival pathway. BAD and Raf-1 are common substrates of group I 
and II PAKs. While the both groups of PAKs phosphorylate Raf-1 on a regulatory 
site Ser338 [51, 187], the group I kinases  may have different preference site on BAD 
and actually PAK1 preferred the adjacent Ser111 rather than Ser112[100]. To test if 
group II PAKs are important kinases for BAD and Raf-1 in U2OS cells, a panel of 
kinase inhibitors were used;  H89 (PKA and ROCK inhibitor) [188, 189], MK-2206 
(Akt inhibitor) [190], TAK-632 (pan Raf inhibitor) [191] and PF3758309 (PAK 
inhibitor) [192]. First, U2OS cells were treated with different concentrations of Akt 
and Raf inhibitors to assess the effective concentration. As I have shown in Figure 
4.1, treatment of U2OS cells (lacking PAK5, Figure 4.13) with PAK inhibitor 
PF3759309 strongly affected BAD Ser112 phosphorylation. It was notable that Raf-1 
Ser338 phosphorylation and the level of p-ERK1/2 were significantly reduced by 
treatment with PF3758309. The effect of the PAK inhibitor on BADSer112 
phosphorylation was much more pronounced than inhibiting PKA or Raf-1. This 
result needs to be validated with other PAK inhibitors such as FRAX120[193].  
It has long been known that phosphorylation of Ser112 and Ser136 of BAD 
allows its interaction with 14-3-3 protein and retention in the cytoplasm [91, 194]. It 
has been established that many apoptotic signals lead to BAD de-phosphorylation, 
and its subsequent translocation to the mitochondria where it binds to BCl-2 and 
prevents the anti-apoptotic properties of this protein by disrupting its binding to the 
BAX protein. BAX-BAK oligomerization forms some pores within mitochondrial 
outer membrane that leads to release of cytochrome C and subsequent apoptosis [77, 
80] (Figures 1.8 and 1.10). PAK5 has been shown to directly phosphorylate  BAD 
Ser112 and indirectly increase the level of phospho-Ser136 [52] which is the 
gatekeeper site for 14-3-3 binding [91]. Given that PAK5 clearly localizes in puncta 
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in multiple mammalian cell types (Figure 4.2), I was interested to know if this 
represents a subset of mitochondria (these never resemble typical elongated and 
interconnected mitochondria [195]). 
4.2 Subcellular distribution of PAK5  
Indirect immuno-staining was performed on COS-7, HeLa and HEK-293 
cells expressing full-length Flag-PAK5 or GFP-PAK5. Mitochondrial localization of 
full-length PAK5 in HeLa and HEK-293 cells has been reported [31, 51]. Figure 4.2 
shows the typical distribution of PAK5 in distinct puncta throughout the cytoplasm. 
In cells co-stained with Mitotracker there was little co-localization between the two 
markers (Figure 4.2). Interestingly truncated constructs such as PAK5(1-236) did 
show some mitochondrial co-localization suggesting that in certain contexts PAK5 
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Figure 4.1 The effect of relevant kinase inhibitors on BAD and Raf-1
phosphorylation. A. U2OS cells were treated with different
concentrations of AKT inhibitor (MK-2206) or pan Raf inhibitor (TAK-632)
to assess the effective concentration of the inhibitors. U2OS cells were
serum starved for 4 hours before addition of the inhibitors. B. U2OS cells
were serum-starved for 4 hours, then treated with PKA inhibitor H89
(10μM) or AKT inhibitor MK-2206 (2.5μM), or pan Raf inhibitor TAK-632
(5μM) or PAK inhibitor PF3758309 (5μM) for 15 minutes before addition
of 10% FCS (where indicated) for additional 10 minutes. The cells were
then lysed in RIPA buffer and 50µg of total protein loaded in each lane
for SDS-PAGE and western blot analyses C. Quantitation of the bands
were carried out using image J. The averaged values from 2
independent experiments were normalized relative to the control




















PAK5 WT GFP PAK5 WT
Figure 4.2 Subcellular localization of PAK5. Flag or GFP-PAK5 constructs
were transfected in COS-7, HEK-293 and HeLa cells as indicated. The
following day, cells were fixed in 4% PFA, permeabilized and processed for
immunostaining with mouse anti-Flag antibody as indicated. GFP-PAK5
transfected cells were analyzed after fixation without further processing.
Mitochondrial staining of live COS-7 cells were performed using Red
Mitotracker (CMXRose) for 20 min, the cells were then washed in PBS and
fixed in 4% PFA. Puncta distribution of PAK5 did not overlap the typical









Figure 4.3 PAK5 contains a cryptic mitochondrial localization
sequence. A. COS-7 cells were transfected with truncated constructs of
Flag-PAK5. the following day, cells were live stained with the red
Mitotracker (CMX Ros, 150nM), then fixed and immunostained with





In previous chapter I demonstrated that PAK5 has an ability to oligomerize, 
which promotes kinase activation. To investigate whether PAK5 oligomerization can 
affect protein compartmentalization, I tested the effect of oligomerization on the 
nuclear localization of PAK5. PAK5 contain a basic nuclear localization sequence 
(NLS) in residues 5-10 as well as a nuclear export sequence (NES) [50]. The 
reported NES is mapped in residues 400-411 of PAK5 which is not conserved in 
PAK4 and PAK6. Several truncated constructs of PAK5 in my study suggested that 
PAK5 should contain another dominant NES. For example PAK5 ∆268-420 (which 
lacks the reported NES at residue 400-411) is still cytoplasmic (Figure 3.12B), 
though its molecular weight is less than the allowable size of  90-110kD  for 
diffusion through the nuclear pore [196]. Work in our laboratory has suggested that 
group II PAKs contain a conserved functional NES at residues 84-94, and selective 
alanine mutations in this motif interfere with the NES function (Yohendran 
Baskaran, unpublished data). A similar set of mutations in PAK5 and PAK5∆268-
420 were tested (Figure 4.4A). The indirect immunofluorescent staining 
demonstrated that PAK4 with a mutated NES accumulated in the nucleus. However, 
although the PAK5 NES mutant was not nuclear enriched, the monomeric 
PAK5∆268-420 (with NES mutant) behaved like the PAK4 mutant (Figure 4.4B). 
This result suggests PAK5 self-association (oligomerization) largely prevents the 
nuclear import of the kinase. 
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Figure 4.4 The effect of mutation on putative nuclear export
sequences of PAK4 and PAK5. A. Schematic showing the alignment of
PAK4 and PAK5 putative NES sequences. Alanine mutations of PAK4 at
the sites shown leads to nuclear accumulation of PAK4 (Yohendran
Baskaran, unpublished data). B. The plasmids encoding wild type or
NES mutated Flag-PAK4, Flag-PAK5 and Flag PAK5∆268-420 were
transfected in COS-7 cells. Indirect immunofluorescence analysis was
performed 16h after transfection. While PAK4mNES accumulates in the
nucleus, PAK5mNES retains its cytoplasmic localization. However,
PAK5∆268-420-mNES which is not able to form puncta is partially




4.3 Analysis of BAD as a PAK5 target 
4.3.1 PAK5 does not co-localize with BAD in the cells 
Mitochondrial localization of PAK5 has been suggested as one mechanism to 
allow access to its substrate BAD [50]. I observed under normal culture conditions 
(ie in 10% serum) PAK5 shows no enrichment on the mitochondrial compartment. 
Since over-expressed BAD tends to accumulate at mitochondria [197], I was 
interested to see if PAK5 would also translocate under this condition. Both COS-7 
and HEK-293 cells were transfected with low levels of HA-PAK5 and Flag-BAD for 
overnight, fixed and analyzed by indirect immune-fluorescent. As can be seen in Fig 
4.5 some Flag-BAD accumulated at mitochondria; however there was no obvious 
change in PAK5 distribution. In normal cells, BAD is phosphorylated and 
sequestered by 14-3-3 protein and therefore the protein is predominantly found in the 
cytosol [85]. I hypothesized that this binding to 14-3-3 protein could prevent PAK5 
binding to the BAD which would result in only a transient interaction (before its 
phosphorylation). Since phosphorylated Ser136 residue is critical for 14-3-3 binding 
[91], I generated a construct encoding BAD(S136A) and then examined its 
distribution with respect to PAK5 (Fig 4.6A,B). The mutated BAD was much more 
efficiently localized to mitochondria but again PAK5 remained in puncta at which 























Figure 4.5 Analysis of co-localization of transiently expressed
PAK5 and BAD. 0.5μg of Flag-BAD and HA-PAK5 were co-expressed
in COS-7 or HEK 293 cells for overnight. Cells were then fixed in 4%
PFA and co-immunostained with anti-Flag and anti-HA antibodies to
analyse co-localization of PAK5 and BAD. (Scale bar:10µm)
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mBAD MGTPKQPSLAPAHALGLRKSDPGIRSLGSDAGGRRWRPAAQSMFQIPEFE 50 
hBAD ------------------------------------------MFQIPEFE  
                                               ******** 
 
mBAD PSEQEDASATDRGLGPSLTEDQPGP-----YLAPGLLGSNIHQQGRAATN 95  
hBAD PSEQEDSSSAERGLGPSPAGDGPSGSGKHHRQAPGLLWDASHQQEQPTSS 58 
     ******:*:::****** : * *.        ***** .  *** :.::. 
 
mBAD SHHGGAGAMETRSRHSSYPAGTEEDEGMEEELSPFRGRSRSAPPNLWAAQ 145 
hBAD SHHGGAGAVEIRSRHSSYPAGTEDDEGMGEEPSPFRGRSRSAPPNLWAAQ 108 
     ********:* ************:**** ** ****************** 
 
mBAD RYGRELRRMSDEFEGSFKG-LPRPKSAGTATQMRQSAGWTRIIQSWWDRN 194 
hBAD RYGRELRRMSDEFVDSFKKGLPRPKSAGTATQMRQSSSWTRVFQSWWDRN 158 
     ************* .***  ****************:.***::******* 
 
mBAD LGKGGSTPSQ 204 
hBAD LGRGSSAPSQ 168 
     **:*.*:*** 






Figure 4.6 Mitochondrial localization of mutated BAD does not
induce PAK5 translocation to the mitochondria. A. Sequence
alignment of BAD protein in human and mouse. Phosphorylation of the
conserved serine 112 and 136 residues (shaded yellow) promotes 14-3-
3 binding which prevents mitochondrial targeting of Bad. The Ser155 lies
within the BH3 domain of BAD and its phosphorylation negatively
regulates binding to the mitochondrial BCL-2. BH3 domain marked gray.
B. COS-7 were co- transfected with 0.5μg of HA-PAK5 and Flag-BAD-
S136A constructs. After overnight expression, mitochondrial staining
using Mitotracker (150nM) was performed. Cells were then fixed and






4.3.2 Camptothecin treatment does not affect PAK5 localization 
A previous report suggested that PAK5 expression can promote 
Camptothecin resistance in colorectal cancer cells [135]. I was therefore interested to 
see if drug treatment (which induces apoptosis) affects the localization of PAK5 
under this stressed condition. COS-7 cells were treated with Camptothecin and Flag-
PAK5 distribution assessed by immunofluorescent staining. Although Camptothecin 
clearly induced apoptosis in COS-7 cells as suggested [198], such a signal (after 
DNA damage) does not influence PAK5 distribution (Figure 4.7 A, B).  
4.3.3 PAK5 promotes BAD Ser112 phosphorylation  
Since in my hands there is little PAK5 associated with mitochondria, I was 
interested to see whether in fact PAK5 promotes BAD phosphorylation nonetheless. 
First, I tried to find an agent that could induce apoptosis coupled to BAD de-
phosphorylation. For example Camptothecin treatment induced BAD 
dephosphorylation in CHO cells [52]. Camptothecin is a topoisomerase I inhibitor 
and induces DNA damage in the cells (during S-phase) [199]. Treatment of HEK293 
cells with 1μM of Camptothecin for 24h induces apoptosis in 60% of cells [200]. 
Using this system, I co-transfected HEK-293 cells with HA-BAD and either Flag-
PAK5 or empty vector for 16h then treated them with 10μM, 25μM and 50μM 
Camptothecin for a further 24h. As can be seen in figure 4.8, this treatment failed to 
reduce BAD pS112 signal (compare lane1 with lanes 2,3,4 or lane 5 with lanes 6,7,8) 
under these conditions. Most importantly, it is clear that ectopic expression of PAK5 






































Figure 4.7 Camptothecin treatment does not induce PAK5 re-localization
to the mitochondria. COS-7 cells transiently expressing Flag PAK5 were
treated with either DMSO or indicated concentration of Camptothecin for 24h.
Next, cells were stained with mitotracker and then fixed and stained with anti-
flag antibody to examine PAK5 localization. A. Increased nuclear fragmentation
is consistent with apoptosis in COS-7 cells treated with 10μM of Camptothecin
for 24h. B. Micrographs indicate Flag-PAK5 distribution is not significantly










1        2       3        4       5       6       7       8
Camptothecin (µM)         - 10   25   50    - 10   25   50
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Figure 4.8 PAK5 phosphorylates BAD on Ser-112 in vivo. HEK293 cells
were co-transfected with HA-BAD and either empty vector or Flag-PAK5
overnight. Then cells were treated with either DMSO or various concentration
of Camptothecine as indicated. After 24h, cells were harvested and lysates
separated on SDS-PAGE to examine the pSer112 status of BAD. Ser-112
phosphorylation in the cells treated with DMSO was compared with
camptothecin treated cells (lane 1 compared to lanes 2,3 and 4 or lane 5
compared to lane 6,7 and 8). Camptothecin treatment did not induce BAD
de-phosphorylation on Ser112. PAK5 transfected cells showed an increased




4.4 Analysis of PAK5 interaction and localization with Raf-1  
4.4.1 PAK5 can co-localize with Raf-1 and phosphorylate it at Ser338 
As I described in the main introduction, Raf-1 activation is a complex 
mechanism involving a number of upstream kinases, small G-proteins and adaptors 
(Figure 1.12). Ras.GTP promotes Raf-1 (auto)phosphorylation on several residues 
that are essential for full Raf-1 activity towards MEK1 [109]. Ser338 residue 
phosphorylation has been suggested to be critical for Raf-1 activation although the 
equivalent residue in B-Raf is constitutively phosphorylated [114, 201, 202]. PAKs 
have been reported as one of the potential Raf-1 ser338 kinase [51, 115, 116, 203-
205]. As can be seen in figure 4.9, I confirmed that Raf-1 is phosphorylated by over-
expressed PAK5 in cells. Although PAK4 was also reported to phosphorylate Ser338 
[51, 116], it has been suggested that PAK5 is much more effective in this regard 
because it can directly bind Raf-1[205]; this observation has not been confirmed by 
other laboratories. Co-expression of Raf-1 with PAK5 has been suggested to 
translocate Raf-1 to the mitochondria independent of PAK5 activity [205]. 
I have shown that the punctate distribution of PAK5 in HEK-293, HeLa and 
COS-7 cells is not significantly co-localized with Mitotracker (Figure 4.3). One 
possibility, given that Raf-1 action at mitochondria [206], is that PAK5 requires 
interaction with Raf-1 in order to form a productive complex at the mitochondrial 
surface. Since the level of Raf-1, A-Raf and B-Raf vary in different cells; it might 
explain the difference in PAK5 localization. COS-7 and HeLa cells were transfected 
with either exogenous HA-Raf-1 or co-transfected with HA-Raf-1 and Flag-PAK5. 
The cells were serum-starved for 16h in order to synchronize them in G1 and to 
reduce basal phosphorylation of Raf-1. Immuno-staining analysis revealed diffuse 
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expression of Raf-1 in the cytoplasm with some concentration in the perinuclear 
region that partially colocalized with mitochondria (Figure 4.10A,B). When Raf-1 
co-expressed with PAK5, in some cells the two proteins were poorly co-localized 
(Figure 4.10C,D), however in some other cells the both proteins were present in 
puncta concentrated in perinuclear region (Figure 4.10E). At higher resolution it was 
apparent that there was not convincing co-staining of the two on mitochondria 
(Figure 4.10E,F). These results were similar when I used HeLa cells (data not 
shown). In summary my results suggest that the two proteins can interact in vivo but 
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Figure 4.9 PAK5 phosphorylates Raf-1 on Ser338 in vivo. COS-7 cells were
co-transfected with HA-Raf-1 and either empty vector or 0.4μg and 0.8μg. of
Flag-PAK5 expression plasmids. The following day, cells were serum starved
for another 16h and then harvested and lysed in RIPA buffer. SDS-PAGE and
western blotting was performed to analyze Raf-1 phosphorylation with the




















Figure 4.10 Analysis of PAK5 and Raf-1 co-localization in COS-7
cells. COS-7 cells were transfected with either HA-Raf-1 or Flag-PAK5
in combination with HA-Raf-1. After overnight expression, cells were
serum starved for 16h and then stained with Mitotracker (150nM) before
fixation (4% PFA). Immuno-staining was carried out with mouse anti HA
and rabbit anti Flag antibodies. A. Representative image of
immunofluorescence staining of COS-7 cells transfected with HA tagged
Raf-1. Scale bar:10µm. The boxed were magnified (3 folds) to better
assess the mitochondrial localization of Raf-1 B. Line scan analysis of
















Figure 4.10 Analysis of PAK5 and Raf-1 co-localization in COS-7
cells. C. Representative image of COS-7 cells transiently co-expressing
HA-Raf-1 and Flag-PAK5 with no colocalization between the two
proteins. The boxed area was enlarged (3 folds) in the lower panel. D.
Line scan analysis of signals from three channels was performed using




















Figure 4.10 Analysis of PAK5 and Raf-1 co-localization in COS-7 cells.
E. Representative image of COS-7 cells co-expressing PAK5 and Raf-1
with some of the signals in puncta that is not associated with the
mitochondria. scale bar: 10µm F. colocalization of the signals from three






4.4.2 Investigating the interaction site of PAK5 with Raf-1  
Since Raf-1 was reported to selectively binds PAK5 versus PAK4 [51], I was 
interested to map the interaction site(s) of Raf-1 with PAK5. Using a Flag tagged N-
terminal deletion construct of PAK5 generated previously, I tested Raf-1 interaction 
by standard co-immunoprecipitation. Full length Flag-PAK5 is able to pull down 
Raf-1 while Flag-PAK5∆268 has largely lost this ability (Figure 4.11A). Because 
removing 268 amino acids from PAK5 disrupts its oligomerization (Figure 3.7)  
there is a possibility that Raf-1 binding requires an oligomeric form of PAK5 or that 
the first 268 amino acids of PAK5 includes the Raf-1 interaction site. To evaluate 
these models, I switched to using glutathione-S-transferase (GST) fusion constructs 
of PAK5 since GST itself is prominently a dimer [207]. The results (Figure 4.11B) 
suggest that the residues 1-268 of PAK5 are required for binding to Raf-1 and PAK5 
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Figure 4.11 Raf-1 can bind to the N-terminal of PAK5. A. COS-7 cells
were co-transfected with HA-Raf-1 and either indicated Flag tagged
constructs of PAK5 or empty vector. The lysates were used for co-
immunoprecipitation analysis using anti-Flag Sepharose (see methods)
and then subjected to western blotting. HA-Raf-1 was detected using
anti-HA coupled to HRP B. COS-7 cells were co-transfected with HA-
Raf-1 and either mutated GST-PAK5 constructs or pXJ-GST vector. The
GST fusion proteins were recovered using glutathione Sepharose and





I have demonstrated that ectopic expressed Flag-PAK5 or GFP-PAK5 shows 
an unusual punctate distribution in COS-7, HeLa and HEK293 cells (Figure 4.2). 
This is unlike protein aggregates that commonly seen when mis-folded proteins are 
expressed in mammalian cells.  In no case, I was able to localize the full-length 
kinase to mitochondria using Mitotracker. The Flag-PAK5 retains a punctate 
distribution after co-expression with BAD (Figure 4.5 and 4.6) or the initiation of 
apoptosis by Camptothecin (Figure 4.7). I could however confirm that PAK5 
contains cryptic mitochondrial localization signals (Figure 4.3) that might allow the 
protein to associate with mitochondria under specific conditions.   
PAK5 is able to drive in vivo BAD phosphorylation at Ser112 (Figure 4.8) 
but it is not co-localized with BAD (when over-expressed) on mitochondria (Figures 
4.5 and 4.6). This is not untypical since many kinase substrates interact with low 
affinity with their kinases. By contrast, I found that PAK5 could interact with Raf-1 
which requires residues 1-268 and this leads to enhanced Raf-1 phosphorylation at 
Ser338 (Figures 4.9 and 4.11). Co-immunostaining results suggest that PAK5 and 
Raf-1 are poorly associated in COS-7 and HeLa cells (Figure 4.10). 
4.6 Characterization of endogenous PAK5  
My previous results suggested that even when expressed at low level (0.2 
ug/ml (see Fig 3.5) PAK5 oligomerized and that this process is responsible for the 
elevated level of PAK5 activity when compared to the fully auto-inhibited 
monomeric PAK4. These PAK5 puncta however were not specifically associated 
with any larger-scale structure in the cell (mitochondria, actin stress fibers, 
endosomes, or microtubules). Therefore, I was interested to compare where 
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endogenous PAK5 localizes in cultured cells and the nature of its oligomerization. 
Previous work has noted that PAK5 can be associated with a number of compartment 
but most of these have been based on ectopic expression of tagged version of the 
kinase [31, 50, 52, 53]. 
In order to find a cell line with high levels of PAK5, the gene expression data 
set was probed (http://www-test.ebi.ac.uk/). Based on a data derived from 950 
samples of 317 different cancer cell lines [208], I found that PAK5 mRNA is higher 
in NCI-H446 and SW962. The small lung cancer cell line NCI-H446 exhibited the 
highest PAK5 mRNA level expression; therefore this cell line was included in the 
analysis. A commercial PAK5 antibody (Abcam 37753) was used to detect PAK5 
expression in NCI-H446 (ATCC) but as can be seen in figure 4.12A and B, the 
antibody was not sensitive enough to detect endogenous level of PAK5. Conversely, 
an antibody that detects the activation loop of PAK4, PAK5 and PAK6 (pS474, 
pS602 and pS560) was extremely sensitive compared to specific PAK5 antibody 
(Figure 4.12A). Because group II PAKs are constitutively phosphorylated on 
activation loop [28], we can assume that the antibody can detect the relative level of 
these proteins. We also raised a specific antibody against PAK5 (residues 142-159) 
which was extensively characterized (Figure 4.12C), however it was not sensitive 
enough to detect endogenous level of PAK5 in NCI-H446 cell line (data not shown). 
Therefore, the antibody against the activation loop of group II PAKs were used to 
compare PAK5 expression in NCI-H446 cell line and a few other cancer derived 
lines that some of them were reported to express PAK5 [3, 130, 131, 209].  As can be 
seen in figure 4.13A, a band corresponding to the expected size of phospho-PAK5 
was only detected in NCI-H446 cells. Unfortunately an unrelated protein band of ~75 
kDa protein is found in most cells. I also tested PAK5 expression in a number of cell 
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lines using another commercial PAK5 antibody (ab110069). This antibody detected a 
non-specific band with a close size to PAK5 in most of the cell lines (Fig 4.13B) but 
not endogenous PAK5. As I have shown, there is no sensitive (and specific) 
polyclonal or monoclonal commercial anti-PAK5 antibody; it is therefore difficult to 
compare results from different labs.  The anti-activation loop antibody indicated that 
PAK5 expression is several times lower than PAK4 expression in NCI-H446 cells. 
This cell line was found to be poorly attached on plastic and glass surfaces and was 
difficult to dissociate during trypsinization; indicating the cell-cell junctions were 
selectively stable. These cells are not easily transfected using standard liposome 
preparations and therefore not suitable for siRNA or transient transfection analysis. 
In order to analyze the effect of PAK5 expression in this line, I therefore used 
shRNA to derive NCI-H446 clonal lines in which the PAK5 level was reduced (Fig 
4.14). Different clones of PAK5 stable knockdown line, exhibited no homogeneity in 
my experiments (such as migration assay and soft agar assay), therefore the results of 
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Figure 4.12 Comparison of sensitivity of PAK5 antibodies. A. B Lysate
of COS-7 cells expressing low levels of Flag-PAK4 or Flag-PAK5 and the
lysate of NCI-H446 cells with endogenous expression of PAK4 and PAK5
were used to compare the sensitivity and specificity of two commercial
anti-PAK5 antibodies using Western blot. Anti-phospho-PAK4(Ser474)/
PAK5(Ser602)/ PAK6(Ser560) (Cell signaling) or anti-PAK5
(Abcam,37753) antibodies were used at 1/1000 and 2/1000 v/v
respectively. The anti-p-PAK4/5/6 antibody clearly detects Flag tagged
PAK4 and PAK5 and endogenous PAK4 (65 kDa) and PAK5 (~85kD),
although it picks up an unrelated band at 70 kDa. The anti-PAK5 (Abcam)
detects overexpressed PAK5 with much less sensitivity versus anti-p-
PAK4/5/6. It cannot detect endogenous PAK5 even in higher concentration
(1/100 v/v) (B). C. Polyclonal antibody raised against the residues 142-159
of PAK5 was affinity purified in 4 fractions (see material and methods).
Lysate of U2OS cells stably expressing GFP-PAK5 were used to test the








































































Figure 4.13 Analysis of endogenous PAK5 expression in different
types of cancer cell lines. A,B. Lung cancer (NCI-H446,NCI-H187),
Osteosarcoma (U2OS), Cervical cancer (HeLa), Hepato cellular
carcinoma (Huh-7), Colorectal cancer (HCT-116, HT-29), Breast cancer
(MCF-7, MDA-MB231) and Prostate cancer (DU-145, LNCap) cell lines
were used to analyze endogenous PAK5 expression. Cells were lysed
with RIPPA buffer and 50μg of proteins were loaded into SDS-PAGE.
The antibody that detects phosphorylated activation loop of PAK4,
PAK5 and Pak6 and a commercial PAK5 antibody (ab110069) were
used for Western blotting. β actin expression was used as a loading
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Figure 4.14 PAK5 expression in PAK5 knockdown stable line NCI-
H446. NCI-H446 clones with stable expression of sh-PAK5 (see
methods) or sh-control were established under G418 selection
(300μg/ml). Sh-PAK5 suppressed PAK5 protein levels but not that of





4.6.1 GFP-PAK5 localizes in junctions of U2OS cells 
Because of the lake of specific and sensitive PAK5 antibody, I was not able 
to analyze endogenous PAK5 localization; therefore I established a number of U2OS 
cell lines which express GFP-PAK5 under Puromycin selection. The PAK5 
expression level could again be compared with endogenous level of PAK4 by 
western blotting (Figure 4.15A). Based on these results, both examined clones seem 
to express PAK5 3 fold of endogenous PAK4. 
When cells were fixed and imaged, it was obvious that the protein was found 
in puncta and also distributed on cell junctions (Figure 4.15B). To find out whether 
PAK5 might move to mitochondria in the absence of cell-cell junctions, the cells 
were grown in low density. But I was not able to co-localize PAK5 significantly with 
Mitotracker (Figure 4.15C,D). 
To investigate the junctional localization of PAK5 in a well characterized 
epithelial cell line, I transfected the kinase in MDCK cells which exhibit well 
organized and stratified junctions [210, 211]. Transient expression of GFP-PAK5 
indicated junctional localization of the protein (Figure 4.16A). p120 catenin has been 
suggested as a binding partner and substrate for PAK5 and a constitutively activated 
GFP PAK5 was found to phosphorylate p120 at Ser288 [54]. As can be seen in 
Figures 4.16B and C, the GFP-PAK5 is partially co-localized with p120 in the 
junctions of MDCK and U2OS cells, indicating that the kinase might be involved 
with several junctional compartments.  The cells tended to exhibit a single or doublet 
spot often above the nucleus (arrows). Further experiments showed colocalization of 
these spots with γ-tubulin, suggesting another new localization site for PAK5 in the 












































GFP-PAK5 (clone 9)U2OS GFP (clone 4)
GFP-PAK5 (clone 14) GFP-PAK5 (clone 22)
Figure 4.15 PAK5 localization in GFP-PAK5 U2OS stable line.
A. The lysate from two GFP-PAK5 stable cell lines and two
control lines were subjected to western blot. The level of GFP-
PAK5 was compared to endogenous PAK4 expression using
antibody directed at the identical p-S474 /pS602 sequence. B.
Typical distribution of GFP-PAK5 in U2OS stable lines after
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Figure 4.15 PAK5 localization in GFP-PAK5 U2OS stable line. C.
Cells were seeded at low density and treated with 150nM of Mitotracker
for 20 min before fixation in 4% PFA. Immuno-staining was performed
with rabbit anti-GFP antibody. Scale bar: 10µm.The boxed area was
magnified (3 folds) to better assess the distribution of mitochondria
versus GFP-PAK5. D. colocalization of GFP-PAK5 and Mitotrcaker was

























































Figure 4.16 Partial co-localization of GFP PAK5 with p120 catenin.
A. MDCK cells with transient expression of GFP-PAK5 were fixed in PFA for
20 minutes followed by methanol for 2 minutes and then co-immunostained
with rabbit anti-GFP and mouse anti-p120 catenin antibodies (B). Line scan
analysis of PAK5 and p120 along the indicated arrow to assess GFP-PAK5
and p120 catenin colocalization.C,D. U2OS cells stably expressing GFP PAK5
were fixed and co-immunostaining was performed using rabbit anti-GFP and










4.7.1 PAK5 phosphorylate BAD and Raf-1 in vivo 
The results in this chapter showed a punctate distribution of ectopically 
expressed Flag- and GFP-PAK5 in multiple cell types (COS-7, HEK-293 and HeLa). 
These puncta do not resemble the typical mitochondrial staining pattern nor do these 
overlap with Mitotracker (Figure 4.2). Such puncta PAK5 have been noted previously 
but was suggested to colocalize with mitochondria [52]; although other failed to 
reproduce this result in the same cell line [53]. Interestingly PAK5 (1-236) but not 
full-length PAK5 clearly localizes to mitochondria (Figure 4.3A) which is consistent 
with a reported mitochondrial localization sequence within residues 30-83 [50]. 
Established mutation that leads to inactivation of the NES in PAK4, did not lead to 
nuclear localization of PAK5 (Figure 4.4B), although PAK4 harboring the same 
mutations is nuclear (Fig 4.4B). One reason could be that PAK5 puncta greatly 
exceed 39nm that does not allow a protein to freely pass through the nuclear pore 
complex [212]. Based on these observations, I proposed that PAK5 self-association 
(oligomerization) may prevent nuclear import of the protein. 
 In no condition tested in this study, such as serum starvation or Camptothecin 
induced apoptosis (Figure 4.7), full length PAK5 showed mitochondrial localization. 
For example, Akt is usually cytoplasmic, however under cell stress the protein can 
accumulate on mitochondria where it can promote cell survival. My results also rule 
out the possibility of PAK5 recruitment to mitochondria via interaction with BAD. 
PAK5 distribution was not co-localized with wild type BAD or predominantly 
mitochondrial BAD(S136A) (Figures 4.5 and 4.6). Nonetheless, PAK5 can clearly 
phosphorylate BAD Ser112 in vivo, as shown with overexpressed BAD (Fig 4.8). 
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Indeed BAD phosphorylation may be a common feature of both group I and II PAKs. 
As it is demonstrated in figure 4.1, U2OS cells (lacking PAK5) treatment with 
PF3758309, leads to dramatic reduction in BAD Ser112 phosphorylation; thus PAKs 
are key BAD kinases in this cell line. Work in our lab has established that PF3758309 
inhibits both group I and II PAKs in vivo (Elsa Ng, unpublished). At 5μM 
concentration, which was used in this experiment, PF3758309 partially inhibits group 
I PAKs and fully inhibits group II PAKs suggesting that the observed effect is mainly 
related to group II PAKs. Further, Ser111 appears to be the preferred site for PAK1 
phosphorylation rather than Ser112 [100]. The former does not generate a 14-3-3 
binding site, thus antagonizing phosphorylation of Ser112.  By contrast the PKA and 
ROCK inhibitor (H89) or the pan Raf inhibitor (TAK-632) has little effect; although 
both are reported as BAD Ser112 kinases [206, 213]. One reason could be the kinase 
selectivity of PF3758309 that has been previously reported [121]. Additional PAK 
inhibitors such as FRAX120 should be tested to validate this result. Unfortunately 
these compounds are not currently available from commercial sources.  
Raf-1 has been established by a number of studies as an important kinase for 
BAD phosphorylation and its anti-apoptotic effect [100, 206]. I have shown that 
PAK5 can bind to Raf-1 through the N-terminal of PAK5 (Figure 4.11) and that this 
event leads to Raf-1 Ser338 phosphorylation (Figure 4.9). Immunofluorescence 
staining showed PAK5 expression can lead to Raf-1 recruitment to the puncta (Figure 
4.10E) however; this is not always apparent (Figure 4.10C). It is possible that another 
protein partner stabilizes this interaction in the cell (my results in the next chapter, 
suggest that LZTS2 could play this role (Figure 5.22). The ability of PAK5 to 
phosphorylate Raf-1 on Ser338, has been noted for other PAK kinases [115, 187, 
205], but if PAK5 binds to Raf-1 it may be more effective in this regard. PAK5 can 
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activate Raf-1 independent of growth factors such as EGF [51]. Raf-1 Ser338 is an 
important site of kinase regulation [114]. Although PAKs have been long known to 
phosphorylate Raf-1 on Ser338, this role is not widely accepted [109, 113]. Indeed 
PAKs may not be necessarily activated by the stimuli that phosphorylate Ser338 [214] 
and may not have the ability to bind Raf-1 at the same region of the plasma 
membrane, where Raf-1 interacts with Ras [214]. Since Ser338 is reported as an auto-
phosphorylated site upon dimerization of Raf-1 [113], the role of PAKs is 
questionable. Based on published data, PF3758309 does not show activity to Raf-1 
[121], which makes it difficult to explain the effects of PF3758309 on Raf-1 
phosphorylation and activation in U2OS cells (Figure 4.1). The effect of the PAK 
inhibitor on ERK phosphorylation was comparable to effect of pan-RAF inhibitor 
TAK-632 (Figure 4.1 B, lanes 7 and 9). Although Sarofenib (Raf inhibitor) has 
significantly reduced phosphorylation of Ser338 in HEK-293 cells [113], TAK-632 
treatment did not significantly affect Ser338 phosphorylation indicating a mechanism 
in this case, not involving auto-phosphorylation. Taken together, these results suggest 
that PAK4 could be an important Raf-1 kinase in U2OS cells; although PF3758309 
has some inhibitory effect on CaMKII kinase [121].  CaMKII kinase is reported to act 
downstream of Ras (via calcium signaling) to mediate the  Raf-1 phosphorylation in 
response to several stimuli [118] and the use of a specific CaMKII inhibitor would be 
needed to assess this in U2OS cells. 
4.7.2 Localization of PAK5 in mammalian cell lines 
PAK5 largely localizes in junctions in U2OS cells in which the kinase is 
stably expressed as a GFP protein (Figure 4.15, B). This localization has not been 
described previously. I have also confirmed the junctional localization of GFP-PAK5 
by transiently expressing the kinase in commonly used epithelial MDCK cells (Figure 
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4.16A). GFP-PAK5 staining was similar to, but may not identical, with p120 catenin 
localization in these cells, as well as in the U2OS cells (Figure 4.16 A, C). The 
punctate distribution of PAK5 appeared to accumulate in a perinuclear region, 
however since this region of the cell contains a large volume of the cytoplasm in 
adherent cells, one must be cautious with the interpretation. Some protein 
concentration was seen in the centrosomal region which was colocalized with the 
centrosomal marker γ-tubulin (Figure 4.16D). The cell-cell junctional localization of 
PAK5 is consistent with the presence of the Drosophila PAK4 orthologue Mbt [215] 
in junctions of photoreceptor cells. PAKs have been suggested to regulate a number of 
junctional components [26, 65, 216]. For example PAK4 localizes in cell-cell 
junctions of nascent lung epithelial cell 16HBE and promotes maturation of these 
junctions in calcium switch experiments [26]. PAK4 can phosphorylate β-catenin at 
Ser675 [66] which is suggested to promote dissociation of β-catenin from E-cadherin 
and subsequent junctional disassembly [65]. A recent report found GFP-PAK6 
concentrated in cell-cell junctions of DU145 prostate cancer and HT29 colorectal 
cancer cells [65]. Here, PAK6 was required for HGF-mediated dissociation of 
junctions by forming a complex with E-cadherin and IQGAP1 (IQ motif containing 
GTPase activating protein). Moreover, they again suggested β-catenin as one 
junctional substrate for PAK6 that promotes junctional disassembly. 
Partial co-localization of PAK5 with p120 catenin in MDCK and U2OS cells 
(Figure 4.16A and C), might indicate p120 catenin phosphorylation by PAK5 [54].  
The role of p120-catenin is to stabilize conventional cadherins at the adherent 
junctions [217]. p120-catenin binding regulates the level of E-cadherin by preventing 
its internalization and degradation [70, 217]. The increased level of p120 has been 
associated with increased cell migration, particularly of cancer cells [218, 219]. 
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Likewise in neurons, p120 catenin is not only associated with N-cadherin cell-cell 
adhesion, but also plays distinct roles in synaptogenesis [220]. Since PAK5 is mainly 
expressed in the brain, PAK5 may influence p120's role in synaptic formation, which 
is consistent with the severe nervous system phenotype of PAK5/6 null mice [49].  
In conclusion, I have shown that both BAD and Raf-1 are PAK5 substrates in vivo. 
My results suggest that mitochondria is not the main resident compartment for PAK5, 
Most importantly, PAK5 accumulates in cell-cell junctions and centrosomal region 
























Chapter 5. Screening and characterization of proteins co-localizing 
with PAK5 in U2OS cells  
 
5.1 Introduction 
 In the previous chapter, I described the junctional localization of PAK5, 
which has not been previously reported although the co-localization of PAK5 with 
cytoplasmic phosphorylated p120 catenin was shown in NIH-3T3 cells [54]. Previous 
attempts to identify partners of PAK5 in the brain used a biochemical purification 
approach to identify Pacsin1 and Synaptojanin as substrates for PAK5 [140]. Both 
Pacsin1 and Synaptojanin regulate the endocytosis and recycling of synaptic vesicles. 
Synaptojanin plays role in un-coating and recycling of synaptic vesicles via its 
phosphatase activity. Pacsin1 is a brain isoform of Pacsin family of proteins 
containing F-BAR and SH3 domain and can drive membrane deformation via its F-
BAR domain [221]. Pacsin1 binds to proline rich domain of Synaptojanin via its SH3 
domain and thus the two form a complex in vivo [222]. PAK5 phosphorylates both 
Pacsin1 and Synaptojanin:  it is suggested that PAK5 phosphorylates Pacsin1 and 
releases its auto-inhibited conformation which promotes its interaction with 
Synaptojanin.  
Several public databases of compiled protein-protein interactions exist, and 
from this, the partners for PAK5 have been summarized (Table 5.1). In this chapter, I 
describe a new method that allows local modification of PAK5 neighbors in suitably 
generated cell lines. This method could successfully identify proximal proteins of 
PAK5 primarily located at cell-cell junctions, and that one of these proteins named 
LZTS2 is shown to be a direct interacting protein with PAK5.   
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Table 5.1 The list of PAK5 interacting partners extracted from data bases 
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5.2. Classical methods for identification of protein-protein interactions 
Several methods have been developed to identify protein-protein interactions 
(PPIs). Yeast two hybrid assay (Y2H), affinity complex purification and chemical 
crosslinking method are traditional approaches for investigation of PPIs [231]. Y2H 
method was developed by Fields and Songs in 1989 [232]. To perform the classical 
Y2H, a bait cDNA is fused in frame to the binding domain (BD) of a transcription 
factor and a library of prey cDNAs, which are fused to an activating domain (AD), are 
tested against this construct [233]. The interaction between bait and prey proteins, 
leads to connection of AD and BD of transcription factor and subsequent transcription 
of a reporter gene which could be detected. The advantage of this method (over the 
affinity purification) is that a weak interactions can be amplified by the reporter gene 
[234]. However the technique suffers from a high rate of false positives [235]. The  
classical Y2H method cannot be used for membrane-bound proteins or for those 
requiring modification that occurs in mammalian cells but not yeast cells [233]. 
Variants of this method can overcome some of these limitations, for example split-
ubiquitin membrane yeast two-hybrid system (MYTH) allows analysis of integral 
membrane proteins [236]. 
 The affinity based methods rely on isolation of the protein of interest (bait) 
with a range of binding proteins (preys), via different methods such as a specific 
antibody. The use of epitope tag sequences fused to the target protein allows a generic 
system to immobilize the 'bait' [237]. However, the tag may interfere with protein 
localization or activation, and over-expression can lead to the identification of non-
physiological targets. Affinity purification allows one to identify multi-protein 
complexes (that cannot be detected by Y2H), or probe interactions that require post 
translational modifications such as phosphorylation: for example 14-3-3 protein 
125 
 
family requires targets to be phosphorylated [238]. The disadvantage of methods that 
require capture and washing is the bias towards strong interactions, while transient 
interactions may not be detected. The binding affinity of two proteins in the cellular 
environment may not survive in the diluted buffer used to assay the protein-protein 
interaction [234]. Multiple forms of affinity purification method have been developed 
to improve the efficiency of this method [237], for example Tandem affinity 
purification (TAP) was developed to increase the specificity of this method [239]. 
TAP method relies on two step affinity purification which reduces non-specific 
binding but one disadvantage of this method is that transient interactions are most 
likely lost during the two step purifications [234].    
 Chemical cross-linking can be used to stabilize protein-protein interactions;  
by adding two or more reactive groups [240], the cross-linker can react randomly with 
amine or sulfhydryl groups. In combination with affinity tagging, one can preserve 
weak in vivo interactions [231]. This method can detect transient interactions and 
provide information of the site of protein-protein interaction [241] however, random 
cross-linking of proteins and the increased complexity of resultant mass spectra are 
problematic  [237].   
 
5.3 Proximal protein labelling by BirA* biotinylation in mammalian cells  
In this study, a new affinity capturing based method termed BioID [242], has 
been applied to allow proximity labelling of a target protein of choice. In this 
protocol, one needs to generate a fusion protein that includes the E.coli BirA* 
(R118G) biotin ligase.  This modified version of BirA* contains a mutation that make 
it more promiscuous [243] compared to the wild type enzyme that only modifies a 
single target (in E.coli). When biotin levels are increased, the BirA* in mammalian 
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cells generates reactive bioAMP in the location of the fusion protein which can 
modify lysine residues on interacting and proximal proteins; thus providing 
information about the average direct and indirect interacting proteins. The unique 
attribute of this method is that biotinylation of local proteins take place in the 
physiological cellular context, and the biotinylation of target proteins remain intact 
during cell lysis. The ability of the biotin-streptavidin interact to survive SDS 
treatment  [244], allows most contaminant proteins to be removed. The sensitivity of 
the BioID assay has not yet been fully assessed [237]. For most proteins in which 
GFP fusions have been tested, the addition of BirA (30 kDa) should not affect 
localization.  
In order to increase the selectivity of the method, we used SILAC (stable 
isotope labelling with amino acids in cell culture) strategy which allows for protein 
quantification by mass spectrometry. This greatly reduces the rate of false positive 
and increases the confidence of positive data [245, 246]. In this method, stable isotope 






N) are introduced to growth media (heavy media), 
which are taken up by the cells to synthesis new proteins. When incorporated in the 
peptides, these amino acids could provide the mass difference compared to non-
labelled proteins. Using this strategy, proteins can be purified from cells which are 
labelled (H) and then combined with 'non-specific' samples with normal isotopic (L) 
composition (typically control). A fractionation protocol is then performed after 
lysates are combined, in order to avoid bias, and single mass spectrometry used to 
quantify the SILAC peptide pairs which can be expressed as a ratio of H/L.  
SILAC have been used for a variety of affinity applications [247, 248]. It can 
be used as adjunct to protein-protein interactions assays or for the analysis of proteins 
binding to specific DNA or RNA sequences (used as 'bait' [249-251]). It is also useful 
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for identification of interacting proteins of small molecules, such as inhibitors, for 
drug discovery [251, 252]. 
 For example, SILAC can be used to monitor quantitative differences or 
changes in protein compositions or interactions under two or three different 
conditions [253]. One of the most important applications of SILAC is for discovery of 
diseases biomarkers. For example the secretome of pancreatic cancer cells has been 
compared with those non-neoplastic pancreatic ductal cells [254]. In addition, SILAC 
has been used to detect significant changes in the nuclear proteome during apoptosis 
[255]. SILAC is particularly powerful as a means of studying intracellular signaling 
pathways, as assessed by changes in post translation modifications of proteins such as 
phosphorylation [256]. For example the change in phosphorylation upon treatment 
with EGF can provide a global view of the EGFR pathway [257]. Specific protein 
modification by palmitoylation [258] or ubiquitination [259] can also be improved by 




H3-methionine has been used to assess methylation 
sites on  protein and  DNA [260]. This strategy has been used for study of histone 
methylation that is critical in the process of gene regulation[260].  
 
5.4 Establishing GFP-BirA*-PAK5 line for BioID 
 I established Puromycin-resistant U2OS cell line expressing either GFP-BirA*-
PAK5 or the parental GFP-BirA*vector (gift of Dr. Dong Jing Ming) and chose two 
clones of each line based on appropriate low expression level of the fusion protein 
(Figure 5.1). In order to carry out high sensitivity mass spectrometry (MS) of the 
PAK5 proximal proteins, I adopted the strategy of stable isotope labelling of cells - 
more widely termed SILAC [245]. The GFP-BirA*-PAK5 lines were isotopically 
labelled by passaging them  for 2 weeks in 'heavy' media containing C13/N15 (H) 
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labelled lysine and arginine, while the control lines were adapted to the same identical 
media with 'light' (L) lysine and arginine (see schematic Figure 5.2). Lys is an 
essential and Arg a semi-essential amino acids for mammalian cells. The application 
of isotope analog of essential amino acids in SILAC ensuring that cells only 
incorporate the isotope analog of these amino acids. Labelled Arg and Lys are 
preferred amino acids applied for SILAC because most of time trypsin is used as 
proteolytic enzyme for mass spectrometry. Trypsin specifically cleaves proteins on C-
terminal side of Arg or Lys residues. Following trypsin digestion of protein each 
peptide typically contains either Lys or Arg at its C-terminus thus ensuring that the 
'heavy' peptides can be paired with their 'light' partner as illustrated in Figure 5.3. The 








N4O2) results to 
8 or 10 Dalton increasing in the mass of heavy peptides compared to light peptides 
which could be distinguished by mass spectrometry. For those proteins that are not 
enriched after streptavidin Sepharose pull down (Figure 5.3), the SILAC ratio for 
corresponding peptides will have a ratio of H/L=1. Higher ratios show an enrichment 
indicating these proteins are 'PAK5- proximal'.  After protein fragmentation by in-gel 
trypsin treatment of the acrylamide gel slices, the recovered peptide mixture is 
separated by HPLC and peptides are introduced in-line to the mass spectrometer. The 
charge ratio (m/z) of peptides and fragmentation pattern (MS/MS) are used to 
determine a probability of a peptide sequence from the relevant database [261]. 
Multiple peptides assigned to the same protein have H/L ratios which indicate the 































































Figure 5.1 Analysis of U2OS stable lines expressing GFP-BirA*-
PAK5 (FL) or GFP-BirA* controls. A. PAK5(FL) were fused to the BioID
vector (kindly provided by Dr. Dong Jing Ming) to generate the GFP-
BirA*-PAK5 construct. These were used to generate stable lines in
U2OS cells under Puromycin selection (0.8 ug/ml). B,C. The two clones
of GFP-BirA*-PAK5 and two control GFP-BirA*-lines (with roughly similar
expression between PAK5 and control lines) were analyzed by western
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Figure 5.2 Schematic of Bio-ID work-flow. GFP-BirA* PAK5 stable lines 
are grown and adapted in heavy media (H) containing heavy isotopes of 
Arg and Lys (13C,15N).  Control lines are grown in the light media (L) 
containing the light (12C,14N) isotopes of Arg and Lys. After two weeks 
adaption of the U2OS stable lines (brown color for heavy isotope, and blue 
color for light isotope) cells then are incubated with 100μM biotin (5h) to 
allow BirA* activity in vivo. GFP-BirA*-PAK5 and GFP-BirA* are assumed to 
label proximal proteins (indicated with red spots). The cells are lysed in 
0.5% deoxycholate and 0.5% Triton x-100 and the nuclei removed by 
centrifugation at low speed. Supernatants of PAK5 and control lines are 
collected and made to 0.2% SDS to dissociate complexes and then  mixed. 
The mixed lysate are then incubated with Neutravidin beads (Thermo 
Scientific) for overnight to capture the biotinylated proteins. The beads then 
are washed in 1% SDS to completely remove contaminants and 1x LDS 
sample buffer (Novex) added at 95°C to release proteins. These are run in 
1mm 10% SDS-PAGE and the gel stained with colloidal CCB (Novax). The 
region >28 kDa is processed into spots for standard trypsin digestion and 
peptide extraction. The on-line LC-MS/MS analysis is set to find (H) and (L) 













































Figure 5.3 Labelling proteins using SILAC for quantitative mass
spectrometry. Cells growing in heavy media containing Lys (13C, 15N)
and Arg (13C, 15N) results to incorporation of heavy amino acids in all
proteins. Protein digestion with trypsin yields peptide fragments which
usually contain C-terminal of Lys or Arg (except mis-cut peptides or the C-
terminal fragment of the protein). The (H) and (L) peptides migrate
identically in the LC fractionation and are processed together during the




5.5 Identification and analysis of PAK5 proximal proteins 
In total, 390 proteins were identified by MS/MS in the Bio-ID. Figure 5.4 
displays the scatter plot of log2 value of SILAC ratio versus percentage of sequence 
coverage for these proteins. The H/L ratios of data were normalized by median and 
proteins with SILAC ratio less than 2 and one peptide only removed. The resultant set 
of proteins is given in Table S1 of the supplementary section.  
Proteins with SILAC ratio ≥3 and the peptide number ≥4 are listed in table 5.2 
as high-confidence 'hits'. Figure 5.5 shows a diagram of classification of these 
proteins. The BioID method identified many junctional proteins as PAK5 proximal 
partners consistent with the junctional localization of PAK5 in U2OS stable lines 
(Figure 4.15B). Of these, p120 catenin and Cdc42 are previously known as PAK5 
interacting partners, providing us with some confidence with the analysis. In this 
SILAC dataset, LZTS2 is suggested to be proximal to PAK5 since it has one of the 
highest H/L ratios, and comparable to nectin-2 and afadin (Table 5.2).  There is also 
extensive overlap with data generated using a PAK4 cell line (Felicia Tay, personal 
communication). LZTS2 is a member of FEZ family of proteins that are poorly 
characterized:  one study has suggested a role for LZTS2 in cytokinesis by binding to 
the microtubule severing protein katanin [154]. Here, I find that LZTS2 is 
predominantly at cell-cell junctions, as will be discussed with more details later 
(section 5.8). The centrosomal protein CEP85 is a functionally uncharacterized 
protein that is part of this protein complex known as the microtubule organizing 
Centre (MTOC). Interestingly, the presence of PAK4-unique peptides in my datasets 
suggests PAK5 and PAK4 localization overlap. Afadin and the trans-membrane 
protein nectin-2 are part of several complexes found next to adherens junctions as 
reviewed [262, 263]. Nectin is a trans-membrane protein whose C-terminus recruits 
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afadin via its PDZ domain [264]. Afadin can bind to F-actin but is also associated 
with other components of the cadherin-catenin complex through interaction with 
ponsin and vinculin proteins [262]. It is suggested that nectin-afadin complex initiates 
formation of adherens junctions by recruiting several proteins including cadherins to 
this compartment [264, 265]. The presence of direct or indirect afadin interacting 
partners such as p120 catenin [266], ZO-1 [267] and ERBB2IP (Erbin) [268] with 
somewhat lower SILAC ratios in the PAK5 BioID data strongly indicates the kinase 
is present in these junctions. The transmembrane protein Neph1 (KIRREL-1) is a 
member of the immuno-globulin superfami1y and is also known to interact with ZO-
1. Neph-1 knockout mice dye in 3-8 weeks of age because of a severe nephrotic 
syndrome [269], suggesting defects in the development and function of the glomerular 
filtration barrier. The C-terminal cytoplasmic domain of Neph-1 interacts with the 
PDZ domain of the tight junction protein ZO-1 in a specialized epithelial cell-cell 
contact called the “slit diaphragm” [270]. Interestingly, Neph1 is extensively 
expressed in the central nervous system and with Neph2 plays important roles in 
synaptogenesis [271], again a very specialized cell-cell contact.     
 It was particularly interesting to find Kif7 as a unique motor protein associated 
with PAK5. Like most kinesins, it binds to microtubules via an N-terminal globular 
motor domain [272], and this isoform is implicated in cilia formation and thereby 
affects Hh (Hedgehog) signaling. Kif7 has been found to act as both positive and 
negative regulator of Hh signaling through its effect on the Gli transcription factor 
[273]. Kif7 knockdown in retinal epithelial cells also indicates that it is required for 
Golgi structure and centrosomal integrity [274]. The Golgi apparatus is usually 
positioned by the MTOC (microtubule-organizing centre) [275].  In summary, the list 
of proteins which were identified by BioID is consistent with a role of PAK5 at 
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specialized cell-cell junctions and perhaps at the centrosome. I did not find evidence 
for PAK5 being associated with proteins involved with the acto-myosin system, not 
proteins such as formins which are important for F-actin nucleation [276]. 
Table 5.2 High-confidence proteins identified by BioID as PAK5 proximal 
proteins in stable cell lines expressing BirA* PAK5  








1 PAK5 PAK5 81 137.2 35 57 
2 LZTS2 LZTS2 73 29.7 11 23 
3 CEP85 
Centrosomal protein of 85 
kDa 
86 19.4 9 17 
4 PVRL2 Nectin-2 51 16.6 6 15 
5 PAK4 PAK4 64 14.1 5 8 
6 KIF7 Kinesin-like protein KIF7 151 13.8 6 5 




Tubuline alpha 3C chain 50 11.4 12 42 
9 FAM83H Protein FAM83H 127 11.3 13 19 
10 MAGED1 NRAGE 92 10.9 7 11 
11 TNRC6B 
Trinucleotide repeat 
containing gene 6B protein 
194 9.6 11 7 
12 PHLDB2 LL5-beta protein 142 9.2 5 6 
13 TBKBP1 TBK1 binding protein 68 8.8 4 7 
14 KIRREL Neph 1 85 7.1 4 8 
15 SEC16A 
Protein transport protein 
Sec16A 
252 6.5 8 4 
16 DLG5 Disks large homolog 5 214 6.3 37 21 
17 SIPA1L1 SPAR 200 6.3 7 4 
18 CTNND1 P120 catenin 108 5.9 11 15 
19 SLC25A13 Citrin 74 5.1 4 6 
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Table 5.2  







20 RPS15A 40s  ribosomal protein S15a 15 5.1 4 31 
21 TP53BP2 ASPP2 126 4.1 4 3 
22 ERBB2IP Erbin 159 4.1 25 23 
23 STAU2 Staufen protein homolog 2 63 3.8 6 11 
24 CAD CAD protein 243 3.3 14 8 




73 3.2 20 40 
27 TJP1 
Tight junctional protein  
ZO-1 
197 3.2 37 25 







































Log2 of ratio GFP-BirA*PAK5/GFP-BirA* control
Figure 5.4 The scatter plot analysis of the SILAC ratio versus
coverage derived from BioID analysis. The Log2 value of the SILAC
ratio is here plotted against sequence coverage (%) for each protein
identified in the Bio-ID dataset (393 proteins). A SILAC ratio >3 was
used as a cutoff for significance in which 4 peptide were required to
provide confidence in the median SILAC H/L value (as indicated with
the black lines). The yellow filled spots show some of the important


































Figure 5.5 The identification of PAK5 proximal proteins by SILAC
BioID. The mass spectrometry data that were obtained from SILAC
BioID experiment using U2OS cells expressing GFP-BirA*PAK5 were
analysed and proteins with ≥3 H/L SILAC ratio and ≥4 peptides were
selected. These proteins were classified manually based on their





5.6 Identification and analysis of PAK5 interacting partners using GFP-pull 
down  
In order to compare sensitivity and efficiency of BioID with traditional tag 
affinity pull down, the GFP-pull down (GFP-PD) were carried out. Because the cell 
lines used for BioID expressed GFP (GFP-BirA*-PAK5 or GFP-BirA*) I was able to 
use the same lines to perform standard GFP pull-down, though using recombinant 
GFP-Trap beads which avoid IgG contamination [277]. The work flow of GFP pull 
down has been illustrated in figure 5.6. After adapting GFP-BirA*-PAK5 cells in 
heavy (H) media and the control lines in light (L) media, the lysates from GFP-BirA*-
PAK5 or GFP-BirA*control lines were separately incubated with GFP-Trap 
Sepharose beads. The proteins were released by heating in SDS and then mixed for 
SDS-PAGE, in-gel digestion and subsequent MS/MS analysis. The scatter plot of 
sequence coverage versus the log2 value of the SILAC ratio for the whole dataset of 
GFP-PD is illustrated in figure 5.7. All those proteins assigned by 2 or more, high 
confidence peptides and SILAC ratio more than 2 are shown in table S2 of 
Supplementary data. As for the BioID data, a working list of high confidence proteins 
were selected based on SILAC ratio (ratio H/L≥3) and peptide number (containing ≥4 
informative peptides) (Table 5.3). Figure 5.8 illustrates the known interactions of 
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Figure 5.6 Schematic of the SILAC GFP pull down experimental
work-flow. U2OS cells stably expressing GFP-BirA* PAK5 or GFP-BirA*
were cultivated in heavy (H) and light (L) medium respectively (see
methods). After adaption, the cells were harvested in a lysis buffer
containing 0.5% triton X-100. The solubilized proteins were clarified
(Eppendorf centrifuge at 13000 rpm, 15min). The supernatant fractions of
the H and L were separately added to GFP-Trap beads (recombinant
anti-GFP) and incubated for 3h at 4°C. The Sepharose beads were
collected and washed with the same lysis buffer (3 x 10 min) and bound
proteins eluted in 1X LDS sample buffer at 95°C. The eluates were mixed
and concentrated. The samples were subjected to 15% SDS-PAGE and































Log2 of Ratio GFP-PAK5/GFP-Control
Figure 5.7 The scatter plot of the complete set of proteins identified
in the GFP-PAK5 pull down. The Log2 SILAC H/L ratio was plotted
against sequence coverage (%) for each of the 377 proteins identified by
SILAC GFP pull down. A 3 SILAC ratio cut off and 4 peptide number cut





Table 5.3 Potential PAK5 interacting partners identified by GFP-PAK5 pull 
down 








1 PAK5 PAK5 81 66.3 37 57 
2 P4HA2 
Prolyl 4-hydroxylase subunit 
alpha-2 
61 30.2 16 39 
3 P4HA1 
Prolyl 4-hydroxylase subunit 
alpha-1 
61 15.6 16 38 
4 BAG2 
BAG family molecular 
chaperone regulator 2 
24 11.8 12 60 
5 CAD CAD protein 243 11.7 68 41 
6 SEC13 Protein SEC13 homolog 41 11.6 5 17 
7 SEC16A 
Protein transport protein 
Sec16A 
252 11.3 22 12 
8 P4HB Protein disulfide-isomerase 57 11.2 18 38 
9 FAM83H Protein FAM83H 127 10.3 19 23 
10 CDC42 Cdc42 21 10.2 4 23 
11 ATAD3A 
ATPase family AAA 
domain-containing protein 
3A 
66 9.2 7 12 
12 AIFM1 
Apoptosis-inducing factor 1, 
mitochondrial 
67 9.1 10 19 
13 KANK2 
KN motif and ankyrin repeat 
domain-containing protein 2 
92 8.5 4 5 
14 TCP1 
T-complex protein 1 subunit 
alpha 
60 7.5 21 44 
15 LRP1 
Low-density lipoprotein 
receptor-related protein 1 
85 kDa subunit 
505 7.5 16 4 
16 CCT7 
T-complex protein 1 subunit 
eta 
59 7.5 10 23 
17 CCT3 
T-complex protein 1 subunit 
gamma 























T-complex protein 1 subunit 
delta 
58 7.2 17 40 
19 CCT5 
T-complex protein 1 subunit 
epsilon 
60 7.0 16 39 
20 PKP2 Plakophilin-2 97 7.0 6 8 
21 CCT6A T-complex protein 1 subunit 
zeta 
58 7.0 12 30 
22 CCT2 T-complex protein 1 subunit 
beta 
57 6.9 11 29 
23 YWHAH 14-3-3 protein eta 28 6.7 6 26 
24 YWHAG 14-3-3 protein gamma 28 6.0 10 37 
25 CCT8 T-complex protein 1 subunit 
theta 
60 6.0 19 39 
26 UBR5 E3 ubiquitin-protein ligase 
UBR5 
309 5.3 13 7 
27 PGAM5 Serine/threonine-protein 
phosphatase PGAM5, 
mitochondrial 
32 5.3 12 40 
28 POLR2B DNA-directed RNA 
polymerase II subunit RPB2 
134 5.0 5 4 
29 EMD Emerin 29 5.0 10 46 
30 YWHAE 14-3-3 protein epsilon 29 4.9 12 48 
31 FLNC Filamin-C 291 4.9 53 27 
32 MAGED1 NRAGE 92 4.7 5 7 


























terminal hydrolase FAF-X 
292 4.6 8 4 
35 LOXL4 Lysyl oxidase homolog 4 84 4.4 5 8 
36 RUVBL2 RuvB-like 2 51 4.3 5 12 
37 HSPA8 Heat shock cognate 71 kDa 
protein 
71 4.2 34 60 




88 3.5 5 8 
39 CHCHD3 Coiled-coil-helix-coiled-coil-
helix domain-containing 
protein 3, mitochondrial 
27 3.5 5 24 
40 HSPA1A Heat shock 70 kDa protein 
1A/1B 
70 3.4 21 37 
41 IMMT Mitochondrial inner 
membrane protein 
84 3.4 11 17 
42 MYO1C Unconventional myosin-I c 120 3.2 12 14 
43 PHB2 Prohibitin-2 33 3.2 9 35 
44 HSPA6 Heat shock 70 kDa protein 
6 
71 3.1 11 17 
45 YWHAB 14-3-3 protein beta/alpha 28 3.1 9 46 
46 CYC1 Cytochrome c1, heme 
protein, mitochondrial 
35 3.1 5 15 
47 HNRNPM Heterogeneous nuclear 
ribonucleoprotein M 





Figure 5.8 Potential PAK5 binding proteins assessed by GFP-PAK5
pull-down with SILAC normalization. The STRING annotation diagram
shows the various known interactions between all the proteins isolated
using GFP-Trap beads, and account for background contamination by
selecting only those proteins with ratio H/L ≥3 and peptide number ≥4.
The cluster of protein chaperones (CTT family) are prominent. PAK5 is





5.7 Analysis of the results of BioID and GFP-PD 
 In contrast to the BioID sub-list, the GFP-PD data did not yield junctional 
proteins associated with PAK5; instead we observed many chaperone proteins and 
scaffolding proteins of the 14-3-3 family. Typically, the abundant 14-3-3 proteins 
bind phosphorylated Ser and Thr residues based on conserved flanking sequence. The 
interaction with group II PAKs has been previously described [279]. Figure 5.9 shows 
a comparison between PAK5 'interactomes' extracted from public databases with the 
high-confidence hits that I found using either BioID or GFP pull-down. The single 
overlapping protein among the three data sets is Cdc42, whose binding site in group II 
PAKs is well characterized [8, 28]. The overlap between BioID list and those proteins 
supposedly interacting with PAK5 (GFP-PD list) is limited. Further experiments are 
needed to test which of these proteins might bind PAK5 directly. 
   FAM83H is among the five proteins which were identified through these two 
different methods, BioID and GFP-PD. The FAM83 (family with sequence similarity 
83) is a well conserved set of proteins with FAM83H implicated genetically in 
amelogenesis [280] through a mechanism that is likely to involve cargo exocytosis 
[281]. One microarray analysis has shown over-expression of this protein in variety of 
cancers [282]. Other members of FAM83 family are also poorly understood but these 
proteins are likely involved in regulating MAPK pathway [283]. Another interesting 
candidate is MAGED1, which I will refer to as NRAGE (neurotrophin receptor-
interacting melanoma antigen). This is a multi-functional protein originally identified 
as one of the many melanoma antigens [284-287]. Overexpression of NRAGE in 
U2OS disrupts E-cadherin/ β-catenin complex [285] which suggests the proteins is a 
modulator of cell-cell junctions. NRAGE is also thought to bind p75NTR (p75 
neurotrophin receptor) and promote apoptosis in sympathetic neuron precursors cells 
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[288]. How NRAGE potentially promotes lung and kidney cancers [289, 290] is 
unclear. The fact that NRAGE interacts with ankyrin-G, a component of cell adhesion 
complex, points to a junctional role [291]. One model for NRAGE function is that 
during epithelial-mesenchymal transition (EMT), the loss of ankyrin-G leads to 
NRAGE movement to the nucleus where it binds to the oncogenic transcriptional 
suppressor protein TBX2 and results in repression of tumor suppressor gene p14ARF 
[291]. Both PAK5 and NRAGE are highly expressed in the nervous system [33, 292] 
and the both proteins can regulate mitochondrial cell death [52, 293].  
 Finally both Sec16A and CAD proteins are potential PAK5 partners. Sec16A 
is involved in cargo transport from ER to Golgi by organizing the ER exit site (ERES) 
[294]. Since we have no evidence for PAK5 localization at the ER, this connection is 
unexpected. While depletion of Sec16A in HeLa cells attenuates cell proliferation and 
its over-expression increases cell numbers [295], the mechanism is obscure. CAD is a 
multi-functional protein involved in de novo synthesis of pyrimidine nucleotides by 
three enzymatic activity; carbamoyl phosphate synthesis, aspartate transcarbamoylase 
and dihydroorotase [296]. Induction of cell proliferation, leads to translocation of a 
fraction of CAD into the nucleus, where its activity is regulated by MAPK, ensuring 
synthesis of proper amount of pyrimidine which is required in cell proliferation [297]. 
CAD has also been contributed with cancer progression and its expression is 
increased in several cancers such as breast cancer [298] and hepatocellular carcinoma 
[299]. A recent study has suggested CAD as a biomarker of prostate cancer. CAD 
regulates transcriptional activity of androgen receptor (AR) in prostate cancer through 
interaction with and nuclear translocation of AR (androgen receptor) [300]. Therefore, 

















Figure 5.9 Weak overlap between PAK5-asscoaietd proteins
extracted from databases and those identified by BioID and GFP
pull-down. Comparison of the complete list of PAK5 'associated'
proteins extracted from four public databases (BioGRID, IntAct-EBI,
Mentha, SPIKE) with the PAK5 associated proteins (Ratio H/L>3 and
peptide number>4 ) identified by either BioID or GFP-PD. Although
PAK5 is predominantly located at cell-cell junctions, neither the GFP-PD
nor the database extracted proteins reflect this.
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but a well conserved coiled-coil regions and C-terminal PDZ domain binding 
sequence which can interact with the scaffolding protein Shank of postsynaptic 
density [162]. LZTS1 is the best studied member of this family and is ubiquitously 
expressed. Its role as a tumor suppressor is widely accepted based on the results using 
LZTS1 knockout mice [301]. LZTS2 is expressed in most tissues with the higher 
expression in prostate and testis [145]. LZTS1 and LZTS2 share all the domain 
features that have been mapped (Figure 5.10). LZTS2 knockout mice are susceptible 
to both spontaneous and carcinogen induced tumor development [152]; however with 
the lower incidence compared to LZTS1 deficient mice [301].  LZTS2 is reported as a 
negative regulator of Wnt signaling via interaction with β-catenin [148]. The role of 
LZTS2 in development could be mediated in part through its effect on Wnt signaling 
[160, 163]. Indeed, LZTS2 knock-out mice show kidney abnormalities, and here 
alteration in β-catenin localization is observed in the renal tubule epithelium [160].   
N-terminal of LZTS2 contains a region, 25 amino-acids downstream of the proposed 
initiation codon (ATG), almost identical to the N-terminal of LZTS1 which contains a 
consensus N-myristoylation sequence (Figure 5.10) [302]. Thus, LZTS2 mRNA 
appears to have the potential for alternate translation from two ATG sequences 
(Figure 5.10) in which the second (LZTS2b) potentially generates a membrane-bound 










hLZTS1      ---------------------------MGSVSSLISGHSFHSKHCRASQY 23 
hLZTS2      MAIVQTLPVPLEP--APEAATAPQAPVMGSVSSLISGRPCPGGPAPPRHH 48 
hLZTS3      MAKLETLPVRADPGRDPLLAFAPRPSELGPPDPRLAMGSVGSGVAHAQEF 50 
                                       :*. .. ::  .  .  . . .. 
 
hLZTS1      KLRKSSHLKKLNRYSDGLLRFGFSQDSGHGKSSSKMGKSED---FFYIKV 70 
hLZTS2      GPPGPTFFRQQ----DGLLRGGYEAQEPLCPAVPPRKAVPV---TSFTYI 91 
hLZTS3      AMKS-VGTRTGGGGSQGSFPGPRGSGSGASRERPGRYPSEDKGLANSLYL 99 
                    :      :* :       .      .               : 
 
hLZTS1      SQKARGSHHPDYTALSSGDLGGQAG---------VDFDPSTPPKLMPFSN 111 
hLZTS2      NEDFRTESPPSPSSDVEDAREQRAH---------NAHLRGPPPKLIPVSG 132 
hLZTS3      NGELRGSDHTDVCGNVVGSSGGSSSSGGSDKAPPQYREPSHPPKLLATSG 149 
            . . * .  ..  .   .     :               . ****:. *. 
 
hLZTS1      QLEMGSEKGAVRPTAFKPVLPRSG------------------------AI 137 
hLZTS2      KLEKNMEKILIRPTAFKPVLPKPRGAPSLPSFMGPRATGLSGSQGSLTQL 182 
hLZTS3      KLDQCSEP-LVRPSAFKPVVPKNFHS---------------------MQN 177 
            :*:   *   :**:*****:*:                             
 
hLZTS1      LHSSPESASHQLHPAPPDKPKEQE-LKPGLCSG----ALSDSGRNSMSSL 182 
hLZTS2      FGGPASSSSSSSSSSAADKPLAFSGWASGCPSG----TLSDSGRNSLSSL 228 
hLZTS3      LCPPQTNGTPEGRQGPGGLKGGLDKSRTMTPAGGSGSGLSDSGRNSLTSL 227 
            :  .  ..: .   .. .     .   .   :*     ********::** 
 
hLZTS1      PTHSTSSSYQLDPLVTPVGPTSRFG-----GSAHNITQGIVLQDSNMMSL 227 
hLZTS2      PTYSTGGAEPTTSSPGGHLPSHGSGRGALPGPARGVPTGPSHSDSGRSSS 278 
hLZTS3      PTYSSSYSQHLAPLSASTSHINRIG----TASYGSGSGGSSGGGSGYQDL 273 
            **:*:. :    .           *     ..  . . *    .*.  .  
 
hLZTS1      KALSFSDGGSKLG------------HSNKADKGPSCVRSPISTDECSIQE 265 
hLZTS2      SKSTGSLGGRVAGGLLGSGTRASPDSSSCGERSPPPPPPPPSDEALLHCV 328 
hLZTS3      GTSDSGRASSKSGSSSSMGRPGHLGSGEGGGGGLPFAACSPPSPSALIQE 323 
                 . ..   *             .. .  . .    . .         
 
hLZTS1      LEQKLLEREGALQKLQRSFEEKELASSLAYEERPRRCRDELEGPEPKGGN 315 
hLZTS2      LEGKLRDREAELQQLRDSLDENEATMCQAYEERQRHWQREREALR----E 374 
hLZTS3      LEERLWEKEQEVAALRRSLEQSEAAVAQVLEERQKAWERELAELRQGCSG 373 
            ** :* ::*  :  *: *:::.* : . . *** :  . *    .      
 
hLZTS1      KLKQASQKSQRAQQVLHLQVLQLQQEKRQLRQELESLMKEQDLLETKLRS 365 
hLZTS2      DCAAQAQRAQRAQQLLQLQVFQLQQEKRQLQDDFAQLLQEREQLERRCAT 424 
hLZTS3      KLQQVARRAQRAQQGLQLQVLRLQQDKKQLQEEAARLMRQREELEDKVAA 423 
            .    ::::***** *:***::***:*:**:::   *::::: ** :  : 
 
hLZTS1      YEREKTSFGPALEETQWEVCQKSGEISLLKQQLKESQTEVNAKASEILGL 415 
hLZTS2      LEREQRELGPRLEETKWEVCQKSGEISLLKQQLKESQAELVQKGSELVAL 474 
hLZTS3      CQKEQADFLPRIEETKWEVCQKAGEISLLKQQLKDSQADVSQKLSEIVGL 473 
            ::*: .: * :***:******:***********:**:::  * **::.* 
  
hLZTS1      KAQLKDTRGKLEGLELRTQDLEGALRTKGLELEVCENELQRKKNE----- 460 
hLZTS2      RVALREARATLRVSEGRARGLQEAARARELELEACSQELQRHRQE----- 519 
hLZTS3      RSQLREGRASLREKEEQLLSLRDSFSSKQASLELGEGELPAACLKPALTP 523 
            :  *:: *..*.  * :  .*. :  ::  .**  . **     :      
 
hLZTS1      --AELLREKVNLLEQELQELRAQAALARDMGPPTFPEDVPALQR------ 502 
hLZTS2      --AEQLREKAGQLDAEAAGLREPPVPPATADPFLLAESDEAKVQRAAAGV 567 
hLZTS3      VDPAEPQDALATCESDEAKMRRQAGVAAAASLVSVDGEAEAGGESGTR-- 571 




hLZTS1      ------ELERLRAELREERQGHDQMSSGFQHERLVWKEEKEKVIQYQKQL 546 
hLZTS2      GGSLRAQVERLRVELQRERRRGEEQRDSFEGERLAWQAEKEQVIRYQKQL 617 
hLZTS3      --ALRREVGRLQAELAAERRARERQGASFAEERRVWLEEKEKVIEYQKQL 619 
                  :: **:.**  **:  :.   .*  ** .*  ***:**.***** 
 
hLZTS1      QQSYVAMYQRNQRLEKALQQLARGDSAGEPLEVDLEGAD----IPYEDII 592 
hLZTS2      QHNYIQMYRRNRQLEQELQQLSLELEARELADLGLAEQAPC--ICLEEIT 665 
hLZTS3      QLSYVEMYQRNQQLERRLRERGAAGGASTPTPQHGEEKKAWTPSRLERIE 669 
            * .*: **:**::**: *:: .    *                   * *  
 
hLZTS1      ATEI 596 
hLZTS2      ATEI 669 
hLZTS3      STEI 673 




hLZTS2  GCCTCTGCCACCATGGCCATTGTGCAGACTCTGCCAGTGCCACTGGAGCCTGC 53 
mLZTS2 GCCTCTGCCACCATGGCCATTGTGCACACTCTGCCAGTGCCTCTGGAGCCCGC  53 
 




Figure 5.10 Sequence alignment of human LZTS family isoforms. A. ClustalW 
sequence alignment of human LZTS1, LZTS2 and LZTS3. Asterisks indicate identical 
amino acids while colon and periods indicate the conservative amino acids 
substitutions. Green highlights show the initiation codon (methionine):  alternate start 
codons are suggested for both LZTS2 and LZTS3 based on manual alignment. 
Isoform one, LZTS2a, is 25 amino acids longer than LZTS2b.  A conserved 
myristoylation consensus sequence (M-G-X-X-X-(S/T)-X-X-X) is highlighted gray in 
LZTS1 and the shorter isoforms of LZTS2 and LZTS3.  The yellow highlights show 
the most conserved sequences among these proteins which are predicted coiled coil 
helices. The PDZ binding motif is highlighted in pink. B. Alignment of parts of mRNA 
sequence from human (h) and mouse (m) LZTS2. The yellow shaded residues 




5.8.1 Identification of the region of PAK5 involved in binding LZTS2 
In order to map the regions of PAK5 involved in LZTS2 binding, I carried out 
a series of immunoprecipitation experiments using GST-LZTS2 and the PAK5 N-
terminal deletion constructs described previously (section 3.7). N-terminal deletions 
greater than 236 amino acids were found to abolish the interaction of LZTS2 (Figure 
5.11A,B). Because I have previously shown that removing 236 amino acids from 
PAK5 disrupts its oligomerization (Figure 3.7), there is a possibility that LZTS2 
binding requires an oligomeric form of PAK5 or that the first 236 amino acids of 
PAK5 includes the LZTS2 interaction site. To evaluate these hypothesizes; I used 
instead GST-tagged versions of series of PAK5 constructs in combination with Flag 
LZTS2 construct to test their interaction using co-immunoprecipitation. As mentioned 
previously (Section 4.4.2), the GST protein under physiological conditions is 
completely dimeric [207]. The data in figure 5.12 showed that all the N-terminal 
truncated forms of GST PAK5 were able to co-precipitate with Flag-LZTS2 with 
similar efficiency. Thus, PAK5 self-association aids its interaction with LZTS2 and 
suggesting that the LZTS2 binding site(s) were more C-terminal. To evaluate these 
potential interaction sites, I compared Flag-LZTS2 interaction with GST-PAK5 (1-
268) and GST-PAK5 (360-719). As seen in figure 5.13A, both N-terminal and C-
terminal regions of PAK5 appeared to bind with similar efficiency. To find out which 
part of LZTS2 plays role in PAK5 interaction, I tested co-immunoprecipitation of 
PAK5 full length with a series of truncated constructs of LZTS2. The results 
suggested that the FEZ domain of LZTS2 is enough for interaction with PAK5 





























































































Figure 5.11 PAK5 interacts directly with LZTS2. A. HEK-293 cells
were co-transfected with a series of N-terminal truncated constructs of
Flag-PAK5 and full-length GST-LZTS2 as indicated. Anti-Flag Sepharose
were used to isolate the complex between Flag-PAK5 and GST-tagged
proteins. The samples then were subjected to SDS-PAGE and Western
blotting to detect LZTS2 co-immunoprecipitation. B. Graph shows the
truncated constructs of PAK5. The results of PAK5 constructs interaction
with LZTS2 and the ability of self-association of these constructs have








































































































Figure 5.12 PAK5 oligomerization promotes interaction with LZTS2.
Flag-LZTS2 was co-expressed with GST-PAK5 constructs as indicated
in HEK-293 cells. The Flag tagged proteins were recovered using anti-
Flag Sepharose followed by SDS-PAGE and Western blot to analyze
GST-PAK5 constructs co-immunoprecipitation. The experiment indicates
that the PAK5 C-terminal construct (PAK5∆360) can bind LZTS2 when is
tagged with GST but not Flag (Figure 5.11).
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Figure 5.13 Investigating the basis for an interaction between PAK5 and
LZTS2. A. Flag LZTS2 co-transfected with either GST constructs of PAK5 or
pXJ-GST vector in HEK-293 cells. Immunoprecipitation with anti-flag beads
were performed and GST-PAK5 constructs binding were identified after



















































































Figure 5.13 Investigating the basis for an interaction between PAK5
and LZTS2. FEZ domain is sufficient to bind PAK5. B. Schematic of
LZTS2 constructs used to test their interaction with full length PAK5 and
summary of these interactions. C. Flag-PAK5 was co-expressed with
GST LZTS2 constructs in HEK-293 cells. After overnight expression the
cells were lysed and the GST fusion proteins were recovered using
glutathione Sepharose and co-immunoprecipitation of PAK5 was
detected after Western blot. Image J were used to quantify the intensity




5.8.2 Identification and localization of a new form of LZTS2  
A previous study suggested that LZTS2 could be found at the centrosome and 
midbody, depending on the stage of the cell cycle [154]. To examine subcellular 
localization of these alternate LZTS2 isoforms, I generated an N-terminally tagged 
GST-LZTS2a construct and a C-terminal GST tagged construct corresponding to 
LZTS2b. These two proteins localized quite differently as one would expect. GST-
LZTS2 was found in puncta that was mainly concentrated near the nucleus whereas 
the shorter N-myristoylated LZTS2b was clearly localized to mitochondria, as 
assessed by the Mitotracker signal (Figure 5.14). Given the lack of consensus 
regarding the localization of endogenous LZTS2, I examined commercial antibodies 
for their ability of detecting endogenous LZTS2 (given that the protein must be 
relatively abundant in U2OS cells). Of these antibodies, only a rabbit polyclonal 
antibody (Protein Tech Group) appeared to detected several bands in the correct 
marker range (Figure 5.15A). siRNA experiments in U2OS cells indicated that only 
the middle band of the triplet (arrow) shows reduced intensity (Figure 5.15B), 
suggesting that the other bands were related LZTS isoforms or unrelated cross-
reacting antigens. LZTS2 expression was assessed in multiple cell lines (Figure 
5.14A). U2OS showed relatively high expression of LZTS2.  
Although the tested LZTS2 antibody did not specifically identify LZTS2, I decided to 
test indirect-immunostaining on the basis that siRNA treatment would lead to specific 
deletion of the protein in U2OS cells. I noted consistent junctional staining in this cell 
line (Figure 5.15C) and siRNA treatment diminished the cell junctional staining but 
not the peri-nuclear signal. Thus it appears LZTS2 is predominantly in cell-cell 
junctions of U2OS cells. To evaluate which of the two isoforms of LZTS2 (Figure 
5.14) is most likely to be expressed in U2OS cells, I tested non-tagged versions of 
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LZTS2a and the shorter LZTS2b and assessed their localization by using indirect 
immunofluorescence staining in which endogenous LZTS2 mRNA was suppressed by 
using an LZTS2 siRNA that target the 3'UTR of the mRNA (siRNA-U-1: residues 
2683-2701 siRNA-U-2: residues 2289-2307). The LZTS2a demonstrated cytoplasmic 
staining as well as punctate with a concentration in the peri-nuclear region, whereas 
myristoylated LZTS2b was found on mitochondria and at cell-cell junctions (Figure 
5.16). Although LZTS2a isoform is 25 amino-acids longer, the presence of the N-
myristoyl generates a form that migrates at a very similar position on SDS- 
polyacrylamide gels and therefore it is not possible to distinguish the two isoforms on 
SDS-PAGE. However, junctional localization of endogenous LZTS2 in U2OS cells 





































Figure 5.14 Subcellular localization of the two isoforms of LZTS2 in the
cell. The N-terminal GST-tagged construct of LZTS2a and C-terminal GST-
fusion construct of LZTS2b were generated. COS-7 cells were transfected
with 0.5µg of either of these constructs. After 16h the cells were live stained
with Mitotracker (150nM) for 20min prior to fixation in 4% PFA. The cells
then were subjected to indirect immunofluorescence staining with Mouse
















































































































Figure 5.15 Analysis of endogenous LZTS2 expression and
localization. A. LZTS2 expression was assessed in several cell lines:
COS-7, HEK-293, Lung cancer (NCI-H446), osteosarcoma (U2OS),
cervical cancer (HeLa), Hepatocellular carcinoma (Huh-7), colorectal
cancer (HCT-116, HT-29), Breast cancer (MCF-7, MDA-MB231) and
Prostate cancer (DU-145, LNCap) cell lines. U2OS, HEK-293 and HCT-
116 cell lines showed high expression of LZTS2 compared to other cell
lines. B. Two different siRNAs that target either ORF (siLZTS2-1) or
3’UTR (siLZTS2-U-1) of LZTS2 mRNA were generated. U2OS cells were
transfected with 50nM of either of these siRANAs or si-scramble. After
48h, cells were lysed using RIPA buffer. A total of 50μg proteins were
loaded per lane for SDS-PAGE and Western blotting. Rabbit anti-LZTS2
(Proteintech Group) were used to detect LZTS2 expression. The LZTS2
antibody detected several bands but only the intensity of the middle band
was weakened after siRNAs treatment C. U2OS cells were transfected
with either si-LZTS2-1 or si-scramble for 48h. Cells were washed and
fixed in methanol for 5 minutes and then subjected to indirect
immunofluorescence staining using rabbit anti-LZTS2 antibody



















Figure 5.16 Subcellular localization of the non-tagged constructs of
LZTS2a and LZTS2b in U2OS and COS-7 cells. U2OS and COS-7 cells
were transfected with siLZTS2-2 that targets 3’ UTR of the endogenous
LZTS2 mRNA. The next day, cells were transfected with 0.5μg/ml of non-
tagged constructs of LZTS2a or LZTS2b for16h. Cells then were fixed in





5.8.3 LZTS2 and PAK5 co-localize to cell-cell junctions 
To determine if PAK5 was co-localized with one or both potential isoforms of 
LZTS2, I expressed Flag-PAK5 and either GST-LZTS2a or LZTS2b-GST constructs 
at low level (0.2ug/ml DNA). Under these conditions, I could observe PAK5 co-
localizes with GST-LZTS2a in puncta or with LZTS2b at mitochondria (Figure 5.17 
A). Given that transient protein expression can alter protein behavior, I decided 
instead to investigate their colocalization in U2OS cells stably expressing GFP-PAK5 
(as described previously in section 4.6.1). Endogenous LZTS2 and GFP-PAK5 clearly 
co-localized at cell-cell junctions (Fig 5.17 B). A function for LZTS2 at cell-cell 
junctions is consistent with the phenotype of LZTS2 knockout mice, which exhibit 
defects in kidney formation [160]. One of the abnormalities noted for LZTS2 null 
mice was cysts formation in renal tissues. This could result from alterations in 
adhesive properties of ureteric epithelium cells, probably as a result of reduced 


















Figure 5.17 Analysis of PAK5 and LZTS2 co-localization in the cell. A.
COS-7 cells were co-transfected with 0.2μg/ml of Flag-PAK5 and either
GST-LZTS2a or LZTS2b-GST (C-terminal tag). After 16h, cells were fixed
in 4% PFA and co-stained with rabbit anti-Flag and mouse anti-GST
antibodies. B. 80-90% confluent culture of U2OS GFP-PAK5 stable lines
were fixed in methanol for 5 minutes and used for co-immunnostaining with



















5.8.4 Junctional localization of PAK5 is independent of LZTS2 
My previous results showed a direct interaction between PAK5 and LZTS2 and their 
co-localization at cell-cell junctions. Because GFP-PAK5 exhibited the both 
junctional and cytoplasmic puncta localization in U2OS stable lines, I asked whether 
junctional PAK5 requires LZTS2 interaction. I then transfected U2OS cells stably 
expressing GFP-PAK5 with si-LZTS2 and assessed PAK5 localization (Figure 5.18). 
The results showed that PAK5 localization is not affected by LZTS2 knock down. 
5.8.5 Afadin is required for junctional localization of LZTS2 and PAK5 
As previously mentioned, nectin and afadin were characterized as PAK5 proximal 
proteins using BioID (Table 5.2). Afadin is a junctional protein that binds to the 
Nectin and the complex of these two proteins along Cadherin-catenin complex form 
the major components of cell adhesions (Figure 1.6). I was therefore interested to 
analyze afadin interaction with PAK5 and check whether afadin is required for 
junctional recruitment of PAK5. Since afadin is a quite large protein, the expression 
vector of this protein is constructed in two fragments as shown in Figure 5.19A [303]. 
Co-immunoprecipitation experiment was carried out to test the HA-PAK5 interaction 
with the Flag tagged afadin constructs (Gift from Prof.Yoshimi Takai). The results 
showed no interaction between the two proteins (Figure 5.19B). Next, I tested the 
requirement of afadin for junctional localization of GFP-PAK5. U2OS stable lines 
expressing GFP-PAK5 were transfected with si-RNA against afadin. Figure 5.19C 
(left panel) shows that si- afadin is extremely efficient to reduce the level of afadin 
expression in U2OS cells. Knockdown of afadin was largely diminished localization 
of PAK5 at cell-cell junctions but not at the centrosomal region (Figure 5.19C, right 
panel). These results indicate that junctional localization of PAK5 required afadin and 
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suggest that other protein(s) mediates afadin and PAK5 connection. Because LZTS2 
is one of the direct interacting partners of PAK5 complex in the junctions, I tested 
whether PAK5 is connected to afadin via LZTS2 though the previous results 
suggested that LZTS2 is not required for recruitment of PAK5 to the junctions. Co-
immunoprecipotation experiment suggested that LZTS2 might not be directly 
interacted with afadin (Figure 5.19D). Afadin si-RNA treatment of U2OS cells does 
not significantly affect β-catenin but was severely reduced LZTS2 at cell-cell 
junctions (Figure 5.19E). These results strongly suggest that PAK5 and LZTS2 are 
more proximal to nectin-afadin complex rather than Cadherin-catenin.  
5.8.6 Binding to LZTS2 does not regulate PAK5 activity 
Given that PAK5 is a constitutively active kinase (Figure 3.2), I was interested 
to see if interaction with LZTS2 could affect PAK5 activity. To this end, I tested the 
activity of PAK5 co-immunoprecipitated with LZTS2a In vitro (Figure 5.17). The 
result showed no difference in activity when PAK5 was recovered with or without 























Figure 5.18 Junctional localization of PAK5 is independent of LZTS2
expression. U2OS cells stably expressing GFP-PAK5 were transfected
with either 50nM of si-scramble. The next day, cells were seeded on
coverslip and incubated for another 24h. Cells then were fixed in 4% PFA
and analyzed for PAK5 localization using fluorescent microscope. (Scale
bar: 10µm)
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Figure 5.19 Afadin-dependent localization of PAK5 and LZTS2 at cell-cell
junction. A. Schematic diagram of Afadin fragment constructs. Both constructs
contain PDZ domain. B. COS-7 cells were co-transfected with HA-PAK5 and either
Flag tagged N-PDZ or PDZ-C constructs of Afadin. Immunoprecipitation was
performed with anti-Flag Sepharose and co-immunoprecipitation of PAK5 was
analyzed using SDS-PAGE and Western blotting. C. U2OS cells or U2OS cells
stably expressing GFP-PAK5 were transfected with either si-Afadin or si-scramble.
The next day, cells were seeded on coverslip and after additional 24h, cells were
fixed and analyzed. U2os cells were subjected to indirect immunostaining using
Rabbit anti-Afadin antibody while U2os stable line were analyzed for PAK5







Figure 5.19 Afadin-dependent localization of PAK5 and LZTS2 at
cell-cell junction. D. COS-7 cells were co-transfected with HA-LZTS2
and either one of the Flag tagged constructs of afadin or Flag-PAK5. Co-
immunoprecipitation experiment with anti-Flag Sepharose following
SDS-PAGE and Western blotting was applied to analyze afadin and
LZTS2 binding. PAK5 and LZTS2 interaction was considered as a
positive control. E. U2OS cells were transfected with either si-Afadin or
si-scramble as described in panel C. After cell fixation in methanol,
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In vitro kinase assay
Figure 5.20 PAK5 activity is not regulated by binding to LZTS2.
COS-7 cells were co-transfected with Flag tagged PAK5 and either GST-
LZTS2a or pXJ-GST vector. The next day, cells were lysed and co-
immunoprecipitation was performed using anti-Flag Sepharose. In vitro
kinase assay was applied to compare the kinase activity of PAK5 or
PAK5:LZTS2 complex in the presence of 500mM ATP and GST-BAD as
substrate (5μg). GST-BAD phosphorylation on Ser112 was detected




5.9 Analyzing the potential interaction between LZTS2 and Raf-1 
The BioID and immuno-localization data indicated that LZTS2 (most likely 
the LZTS2b isoform), and a number of other junctional proteins can form a complex 
with PAK5. Co-localization of LZTS2b and PAK5 on mitochondria, indicates they 
might form also a complex at this site. Raf-1 is a reported interacting partner of PAK5 
that can localize to mitochondria via binding to Bcl-2 [304]. I hypothesized that Raf-1 
could be a component of PAK5 and LZTS2 mitochondrial complex. To test whether 
Raf-1 could interact with LZTS2 and to map the possible interaction site of the two 
proteins, full length HA-Raf-1 was co-transfected with various truncated constructs of 
LZTS2 (Figure 5.21A) and binding assessed by co-immunoprecipitation. As for 
PAK5, I noted that the minimal LZTS2 construct capable of binding Raf-1 largely 
requires the coiled-coil FEZ (Figure 5.21B). Raf-1 interaction with other coiled-coil 
proteins is reported. For example Raf-1 and ROCK interaction plays role in regulating 












































































Figure 5.21 Investigating the interaction site of LZTS2 with Raf-1.
A. Schematic of LZTS2 constructs were used to test their interaction
with full length Raf-1. B.HEK-293 cells were co-transfected with GST
tagged truncated constructs of LZTS2 and HA-Raf-1 as indicated. The
next day, cells were lysed and harvested. Glutathione Sepharose were
used to recover the GST-LZTS2 protein. HA-Raf-1 binding were





5.10 LZTS2 mediates PAK5 and Raf-1 co-localization at mitochondria 
It has been reported previously that full-length PAK5 and Raf-1 can co-
localize on mitochondria [51]. My results did not show a consistent co-localization of 
the two proteins (Figure 4.10) and in low expression the two proteins were not co-
localized. These results suggested that PAK5 and Raf-1 interaction may not be stable 
in COS-7 cells. Since I showed that LZTS2 could interact with both PAK5 and Raf-1, 
one explanation might be the presence (or not) of sufficient LZTS2b protein whose 
translation might be cell-type specific. To test whether LZTS2b expression stabilizes 
PAK5 and Raf-1 interaction, COS-7 cells were transfected with GFP-PAK5 and 
LZTS2b isoform in addition to low levels of HA-Raf-1. All three proteins 
accumulated in peri-nuclear region (Figure 5.22 A,B); however in some of these cells 
the mitochondrial distribution is disrupted making the localization ambiguous (data 
not shown). In the previous section (Figure 5.14) the localization of LZTS2b was 
clearly mitochondrial suggesting these proteins (PAK5, Raf-1 and LZTS2b) are 
associated with mitochondria. These results suggest that myristoylated isoform of 
LZTS2 (LZTS2b) may stabilize PAK5 and Raf-1 interaction and mediate their co-






















Figure 5.22 Analysis of colocalization of expressed PAK5, LZTS2b
and Raf-1 in COS-7 cells. A. Representative confocal microscopic image
of cells transfected with 0.3 µg of each of HA-Raf-1, GFP-PAK5 and GST
tagged LZTS2b constructs. After 16h, the cells were fixed in 4% PFA and
co-immunostained for Raf-1 and LZTS2b using mouse anti-HA and rabbit
anti-GST antibodies respectively. B. Line scan analysis of signals from







5.11 LZTS2 does not affect Raf-1 Ser338 phosphorylation. 
The mechanism of Raf-1 activation is complex and involves the participation 
of scaffolding proteins such as KSR and 14-3-3 proteins [112]. Since there seemed to 
be evidence of LZTS2 interaction with Raf-1 (as with PAK5), thus at cell-cell 
junctions LZTS2 could play role on regulation of Raf-1 activity. I then treated U2OS 
cells with siRNA to LZTS2 and investigated the phosphorylation status of Ser338 of 
Raf-1 and its downstream kinase (ERK1/2) phosphorylation [112, 306]. I also probed 
the status of phosphorylation on BAD Ser112, because Raf-1 acts upstream of BAD 
[307]. Lowering of LZTS2 levels did not appear to directly play an important role in 
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Figure 5.23 The effect of LZTS2 suppression on Raf-1 and BAD
phosphorylation. U2OS cells were transfected with either si-LZTS2-2 (50 nM)
or Si-scramble (50nM) for 24h. Cells were then serum starved for 20h before
adding10% FCS for 10 min as indicated. Cell lysate prepared using RIPA
buffer(see methods) containing 0.1% SDS. A total of 50μg proteins were




5.11 Discussion  
5.11.1 Identification of PAK5 interacting partners in U2OS cells 
Protein-protein interactions are a fundamental requirement for many cellular 
processes. The ability of proteins to form specific associations with neighboring 
proteins often underlies their function (for adaptor proteins) or allows for targeting of 
enzymes to the correct location. In the recent years, several studies have reported that 
increased PAK5 expression promotes or is associated with the cancer development 
[130-132, 134, 209], but the signaling pathway(s) underlying this phenomenon are 
poorly understood. One reason might be that the intracellular site of PAK5 activity is 
not known, and only few partners of PAK5 have been uncovered (Figure 1.5). A 
summary of published PAK5 partners is given below. 
 Affinity pull-down mass spectrometry (AP-MS) demonstrate p120-catenin as 
a PAK5 partner in HeLa cells [54]. PAK5 was shown to phosphorylate p120 on 
Ser288; though the function of this interaction is unknown. A yeast two hybrid (Y2H) 
screen against a brain cDNA library identified MARK-2 kinase and transcription 
factor E47 as interactors of PAK5 [53, 138]. PAK5 was found to interact with 
MARK-2 via the kinase domain and down-regulated its activity. In vitro kinase assay 
suggested E47 is a substrate for PAK5 and its phosphorylation correlates with PAK5 
expression and colon cancer progression in tissue samples. Synaptojanin and Pacsin-1 
were found in vitro substrates for recombinant PAK5 isolated from mouse brain lysate 
[140]. These two proteins act in a complex to regulate synaptic vesicle recycling and 
PAK5 was suggested to promote Pacsin-1 and synaptojanin interaction by their 
phosphorylation. PAK5 was found to phosphorylate transcription factor GATA1 in 
vitro. This phosphorylation was connected to the increased epithelial-mesenchymal 
176 
 
transition in breast cancer cells [139]. Raf-1 was identified as a PAK5 interactor by 
co-immunoprecipitation analysis of overexpressed proteins in HEK-293 cells and in 
the context of brain lysate [51]. Finally on the basis of what was known about PAK4 
[40], BAD was suggested as a PAK5 substrate [52]. 
 This study is the first to implicate PAK5 in cell-cell junctions. This new 
localization at cell-cell junctions of osteosarcoma cell line U2OS (Figure 4.15) has 
been used to identify proximal 'partners' for PAK5 in this compartment. The two 
methods that I employed include the recently described BioID method [242] which 
has been used to define the ZO-1 compartment [308], and a more traditional GFP pull 
down (GFP-PD), but using SILAC analysis for mass spectrometry (MS) in order to 
remove 'background' signal. The SILAC approach allows one to distinguish non-
specific light proteins [245] such as keratins and proteins that non-specifically bind 
Sepharose (Referred to as the Crapome, http://www.crapome.org). 
 Two high confidence data sets (ratio H/L≥3 and the peptide number≥4) were 
prepared from the BioID and GFP-PD data (Table 5.2 and 5.3). The majority of 
proteins were not shared between the two methods (Figure 5.9) and since the BioID 
yields primarily junctional proteins (where PAK5 was enriched), we must assume that 
this is the most accurate list.  
Among the previously reported PAK5 partners, p120 catenin was identified by BioID 
method (SILAC ratio= 5.9) and Cdc42 was seen in both BioID and GFP-PD data sets.  
 The PAK5 Bio-ID method identified a relatively small number of cell-cell 
junction proteins set (Figure 5.5) compared with the reported ZO-1 associated set 
[308]. The fact that junctional proteins are totally absent in GFP-PAK5 PD data set 
indicates the pull-down method is unreliable, perhaps because the genuine 'interactors' 
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cannot be solubilized effectively (Table 5.3). The PAK5 is likely to form a protein 
complex in the cell membrane which may not be extracted under mild lysis buffer 
(0.5 % Triton X-100) that were used for cell lysis in GFP-PD. Additional ionic 
detergents for example sodium deoxycholate (DOC) might help in this respect. The 
BioID process does not require the protein-protein interactions to be maintained, and 
indeed SDS is used to ensure these are disrupted (see figure 5.2). Standard affinity 
purification methods need to maintain protein-protein interactions, which is why a 
mild lysis buffer was used. In the case of BioID, the labelling of proximal proteins 
occurs in the cell and covalently attaches the label. The capture of biotin with 
streptavidin is one of the most stable non-covalent interactions and can survive 1% 
SDS [244]. 
 Among the junctional proteins identified with BioID (Table 5.2), Nectin-2 and 
Afadin show a SILAC ratio >10 suggesting they are the most proximal to PAK5 
versus ZO-1 with much lower SILAC ratio (ratio H/L 3.2). In this cell type, the 
adhesions are not well organized consistent with immature junctions in these cancer 
cells that may undergo continuous remodeling. The ZO-1 compartment cannot be 
found as a 'tight' band typical for say MDCK cells [309]. Figure 5.5 shows that most 
of the junctional proteins are associated together as annotated by STRING 
(http://string-db.org). Beside the well validated junctional proteins (as classified in 
Figure 5.5) some other proteins in our BioID set have also been found associated with 
junctions such as NRAGE [285], ASPP2 [310] and LL5-β [311] suggesting these 
proteins could be part of a subset of proteins neighboring PAK5. Comparison of 
neighboring proteins of PAK5 (in my study) with those identified for ZO-1[308] 
showed partially overlaps: Afadin, p120-catenin, Nectin-2 and Aspp2 were identified 
as common neighboring proteins for PAK5 and ZO-1 in junctions. ASPP2 (TP53BP2) 
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is an interesting PAK5 proximal protein because it is reported to interact with both 
junctional and mitochondrial proteins [310, 312]. This protein was first identified as a 
tumor suppressor protein that interacts with p53 and Bcl-2 and induces p53 mediated 
mitochondrial death pathway [312]. ASPP2 was also shown to form a complex with 
β-catenin and E-cadherin in the junctions of multiple epithelial cell lines [310]. 
 Identification of some microtubule associated proteins in the PAK5 BioID set, 
such as CEP85, could indicate that the kinase associates with the centrosome. This is 
consistence with co-localization of PAK5 with centrosomal marker γ-tubulin (Figure 
4.16D). It would be interesting to test CEP85 as LZTS2 interacting partner because 
LZTS2 is thought to localize to the centrosome and bind the centrosomal protein 
“katanin” [154].  
 Since PAK5 has previously been associated with mitochondria [50-52], any 
putative mitochondrial proteins are of interest. The protein Citrin is a Ca
2+
 binding 
mitochondrial carrier of Aspartate-Glutamate found within the inner membrane of 
mitochondria [268] and which does not contain biotin (though it might bind the 
mitochondrial biotinylated proteins such as PCCA (Propionyl-CoA carboxylase) and  
PC (Pyruvate carboxylase)). Since PAK5 probably only accesses the mitochondrial 
outer membrane [52], one would not expect these PAK5 and citrin to interact directly. 
The estimated radius of activity for BirA* is 20-30nm in vivo [242] while the distance 
between the cytoplasmic surface of outer membrane and the matrix surface of inner 
membrane of mitochondria is 17-20nm [313]. However, given the large number of 
proteins that should be detected on the mitochondrial surface (which are not), I 
suggest citrin is an artifact.  
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The GFP-PAK5 PD detected several mitochondrial proteins (like AIFM and 
ATAD3A) which are likely to be false positives typically found with tag affinity pull-
down [234]: it is easy to imagine that after cell lysis mitochondrial proteins are often 
released into the lysate, allowing them to interact non-specifically.   
 Analysis of the two data sets of SILAC-enriched proteins identified using 
BioID and GFP-PD from the same cell-line shows the presence of 5 common 
proteins, FAM83H, MAGE-D1, Sec16A, CAD and Cdc42 (Figure5.9). These proteins 
could well represent those can complex with PAK5 (directly or indirectly), which 
could be considered as interesting candidates for further studies. Among these 
proteins, only Cdc42 is a known interacting partner of the group II PAKs. The GFP-
PD identified Cdc42 with relatively high SILAC ratio (=10.3) but this was not the 
case with the BioID analysis (SILAC ratio <2). This might be because the interaction 
with PAK5 masks key residues involved in Cdc42 modification and actually prevents 
its biotinylation. Cdc42 is a small single domain protein with multiple interactors in 
its active and inactive state [314, 315]. We would not expect the protein to be easily 
labelled by active AMP-biotin.  
 Of the five proteins mentioned above, NRAGE (MAGE-D1) could be an 
interesting candidate for further studies. Both PAK5 and NRAGE are involved in 
apoptosis regulation pathway [52, 288, 316]. Although PAK5 is generally considered 
anti-apoptotic, NRAGE is reported to be both pro- and anti-apoptotic under different 
conditions [293, 316, 317]. The primary sequence of NRAGE indicates that it has a 
cysteine-rich N-terminus that is likely palmitoylated and a hydrophobic C-terminus 
that could act as a membrane anchor. Both NRAGE and PAK5 expression are linked 
to increased tumor cell migration [130, 131, 134, 285]. NRAGE may interfere with 
cell adhesions by disrupting E-cadherin-β-catenin interactions [285]. How PAK5 
180 
 
promotes migration is unclear: it could affect cell-cell junctions or up-regulate the 
metalloproteinase MMP2 that can disrupt the extracellular matrix [131, 134].   
 The biotinylation of some ribosomal and RNA associated proteins is expected 
but should be controlled for the biotin ligase [308]. In addition, (random) clonal 
differences in the level of translational proteins might well be picked up by SILAC. 
The protein TNRC6B exhibited a SILAC ratio >9 in the PAK5 BioID set (Table 5.2). 
This protein encodes a component of RNA interference machinery which is required 
for the gene silencing mediated with microRNAs/small interfering RNAs [318].  One 
would expect other members of the complex to be identified, if they were the 'PAK5-
proximal' complex. 
 Taken together I have seen that the bulk of PAK5 BioID derived 'partners' are 
junctional, suggesting that the method as applied by our lab is a sensitive and reliable 
technique for identification of proximal proteins. The PAK5 neighbors seen here have 
not been identified previously and overlap in part with those identified using a similar 
analysis of PAK4 (Felicia Tay, personal communication). Although in this study I 
have only a single biological experiment to determine PAK5 GFP-PD or BioID 
targets, the technique which was developed in the Manser lab has an estimated 
reliability of 90% based on the studies using Paxillin and Kindlin-2 (Dong Jing-Ming, 
personal communication). This means that on average 10% of 'hits' will not fulfill the 
H/L SILAC ratio >3 in different experiments. Other non-SILAC studies have also 
suggested BioID is potentially more reproducible than protein-protein interaction 
based techniques [242, 308, 319]. 
181 
 
5.11.2 Is LZTS2 a key partner for PAK5? 
The result of BioID suggested LZTS2 is closely associated with PAK5. The 
higher SILAC ratio of LZTS2 versus to other hits (Table 5.2) suggests that this 
protein is the most proximal interacting partner of PAK5.   
 Co-immunoprecipitation analysis (Figure 5.11) demonstrated that the so called 
FEZ domain of LZTS2 (which is unrelated to the protein FEZ1 [320]) interacts with 
both N-terminal and C-terminal regions of PAK5 (Figure5.13). PAK5 oligomerization 
promotes this interaction; again highlighting the importance of PAK5 self-association 
to its localization (Figure 3.7) and interaction with other proteins (Figure 5.12). 
Binding to LZTS2 did not affect PAK5 activity as measured in vitro (Figure 5.20).  
Nonetheless, co-expression of PAK5 and LZTS2 leads to an obvious mobility shift of 
LZTS2 on SDS-PAGE suggesting LZTS2 phosphorylation (Figure 5.12). Further 
analysis suggested PAK5 sites were present throughout the protein.' Phospho Site 
Plus' showed several phosphorylation sites in LZTS2. Based on optimal substrate 
sequence of group II PAKs [37], I suggest that Ser 99, Ser 276, Ser278 and Ser281 
have the potential of phosphorylation by group II PAKs. 
 I have proposed that two translational isoforms of LZTS2 exist in cells based 
on the different localization of these isoforms (Figure 5.14). The N-terminal residues 
of shorter isoform contain a consensus myristoylation sequences almost identical to 
N-terminal of LZTS1 (Figure 5.10), and shown to be N-myristoylated [302]. 
Myristoylation is an irreversible attachment of myristic acid to an N-terminal glycine 
[321] after removal of the (initiation) methionine. Rare examples of modification to 
internal Lysines have also been reported [322]. Myristoylation strongly affect protein 
localization in the same way as C-terminal farnesylation [321]. The post-translational 
modification of Gly (at position +2) is the most common form of modification; but 
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myristoylation can be occurred in exposed internal Glycine(s). For example caspase 
cleavage of Bid leads to exposure of an internal myristoylation motif in C-terminal 
fragment (ctBid) [323]. Myristoylated ctBid translocates to the mitochondrial 
membrane where it promotes release of cytochrome c.  In the case of LZTS2, we 
propose that myristoylation should be a co-translational modification with ribosomal 
selection of the second ATG sequence which fits the Kozak consensus [324] (Figure 
5.10B). We hypothesize that the conservation of this internal N-myristoylation 
sequence (with LZTS1) only occurs because this ATG is functional. The two isoforms 
which I term LZTS2a and LZTS2b show quite different localization: LZTS2a 
demonstrated a punctate distribution particularly near the nucleus (Figures 5.14 and 
5.16) and is consistent with a centrosomal-enriched localization of LZTS2 in 
osteosarcoma cell line SaOs-2 [154]. I have not tested the ability of LZTS2 to interact 
with the p80 subunit of katanin at this site as reported [157]. The LZTS2b isoform 
localizes on mitochondria and cell membrane (Figures 5.14 and 5.16) consistent with 
the membrane localization of LZTS1 in hippocampal neurons [302]. Although the 
anti-LZTS2 antibody shows significant non-specific signal (based on siRNA effects), 
clearly, endogenous LZTS2 is largely junctional in U2OS cells (Figure 5.15) 
suggesting that myristoylated isoform might be the dominant isoform of LZTS2 in 
this cell line. The mitochondrial localization of the protein was not seen by indirect 
immunofluorescent staining because of this background signal in peri-nuclear region. 
Cell fractionation is probably required to reveal any mitochondrial localization of the 
protein.  
 My results are the first report of a junctional localization of LZTS2, which fits 
with a role in regulating β-catenin location in the kidney cells of LZTS2 null mice 
[160]. My current model suggests that the LZTS2b may stabilize the β-catenin 
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complex in cell junctions (of epithelium of ductal tubes) and decrease the amount of 
β-catenin in the cytoplasm. The interaction of the LZTS2b with β-catenin, should be 
tested in the light of these results 
 Interestingly ASPP2, another tumor suppressor, is also though to enhance β-catenin 
levels at cell-cell junctions [310]. It should be noted that we did not detect β-catenin 
in the PAK5 BioID in U2OS cells although β-catenin is abundant in these cells 
(Tables 5.2 and S1).  
Interestingly, PAK5 was shown to localize on mitochondria when co-
expressed with LZTS2b in COS-7 cells where mitochondria are well resolved (Figure 
5.17A). Endogenous LZTS2 was clearly co-localized with GFP-PAK5 at junctions; 
however, the lower level of protein at mitochondria could not be resolved (Figure 
5.17B). The PAK5 BioID analysis (Table 5.2) suggests LZTS2 is a close partner for 
PAK5 in cell-cell junctions. Since I did not observe a significant change of the GFP-
PAK5 signal with LZTS2 siRNA (Figure 5.18), it seems likely that PAK5 does not 
depend on LZTS2b for its junctional localization. Instead, I found that this 
localization is dependent to the presence of afadin, another ‘proximal PAK5’ protein 
identified using BioID. In addition, afadin is appeared to be required for junctional 
recruitment of LZTS2, although neither PAK5 nor LZTS2 could interact with afadin. 
 It would be interesting to test Nectin interaction with PAK5 and LZTS2, 
because except LZTS2, this protein is supposed to be the most proximal junctional 
protein to PAK5.  
 I have shown that LZTS2 can also directly interact with Raf-1 through the 
coiled-coil region known as the FEZ domain (Figure 5.21) and demonstrated a 
mitochondrial ternary complex between PAK5, Raf-1 and LZTS2 (Figure 5.22). Since 
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we did not observe Raf-1 in the PAK5 BioID analysis, future experiments to validate 
this potential interaction using GFP-BirA
*
-LZTS2 need to be carried out. If LZTS2 
indeed interacts with Raf-1, a ternary complex between PAK5, Raf-1 and LZTS2 
might be important for the biology of both PAK5 and LZTS2 particularly in the 
context of mitochondria. Co-immunoprecipitation experiment using brain lysate has 
suggested an interaction between PAK5 and Raf-1 [51]; but this could be indirect 
because PAK5 and Raf-1 do not appear to form a stable complex in COS-7 cells 
(Figure 4.10C). The addition of LZTS2 to the system might well stabilize this 
complex as I have shown (Figure 5.23). One should note that LZTS2 levels are low in 
COS-7 cells (Figure 5.15A); but the Raf-1 connection could be important in tissues in 
which LZTS2 level are high.  
The mitochondrial localization of PAK5/Raf-1/LZTS2b in COS-7 cells (Figure 
5.22) which do not normally form cell-cell junctions should be re-tested in cells with 
well-organized junctions. This would allow us to test the hypothesis that if LZTS2 
mediates Raf-1 and PAK5 interaction in the junctions where it may play roles other 
than classical ERK activation, although presently Raf-1 is not known to be a 
junctional component.  Attempts to detect endogenous Raf-1 either at junctions or on 
mitochondria have been unsuccessful (data not shown). 
 On the other hand, the jucntional protein ASPP2, which promotes oncogenic-induced 
senescence, is reported to act through Ras/Raf/MEK/ERK pathway [325]. It is notable 
that LZTS2 knockdown did not affect Raf-1 phosphorylation in U2OS cells (Figure 
5.23), which might indicate that only a pool of Raf-1 is affected.  
 Taken together, I have confirmed the direct interaction of PAK5 and LZTS2 
and mapped the regions responsible for their mutual interaction. I found that LZTS2b 
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could target mitochondria in addition to cell-cell junctions and find that LZTS2 co-
localized with PAK5 in GFP-PAK5 U2OS cells. Although the LZTS2 interaction does 
not affect PAK5 activity, it is likely to be involved in substrate recruitment: the C-
terminal region of LZTS proteins bind to PDZ domain containing proteins such as 
ProSAP2/Shank3 [149, 162]. The role of LZTS2 in linking PAK5 to Raf-1 required 
further investigation. My current model suggests that both LZTS1 and LZTS2 binds 
to a variety of proteins through their coiled-coil domains and act as an adaptor for as 















Chapter 6. General Conclusions  
6.1 The group II PAK5 oligomerization underlies its high basal activity 
 Based on several lines of evidence from biochemical experiments (Figures 3.9, 
3.10), indirect immunofluorescence staining (Figure 3.7) and size estimation based on 
gel filtration (Figure 3.11), it appears that PAK5 is an oligomeric protein and its 
cellular puncta distribution reflects this. I have shown that PAK5 contains a conserved 
central specific-region (residues 109-420) that is not found (or not conserved) in 
PAK4 (Figure 3.6) and this region is critical for the protein self-association. PAK5 
oligomerization is directly implicated in the known elevated levels of PAK5 activity 
(in the absence of co-transfected activated Cdc42).  PAK5 has long been known to be 
a constitutively activated protein [33] and here I have demonstrated that it contains a 
functional auto-inhibitory domain at an N-terminal position as for PAK4 [28, 29] 
which seems paradoxical. I have shown that elevated basal activity of Flag-PAK5 
results from kinase oligomerization (Figure 3.12).  
  My current model (Figure 6.1A) suggests that PAK5 is in equilibrium between 
monomer, dimer and oligomeric state. Self-association antagonizes the auto-inhibited 
conformation of the kinase in which the N-terminal AID normally binds to the C-
terminal catalytic domain [28]. This probably occurs by preventing the AID binding 
to the kinase domain, perhaps by conformationally blocking the interaction (Figure 
6.1A). Based on this model, PAK5 is more active as an oligomer, and the loss of self-
association likely drives an auto-inhibited state.  
Based on careful biochemical studies, I showed that PAK5 is ~35% active relative to 
the full activity of PAK5 when it is bound to Cdc42 (Figure 3.3). Cdc42(G12V) 
expression leads to the  loss of PAK5 puncta (data not shown), indicating that  Cdc42 
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also blocks kinase oligomerization. The complex between Cdc42(G12V) and PAK5 is 
difficult to probe by gel filtration because we require detergent to solubilize the 
protein. However, all of this data is consistent with the distribution of Flag or GFP-
PAK5 in the cytoplasm where it forms the puncta (Figures 3.5, 3.7, 4.2) and GFP-
PAK5 behavior at junctions of U2OS stable lines where it likely binds to Cdc42 and 
normally do not form the puncta (Figure 4.15B).  
 The gene expression data base (http://www.ebi.ac.uk/) suggests that PAK5 
expression is always significantly lower than PAK4. Using the phospho-specific 
antibody (recognizes phospho-Ser602 and phospho-Ser474 of PAK5 and PAK4 
activation loop respectively), I estimate that NCI-H446 cells contain 30% PAK5 
relative to PAK4 and actually this cell line expresses one of the highest levels of 
PAK5 mRNA (Based on gene expression data base). 
 At low levels of the kinase, PAK5 is likely to be predominantly at cell-cell junctions 
and very little in 'active' punctate state. The ability of PAK5 to be active without 
Cdc42 interaction may be one reason that its level is generally low (compared with 
PAK4). Nonetheless, PAK5 has been found to be overexpressed in variety of cancers 
[130, 132, 133]; but whether it is a 'driver' mutation in cancer is not resolved.  
 My suggested model provides an explanation for the previous proposal that a 
fragment of central region (residues 60-180) acts as an 'auto-inhibitory domain' [30]. 
Incubation of the full length PAK5 with GST-PAK5(1-180) blocked PAK5 activity in 
vitro. As shown in figure 6.1B, this fragment in excess is likely to compete for 
binding with other full length PAK5 molecules. This binding however, may not 
interfere with the (monomeric) auto-inhibited conformation, thus shifting the balance 







Figure 6.1. A model for PAK5 oligomerization and subsequent 
activation. A. in monomeric state PAK5 is autoinhibited by the binding 
of the AID to the catalytic domain. The presence of a conserved specific 
central region (residues 109-420) in PAK5 promotes its oligomerization 
which antagonizes the AID association with the catalytic domain. B. 
PAK5 1-180 fragment reduces PAK5 activity in vitro.[30]. We suggest 
that this can occur by promoting the 'monomeric' PAK5 state (left side) or 
by promoting AID binding with the full-length (active) PAK5. 
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6.2 Identification of PAK5 as a junctional kinase 
In contrast to previous studies [31, 52], my findings suggest that GFP-PAK5 is not 
primarily resident of mitochondria (Figure 4.2). Instead, PAK5 is clearly present at 
cell-cell junctions (Figures 4.15 and 4.16) and may be directly associated with 
junctional proteins such as LZTS2 in this compartment (Figure 5.17B). The BioID 
assay also indicated that afadin and a number of other junctional proteins including 
Nectin-2, PAK4 and p120 catenin are proximal to PAK5 in U2OS cells (Table 5.2).  
Because this analysis will reveal the 'average' behavior of the protein in cell junctions 
(Figure 5.16), we may not be able to detect proteins proximal to a minority of the 
kinase (such as at mitochondria). My current model (Figure 6.2) suggests that PAK5 
is associated with the myristoylated isoform of LZTS2 (and possibly LZTS1) in 
junctions, however its localization does not appear to depend on this interaction 
(Figure 5.18). The junctional PAK5 is likely to be in vicinity of nectin-afadin because 
afadin knockdown had a great effect on junctional localization of PAK5 but not β-
catenin (Figure 5.19). I have not seen a significant difference in the overall structure 
of cell-cell adhesions in the GFP-PAK5 cell lines. Since PAK5 is not directly 
associated with the plasma membrane, it is likely to be in equilibrium with 
cytoplasmic PAK5 and is also enriched at centrosome where it may associate with 
CEP85. At present, it is possible that the labelling of Kif7 is the result of its 
accumulation at cell-cell junctions in these cells. The presence of PAK5 at 
mitochondria (via interaction with LZTS2b) has yet to be demonstrated. PAK5 
activity at the mitochondrial surface might be expected to protect the organelle from 
BAD. At mitochondria, PAK5 phosphorylates BAD on Ser112 directly. If interacts 
with Raf-1, PAK5 can induce BAD phosphorylation on Ser136 via Raf-1/Akt 
pathway. Phosphorylated BAD on Ser112/136 is inactive and will be sequestered by 
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14-3-3 protein in the cytoplasm. It should be noted however that Raf-1 has not been 
identified by BioID (Table 5.2).  
 This model (Figure 6.2) is based on the expression of GFP-BirA* PAK5 in the 
U2OS cells. Because PAK5 expression is dominant in the brain, it is interesting to 
speculate that similar proteins associate with PAK5 in neurons: cell-cell junctions 
between neurons occur primarily at synapses, and both afadin and cadherins play a 
key role in establishing and maintaining these structures [326, 327]. A number of 
PAK5 proximal proteins (listed in Table 5.2) are shown to localize at post synaptic 
density (PSD), such as LZTS2 [149], SPAR [149] and Erbin [328]. The phenotype of 
PAK5/PAK6 double knockout mice indicates defects in neurite outgrowth resulting in 
deficits in memory and learning [49, 329] which could be the consequence of defects 
in synaptic contacts [330].  The proteins that are assumed to be proximal to PAK5 in 
vivo (Table 5.2), are potentially kinase targets of PAK5, and it would be an important 











































































Figure 6.2 A proposed model for PAK5 localization in the cell and its
association with neighboring proteins. PAK5 is reported to localize to the
mitochondria [52]. Here, I show new localization sites for PAK5 at cell-cell
junctions and centrosomal region. In cell junctions, I suggest that PAK5 is
surrounded by a complex of proteins which are most likely associated with the
nectin-afadin compartment. LZTS2 is one of the direct interacting partners of
PAK5 at cell-cell junctions and probably centrosome and mitochondria. PAK5
may target several proteins in the junctions which has yet to be identified. On
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 List of the buffers and media 
Mammalian cell lysis buffer:  
50mM Tris HCL pH 7.4-8 
150mM NaCl 
20mM MgCl2 
0.5% Triton X-100 
RIPA buffer 
50mM Tris HCL pH 7.4-8 
150mM NaCl 
1% Triton X-100 
0.5% Sodium Deoxycholate (DOC) 
0.1% SDS 
1mM EDTA 
Bacterial lysis buffer 
50mM Tris HCL pH 8 
0.5% Triton X-100 
0.5mM MgCl2 
1mg/ml Lysozyme 









CCMB buffer   
11.8g/L CaCl2.2H2O                  
4g/L Mn.Cl2.4H2O                
2g/L Mg.Cl2.6H2O                 pH 6.4 
10ml/L1M KOAc pH 7             
100ml/L Glycerol        
10X SDS running buffer 
0.25M Tris Base 
2M Glycine 
1% SDS  
10X transfer buffer 
0.8M Glycine 
0.25M Tris Base 
50X TAE buffer 
2M Tris Base 
0.05 M EDTA, pH 7.5-8 
57.1ml Glacial Acetic Acid 
2X SDS sample buffer 
50mM Tris HCL pH 6.8 
6% SDS 
100 mM DTT 
0.1% bromophenol blue 
50% Glycerol 
2X Kinase buffer  
50mM HEPES pH 7.3 
100mM KCl 
20mM MgCl2  





0.1 M NaHCO3 
0.5 M NaCl, pH 8.3–8.5 
Low pH washing buffer 
0.1 M acetate buffer pH 4  
0.5 M NaCl 
TBS buffer 
24g/L Tris HCL 
5.6g/L Tris Base         pH 6.4 
88g NaCl 
 
SILAC DMEM:  (Light) 
444 ml of SILAC DMEM  
50 ml of Dialyzed Fetal Bovine Serum 
0.5 ml of light Arginine stock (85mg/ml)  
0.5 ml of light Lysine (146 mg/mL)  
5 ml of Penicillin Streptomycin 
 
SILAC DMEM: (Heavy) 
444 ml of SILAC DMEM  
50 ml of Dialyzed Fetal Bovine Serum 
0.5 ml of heavy Arginine (85mg/ml)  
0.5 ml of heavy Lysine (146 mg/mL)  






Table S1. List of the proteins identified by BioID as PAK5 proximal 















kinase PAK 5 
81 137.2 35 57 
2 LZTS2 
Leucine zipper putative 
tumor suppressor 2 
73 29.7 11 23 
3 CEP85 
Centrosomal protein of 85 
kDa 
86 19.4 9 17 
4 PVRL2 Nectin 2 51 16.6 6 15 
5 PAK4 
Serine/threonine-protein 
kinase PAK 4 
64 14.1 5 8 
6 KIF7 Kinesin-like protein KIF7 151 13.8 6 5 
7 MLLT4 Afadin 208 13.1 52 38 
8 USP54 
Inactive ubiquitin carboxyl-
terminal hydrolase 54 
187 12.0 2 2 
9 TUBA3C Tubulin alpha-3C/D chain 50 11.4 12 42 




92 10.9 7 11 
12 TNRC6A 
Trinucleotide repeat-
containing gene 6A protein 
210 10.8 3 2 
13 PKP2 Plakophilin-2 97 9.8 2 3 
14 TNRC6B 
Trinucleotide repeat-
containing gene 6B protein 
194 9.6 11 7 
15 PHLDB2 
Pleckstrin homology-like 
domain family B member 2 
142 9.2 5 6 
16 TBKBP1 
TANK-binding kinase 1-
binding protein 1 
68 8.8 4 7 




122 6.9 2 2 
19 GIGYF1 
PERQ amino acid-rich with 
GYF domain-containing 
protein 1 
115 6.7 2 3 
20 SEC16A 
Protein transport protein 
Sec16A 
252 6.5 8 4 




like protein 1 
200 6.3 7 4 
23 ODF2 Outer dense fiber protein 2 95 6.0 3 4 
24 CTNND1 p120 Catenin  108 5.9 11 15 

























74 5.1 4 6 








17 4.9 2 22 
30 TP53BP2 
Apoptosis-stimulating of 
p53 protein 2 
126 4.1 4 3 
31 ERBB2IP Protein LAP2 159 4.1 25 23 
32 STAU2 
Double-stranded RNA-
binding protein Staufen 
homolog 2 
63 3.8 6 11 
33 EIF3E 
Eukaryotic translation 
initiation factor 3 subunit E 
52 3.8 2 4 
34 CNOT1 
CCR4-NOT transcription 
complex subunit 1 
267 3.6 3 1 
35 CAD CAD protein 243 3.3 14 8 
36 EIF4ENIF1 
Eukaryotic translation 
initiation factor 4E 
transporter 






73 3.2 20 40 
38 TJP1 Tight junction protein ZO-1 197 3.2 37 25 
39 ERC2 ERC protein 2 111 3.2 3 4 
40 SSR4 
Translocon-associated 
protein subunit delta 
19 3.2 2 17 
41 SLC3A2 
4F2 cell-surface antigen 
heavy chain 
71 2.9 7 14 
42 PLEKHA5 
Pleckstrin homology 
domain-containing family A 
member 5 





128 2.9 12 12 
44 CEP192 
Centrosomal protein of 192 
kDa 
279 2.9 3 1 




Sickle tail protein homolog 214 2.8 8 5 
47 KANK2 
KN motif and ankyrin 
repeat domain-containing 
protein 2 
92 2.8 6 9 
48 PLEKHA7 
Pleckstrin homology 
domain-containing family A 
member 7 


















PDZ and LIM domain 
protein 7 




RanBP2-like and GRIP 
domain-containing protein 
1/2/3/4 
198 2.7 26 18 
51 RPL9 60S ribosomal protein L9 22 2.7 2 13 









kinase A/ B 
33 2.6 2 14 
55 RPL22 60S ribosomal protein L22 15 2.5 2 19 
  56 MYO18B 
Unconventional myosin-
XVIIIb 
285 2.5 2 1 




75 2.5 8 14 
59 YTHDF1/3 
YTH domain family protein 
1/ 3 
61 2.4 4 8 
60 SERPINH1 Serpin H1 46 2.4 6 19 
61 YTHDF2 
YTH domain family protein 
2 
62 2.4 3 5 
62 PALLD Palladin 151 2.4 14 12 
63 PRKDC 
DNA-dependent protein 
kinase catalytic subunit 
469 2.3 24 6 
64 SCRIB Protein scribble homolog 178 2.3 10 8 




98 2.3 5 8 




49 2.3 5 14 
69 TUBB2B Tubulin beta-2B chain 50 2.2 14 43 
70 RPLP2 
60S acidic ribosomal 
protein P2 







18 2.2 4 28 
72 RANBP2 
E3 SUMO-protein ligase 
RanBP2;Putative peptidyl-
prolyl cis-trans isomerase 
358 2.2 76 32 
73 MCM7 
DNA replication licensing 
factor MCM7 
81 2.2 9 18 
74 IRAK1 
Interleukin-1 receptor-
associated kinase 1 

























72 2.1 4 8 




87 2.1 3 5 
79 TUBB4A Tubulin beta-4A chain 50 2.1 16 54 
80 RPS14 40S ribosomal protein S14 16 2.1 3 28 
81 TUBB6 Tubulin beta-6 chain 50 2.0 9 28 
82 EIF5 
Eukaryotic translation 
initiation factor 5 
49 2.0 8 23 
83 RPS16 40S ribosomal protein S16 16 2.0 3 20 
84 TUFM 
Elongation factor Tu, 
mitochondrial 
50 2.0 2 6 
85 TUBB Tubulin beta chain 50 2.0 19 61 




Table S2. List of the Potential PAK5 interacting partners identified by 















kinase PAK 7 
81 64.9 37 57 
2 P4HA2 
Prolyl 4-hydroxylase subunit 
alpha-2 
61 29.6 16 39 
3 P4HA1 
Prolyl 4-hydroxylase subunit 
alpha-1 
61 15.3 16 38 
4 BAG2 
BAG family molecular 
chaperone regulator 2 







243 11.5 68 41 
6 SEC13 Protein SEC13 homolog 41 11.3 5 17 
7 SEC16A 
Protein transport protein 
Sec16A 
252 11.1 22 12 
8 P4HB Protein disulfide-isomerase 57 10.9 18 38 
9 AKAP8L A-kinase anchor protein 8-like 72 10.8 3 5 
10 FAM83H Protein FAM83H 127 10.0 19 23 
11 CDC42 
Cell division control protein 42 
homolog 
21 10.0 4 23 
12 ATAD3A 
ATPase family AAA domain-
containing protein 3A 
66 9.0 7 12 
13 AIFM1 
Apoptosis-inducing factor 1, 
mitochondrial 
67 8.9 10 19 
14 KANK2 
KN motif and ankyrin repeat 
domain-containing protein 2 
92 8.3 4 5 
15 LGALS3BP Galectin-3-binding protein 65 8.2 3 7 
16 TCP1 
T-complex protein 1 subunit 
alpha 
60 7.4 21 44 
17 LRP1 
Prolow-density lipoprotein 
receptor-related protein 1; 
505 7.4 16 4 
18 CCT7 
T-complex protein 1 subunit 
eta 
59 7.4 10 23 
19 CCT3 
T-complex protein 1 subunit 
gamma 
61 7.1 16 32 
20 CCT4 
T-complex protein 1 subunit 
delta 
58 7.1 17 40 
21 MAPRE1 
Microtubule-associated 
protein RP/EB family member 
1 
30 7.0 2 14 
22 CCT5 
T-complex protein 1 subunit 
epsilon 




















23 PKP2 Plakophilin-2 97 6.9 6 8 
24 CCT6A 
T-complex protein 1 subunit 
zeta 
58 6.8 12 30 
25 CCT2 
T-complex protein 1 subunit 
beta 
57 6.8 11 29 
26 YWHAH 14-3-3 protein eta 28 6.6 6 26 
27 YWHAG 
14-3-3 protein gamma;14-3-3 
protein gamma, N-terminally 
processed 
28 5.9 10 37 
28 CCT8 
T-complex protein 1 subunit 
theta 
60 5.9 19 39 




185 5.4 2 1 
31 UBR5 
E3 ubiquitin-protein ligase 
UBR5 





32 5.2 12 40 
33 POLR2B 
DNA-directed RNA 
polymerase II subunit 
RPB2;DNA-directed RNA 
polymerase 
134 4.9 5 4 
34 EMD Emerin 29 4.9 10 46 
35 YWHAE 14-3-3 protein epsilon 29 4.8 12 48 




92 4.6 5 7 







terminal hydrolase FAF-Y 
292 4.5 8 4 
40 LOXL4 Lysyl oxidase homolog 4 84 4.3 5 8 
41 RUVBL2 RuvB-like 2 51 4.3 5 12 
42 HSPA8 
Heat shock cognate 71 kDa 
protein 
71 4.1 34 60 
43 FLNB Filamin-B 282 3.6 5 2 
44 RICTOR 
Rapamycin-insensitive 
companion of mTOR 
195 3.4 2 1 
45 PLOD1 
Procollagen-lysine,2-
oxoglutarate 5-dioxygenase 1 




protein 3, mitochondrial 
27 3.4 5 24 
47 HSPA1A 
Heat shock 70 kDa protein 
1A/1B 
70 3.3 21 37 
48 IMMT 
Mitochondrial inner membrane 
protein 



















[ubiquinone] 1 alpha 
subcomplex assembly factor 4 
20 3.2 2 10 
50 HAX1 HCLS1-associated protein X-1 32 3.2 3 12 
51 MYO1C Unconventional myosin-Ic 120 3.1 12 14 
52 PHB2 Prohibitin-2 33 3.1 9 35 
53 HSPA6 Heat shock 70 kDa protein 6 71 3.1 11 17 
54 YWHAB 
14-3-3 protein beta/alpha;14-
3-3 protein beta/alpha, N-
terminally processed 
28 3.1 9 46 
55 CYC1 
Cytochrome c1, heme protein, 
mitochondrial 




78 3.0 8 15 
57 PPP6C 
Serine/threonine-protein 
phosphatase 6 catalytic 
subunit 
39 2.9 4 14 
58 PHB Prohibitin 30 2.8 8 32 
59 DNAJB6 
DnaJ homolog subfamily B 
member 6 
36 2.8 5 15 
60 MSH6 
DNA mismatch repair protein 
Msh6 
153 2.7 14 13 
61 YWHAQ 14-3-3 protein theta 28 2.6 12 42 
62 TIMM21 
Mitochondrial import inner 
membrane translocase 
subunit Tim21 
28 2.6 4 17 
63 MYO1B Unconventional myosin-Ib 132 2.6 4 5 
64 FUS RNA-binding protein FUS 53 2.5 2 6 
65 PRKDC 
DNA-dependent protein 
kinase catalytic subunit 
469 2.5 70 20 
66 DNAJA1 
DnaJ homolog subfamily A 
member 1 
45 2.5 2 7 
67 SLC25A13 
Calcium-binding mitochondrial 
carrier protein Aralar2 






69 2.3 3 7 
69 YWHAZ 14-3-3 protein zeta/delta 28 2.3 14 61 
70 CRYAB Alpha-crystallin B chain 20 2.2 4 23 
71 TIMM50 
Mitochondrial import inner 
membrane translocase 
subunit TIM50 
50 2.2 4 12 
72 UQCRQ 
Cytochrome b-c1 complex 
subunit 8 




32 2.1 9 31 
